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Summary: 
Acute leukemia (AL) is a heterogeneous and aggressive disease, with an incidence of 
approximately 5 cases per 100.000 individuals and per year. It consists of several subgroups 
with different specific cytogenetic and molecular genetic aberrations, clinical presentations 
and outcomes. Classification of AL is done (i) by clinical parameters and (ii) based on the 
bone marrow karyotype. Banding cytogenetics plays a pivotal role in the detection of 
recurrent chromosomal rearrangements and is the starting point of genetic analysis in AL, 
still. Nowadays, molecular (cyto)genetic tools provide substantially to identify previously 
non-detectable, so-called cryptic chromosomal aberrations in AL. However, AL according to 
banding cytogenetics with normal karyotype - in short cytogenetically normal AL (CN-AL) - 
represent up to ~50% of all new diagnosed AL cases and prognosis is unclear or denominated 
as intermediate. Thus, the overall goals of this thesis were (i) to identify and characterize the 
rate of cryptic alterations in CN-AL, (ii) to detect submicroscopic structural copy number 
alterations (CNAs) in AL and (iii) to identify yet unreported clonal acquired chromosomal 
rearrangements (therefore also 8 complex rearranged AL cases were studied) and align them  
with clinical outcome, as far as possible. This work included 103 AL cases and they were 
studies comprehensively using high resolution fluorescence in situ hybridization (FISH) 
based-banding technique, locus-specific probes (LSPs), array-based comparative genomic 
hybridization (aCGH), multiplex-ligation dependent probe amplification (MLPA) and 
analyses of the breakpoints by genomic browsers. DNA sequencing and single nucleotide 
polymorphism array-based comparative genomic hybridization (SNP array-CGH) have been 
used to detect mutations for a number of target genes that are known to key roles in lymphoid 
and myeloid development. Cryptic chromosomal aberrations were identified in 34% of 
cytogenetically normal acute lymphoblastic leukemia (CN-ALL) and in 28% of 
cytogenetically normal acute myeloid leukemia (CN-AML) cases respectively. Surprisingly, 
we detected high rates of CNAs in CN-ALL, whereas AML cases showed lower rates. 
Besides, we identified three new candidate genes; CDK6 (7q12.2), CDH2 (15q26.2) and DCC 
(18q21.2) that may play a key role in leukemogensis and progression. 
In conclusion, the present study highlights, that most likely all CN-AL cases hold cryptic 
genomic alterations and that complex AL still are a valuable source for detection of yet 
unrecognized chromosomal aberrations. Overall, the molecular cytogenetic approaches 
together with molecular methods are suited to identify cryptic chromosomal aberrations in AL 
and useful to define the genetic risk–based classification and correct determination of 
treatment protocols. 
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Zusammenfassung:  
Die akute Leukämie (AL) ist eine heterogene und aggressive Erkrankung mit einer Inzidenz 
von etwa 5 Fällen pro 100.000 Individuen und Jahr. Sie besteht aus mehreren Untergruppen 
mit unterschiedlichen zyto- und molekular-genetischen Aberrationen, klinischen Bildern und 
Verläufen. Die Klassifizierung von AL basiert v.a. auf (i) klinischen Parametern und (ii) einer 
Karyotypisierung des Knochenmarks. Die Zytogenetik spielt eine zentrale Rolle beim 
Nachweis von wiederkehrenden Chromosomenaberrationen und ist immer noch der 
Ausgangspunkt für jedwede weiterführende genetische Analyse der AL. Heutzutage bieten 
moderne, molekular (zyto-)genetische Verfahren die Möglichkeit früher nicht nachweisbare, 
sog. kryptische Chromosomenaberrationen bei der AL zu identifizieren. Dennoch sind nach 
Bänderungszytogenetik heute immer noch bis zu ~50% der neu diagnostizierten ALs 
zytogenetisch unauffällig (abgekürzt CN-AL) und deren Prognose gilt als unklar oder 
intermediär. Ziele dieser Arbeit waren (i) den Anteil und die Art der vorhandenen kryptischen 
Veränderungen bei CN-AL Fällen zu bestimmen, (ii) submikroskopische Struktur- bzw. 
Kopienzahl-Veränderungen (CNAs) in ALs nachzuweisen, und (iii) bislang noch nicht 
beschriebene, erworbene klonale chromosomale Rearrangements in CN-AL sowie 8-
komplexaberranten AL Fällen zu identifizieren und mit dem klinischen Verlauf zu 
korrelieren. In der vorliegenden Arbeit wurden 103 AL Fälle umfassend mittels 
hochauflösender Fluoreszenz in situ Hybridisierungs (FISH)-Bänderungs-Techniken, lokus-
spezifischen Sonden, array-basierender vergleichender genomischer Hybridisierung (aCGH), 
MLPA (multiplex-ligation dependent probe amplification) und durch Bruchpunktanalysen 
mittels genomischer Browser untersucht. DNA-Sequenzierung und Single Nucleotide 
Polymorphismus basierte aCGH wurden verwendet, um Mutationen für eine Anzahl von 
Zielgenen, welche Schlüsselrollen bei der lymphoiden und myeloiden Entwicklung haben 
weiter zu untersuchen. Kryptische Chromosomenaberrationen wurden in 34% der 
zytogenetisch unauffälligen akuten lymphatischen Leukämiefälle (CN-ALL) und in 28% der 
zytogenetisch unauffälligen akuten myeloischen Leukämien (CN-AML) identifiziert. Es 
fanden sich mehr CNAs in CN-ALL als in CN-AML Fällen. Schließlich wurden 3 neue AL-
assoziierte Kandidaten-Gene gefunden: CDK6 (7q12.2), CDH2 (15q26.2) und DCC 
(18q21.2), die eine wichtige Rolle in der Leukemogenese und Progression spielen könnten. 
Insgesamt ergab die vorliegende Arbeit, dass wohl alle CN-AL Fälle kryptische genomische 
Veränderungen tragen, und dass komplexe AL Fälle eine wertvolle Quelle für noch nicht 
erfasste Chromosomenaberrationen darstellen. Zusammenfassend konnte weiterhin gezeigt 
werden, dass molekularzytogenetische zusammen mit molekularen Methoden zur 
Klassifizierung kryptischer Chromosomenaberrationen in AL geeignet sind; diese Daten 
können künftig verwendet werden für eine korrekte Risikobestimmung und Auswahl 
geeigneter Behandlungsmethoden bei AL-Patienten. 
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1. Introduction 
Hematological malignancies are the most common cancer disease worldwide, particularly 
acute leukemia (AL). AL is the severest life threatening acquired disorder, studies are 
required for better understanding of underlying disease biology. The latter is primarily based 
on identification and characterization of acquired genetic alterations in AL. This chapter, first 
covers the molecular cyto(genetic) techniques nowadays used to identify acquired cryptic 
alterations in AL as well as to characterize complex chromosomal rearrangements (chapter 
1.1). Afterwards an overview on AL is provided, including definition, classification, 
cytogenetics and molecular genetics (chapters 1.2 to 1.5). These data will lead to the questions 
treated in this work (chapter 1.6). The present work is cumulative and based on ten own 
papers; thus, after showing them (chapter 2) they are discussed (chapter 3) and a finally 
conclusion and outlook on further possible developments based on presented data is given 
(chapter 4).  
 
1.1. Cytogenetic and molecular (cyto)genetics 
The beginning of human cytogenetics is ascribed to the end of 19th century. Tjio and Levan 
reported in 1956, based on their study of human embryonic lung tissues from several 
individuals, that the human diploid chromosome number is 46 (2n = 46) (Tjio and Levan 
1956). Continued developments of cell culture and harvesting techniques allowed for the 
identification of chromosomal abnormalities correlated with specific disorders and diseases. 
Thus, in 1959, Lejeune and colleagues described an extra chromosome in patients with Down 
syndrome (Lejeune et al. 1959). The first and most important finding of tumor cytogenetics in 
these early years was attributed to Peter Nowell and David Hungerford in 1960. They found a 
small acrocentric chromosome in the white blood cells (WBCs) of patients with chronic 
myelogenous leukemia (CML). This abnormal chromosome appeared to be terminally 
deleted, and was denominated as “Philadelphia chromosome” (Nowell and Hungerford 1960).  
The development of chromosome banding techniques started in the end of the 1960s. They 
allowed the chromosomes to be individually identified and specifically addressed in inherited 
diseases, and in case of acquired alterations in human malignancies (Caspersson et al. 1968). 
Therefore, the reciprocal translocation t(8;21)(q22;q22) was the first by means of banding 
approaches characterized alteration in acute myeloid leukemia (AML) in 1972 (Caspersson et 
al. 1972, Rowley 1973a). Shortly afterwards also the “Philadelphia chromosome” was 
identified to be part of a balanced translocation between the long arms of chromosomes 9 and 
chromosome 22; specifically a t(9;22)(q34;q11) (Rowley 1973b).  
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1.1.1. Chromosome banding 
A number of banding and staining techniques directed towards metaphase chromosomes have 
been developed between 1968 and 1980s. Thus, since the 1970s chromosome analysis became 
an essential tool in diagnosis of leukemia and lymphoma, as many recurrent numerical and 
structural aberrations were recognized (Lawler 1977). G-banding still known as a gold 
standard of banding techniques; it is considered as the most commonly used method in routine 
clinical and tumor cytogenetic diagnostic worldwide. G-bands are obtained, when the 
chromosomes are pretreated with a proteolytic enzyme, like trypsin and then stained with 
Giemsa, to produce reproducibly dark and light bands along the human chromosomes, which 
can be seen and analyzed by standard light microscopy. G-banding enables to detect both 
numerical (gain or loss of a chromosome) and structural aberrations (e.g., translocation, 
deletion, inversion, etc.). This method has, however, several weaknesses. The resolution of 
this technique is still limited, with a count of approximately 400-550 bands per haploid tumor 
cytogenetic genome; due to this many important chromosomal alterations can be missed and 
complex aberrations are too difficult to be interpreted (Wang and Fedoroff 1972, Yunis 1976, 
Othman et al. 2014). The designation of the regions, bands and sub-bands for each 
chromosome are describe in the International System for Human Cytogenetic Nomenclature 
(ISCN) (Shaffer et al. 2013). 
 
1.1.2. Molecular cytogenetics 
The term molecular cytogenetics refers to the study of DNA or genes visualised at 
chromosome or cell-level (Speicher and Carter 2005). In 1986, the first successful 
fluorescence in situ hybridization (FISH) experiments was carried out by the group of Dan 
Pinkel using chromosome-specific probe sets and to recognize the numerical and structural 
chromosomal abnormalities (Pinkel et al. 1986). Indeed, introducing of molecular 
cytogenetics, namely the FISH approach (see 1.1.2.1) is to overcame the lower resolution of 
banding techniques (>5-10 Mb). Nowadays, one of the best ways to characterize 
chromosomal breakpoints, particularly in leukemia, is application of the FISH-technique. 
Currently, major advances in molecular technology and bioinformatics, precisely comparative 
genomic hybridization (CGH), array-CGH and single nucleotide polymorphism array-based 
comparative genomic hybridization (SNP array-CGH), are powerful tools used to study copy 
number alterations (CNAs) across the genome. The goal of such studies is to improve the 
understanding of leukemia/cancer genesis, the identification of new biomarkers and potential 
therapeutic targets (Glassman and Hayes 2005, Le Scouarnec and Gribble 2012).  
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1.1.2.1. The technique of fluorescence in situ hybridization (FISH) 
The principle of FISH technique is based on the ability of a single-stranded DNA sequence to 
hybridize to its complementary target DNA sequence. The targets DNA are metaphase 
chromosomes, interphase nuclei, or tissue sections fixed to a glass slide (Fig. 1.1). The 
potential of all FISH-technologies is their ability to detect also submicroscopic deletions, 
duplications or rearrangements of single genes. Additionally, cryptic aberrations and complex 
chromosomal rearrangements can be fully characterized by FISH. Furthermore, interphase 
directed FISH is possible in case of low mitosic yield in leukemia (Liehr 2009, Bishop 2010).   
 
Figure 1.1. Principle of a FISH experiment performed on metaphase chromosomes. Fluorescent-
labeled DNA probe complementary to a chromosomal region of interest is used together with the 
target DNA which is fixed onto the slide surface. DNA probes and target DNA are denatured and 
hybridized together. Not shown in the figure, the Cot-1 DNA is necessary to cohybridized with the 
probe to reduce the binding of repetitive sequences. After washing the slides they can be visualized 
under a fluorescence microscope. If the DNA complementary to the probe is present a signal with the 
color of the emission wavelength of the fluorochrome of the probe is seen [figure adapted from the 
Department of Medical Genetics, Université de Sherbrooke, Sherbrooke, Quebec, Canada]. 
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1.1.2.2. Probes used for FISH 
For FISH many different DNA probes can be applied, which can be grouped as outlined 
below.  
 
1.1.2.2.1. Locus-specific probes (LSP) 
LSP cover chromosomal regions or loci of 0.1 to several megabase pairs (Mb) in size. In 
leukemia diagnostics and research LSP are applied to identify amplified oncogenes, deletion 
of tumor suppressor genes, or fusion genes or fissions (Liehr et al. 2015). 
 
1.1.2.2.2. Chromosome painting probes 
Whole chromosome painting (WCP) probes are generated by flow sorting or whole 
chromosome microdissection. The short and long arm of a particular chromosome can be 
painted by so-called partial chromosome painting (PCP) probe; PCPs can only be generated 
by microdissection. PCPs and WCPs have been particularly valuable in leukemia where 
specific chromosome rearrangements (numerical or structural) correlate with the severity of 
disease and may influence the plan of therapy (Cremer et al. 1988, Pinkel et al. 1988, Guan et 
al. 1994).  
 
1.1.2.2.3. Centromeric probes 
Chromosome‐specific centromeric probe (CEP) hybridize to centromeric regions of one (in 
case of D13/21Z1 and D14/22Z1 to two and in case of D1/5/19Z1 to three) specific human 
chromosome(s). They are commercially available and used to detect aneuploidy in both 
interphase and metaphase. In clinical diagnosis, for example, CEP are useful to confirm a 
trisomy of chromosome 21 in Down syndrome, while in AL typically monosomy 7 and/or 
trisomy 8 need to be checked, as they implicate in the prognosis of AML during therapy 
(Liehr et al. 2015). 
 
1.1.2.2.4. Multicolor FISH probe (mFISH) 
Several methods have been developed to paint each of the 24 human chromosomes in a 
specific color combination: spectral karyotyping (SKY) (Schröck et al. 1996), multiplex FISH 
(M-FISH) (Speicher et al. 1996), m-FISH (Senger et al. 1998), COmbined Binary Ratio 
labelling-FISH (COBRA-FISH) (Tanke et al., 1999) and 24-color-FISH (Azofeifa et al., 
2000). These approaches use four to seven different fluorochromes in a combinatorial labeling 
and/or ratio-labeling (Riegel 2014, Liehr et al. 2004, Liehr 2009). Nowadays, SKY, M-FISH, 
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and COBRA-FISH are the most advanced WCP-based FISH approaches, and allow the 
simultaneous visualization of all 24 human chromosomes, in a single hybridization, and in 
one metaphase spread. It is useful in defining complex translocations and marker 
chromosomes with unknown origin (Liehr 2015). 
 
1.1.2.2.5. FISH-banding approaches  
Many different FISH-banding approaches were introduced in the end of last century. 
Multitude multicolor banding (mMCB) is a FISH-banding technique which provides the 
possibility to characterize simultaneously subregions in each chromosome, using overlapping 
microdissection derived libraries, that are differentially labeled, and produce reproducible 
multicolored bands and unique patterns of fluorescence ratios along all chromosomes. These 
fluorescence ratios can be transformed into pseudocolour banding by specific software. This 
approach allows the differentiation of chromosome region specific areas at the band and 
subband level, with resolutions between 400-800 bands per haploid karyotype, and provides 
the possibility to analyses chromosomes irrespective of their condensation grades (Weise et 
al. 2003, Liehr et al. 2002a). mMCB is applied to characterize inter-and intra-chromosomal 
rearrangements of the whole human karyotype in one single experiment, to describe marker 
and/or derivative chromosomes in clinical and tumor cytogenetics (Liehr et al. 2002b, Liehr 
2009). Besides, this approach is also available, and was first introduced as a single-
chromosome directed application, called multicolor banding (MCB) (Liehr et al. 2002a).  
 
1.1.2.3. Array comparative genomic hybridization (array-CGH) 
Array-CGH was developed based on the same principles as CGH on chromosome level. The 
latter was already introduced in 1992 and enabled the characterization of genetic imbalances 
in tumors, which could not be karyotyped (Kallioniemi et al. 1992). The development of 
array-CGH technology for ‘molecular karyotyping’  with a much higher resolution than CGH 
(i.e. ~50-100 kilobases (kb)) is an example of the tremendous technical advances in 
cytogenetics. It offers higher resolution for genome-wide detection of chromosomal 
alterations and enables diagnostic and research to analyze hundreds to thousands of genes in 
one experiment. This lead to massive changes in clinical diagnostics and tumor research 
approaches (Le Scouarnec and Gribble 2012). In array-CGH the target-DNA are large 
numbers of mapped genomic clones, initially BAC or PAC (bacterial/P1-derived artificial 
chromosomes), which are spotted onto a standard glass slide (Fig.1.2) (Pinkel et al. 1998). 
The resolution of the different platforms is dependent on the size, number, and uniformity of 
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the genomic distribution of the probes. Array-CGH has been widely used to identify 
chromosomal imbalances through the detection of CNAs especially in leukemia and 
lymphoma, to distinguish the candidate genes that involved in the pathogenesis of cancer, and 
leading to cancer classification proposals. Indeed, array-CGH is not suitable technique to 
detect the recurrent balanced translocations, inversions or insertions but only to identify 
submicroscopic imbalances (Riegel 2014, Le Scouarnec and Gribble 2012). 
Besides, SNP array-CGH based approaches greatly improved the resolution of this approach 
down to ~1kb and enables the detection of stretches of homozygosity, which may be hints on 
deletions or uniparental disomy (UPD) (Le Scouarnec and Gribble 2012).  
 
 
Figure 1.2. Principle of array-CGH. Test DNA and control DNA are differentially labeled. Here 
shown examples of a T-ALL case with deletion in 9p21.3 to 9p21.3 and duplication in 9q34.12 to 
9q34.13 were identified [adapted from Othman et al. 2015]. 
 
 
1.1.3. Molecular genetics 
In the 1980s technical improvements led to the discovery of genes. Our understanding of the 
mechanisms and pathways involved in leukemogenesis became to be uncovered. In 1983 and 
1984 Grosveld and colleagues cloned the genes involved in the CML-specific translocation 
t(9;22). They could show, that the 5’ ABL gene which maps to chromosome 9q34 fused to the 
3’ BCR gene mapping to chromosome 22q11. Also they could show that a novel chimeric 
BCR-ABL gene was formed (Heisterkamp et al. 1983, Groffen et al. 1984, Rowley 1999). 
Nowadays there are countless molecular genetic approaches available (Murphy and Bustin 
2009, Kohlmann et al. 2013). In the following emphases is given only to three selected 
approaches that are of special interest for this work. 
 
1.1.3.1. Multiplex ligation-dependant probe amplification (MLPA) 
MLPA is one of the many different polymerase chain (PCR) reaction based approaches 
invented during the last 2 decades. It was first described for the detection of exon deletions 
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and duplications for BRCA1, MSH2 and MLH1 genes and for detection of trisomies (Schouten 
et al. 2002). So far, several modifications of MLPA technique have been developed, that 
include expression profiling (RT-MLPA), detection of known point mutations (array-based 
MLPA), and determination of the methylation status for imprinted genes and promoter 
regions (MS-MLPA) (Hömig-Hölzel and Savola 2012). MLPA is a multiplex polymerase 
chain reaction (M-PCR)-based technique, used to detect small CNAs within DNA sequences 
in a quantitative way. It enables to detect an aberrant copy number of up to 50 genomic DNA 
sequences in a single experiment (Fig 1.3). Still it cannot differentiate between a point 
mutation hampering PCR itself from a loss of copy numbers. MLPA is relatively fast, easily 
interpreted, cost effective, and e.g. method of choice for routine diagnostic of chronic 
lymphocytic leukemia (CLL). MLPA has also limitation and not suitable for the detection of 
the balanced translocations, inversions, unknown point mutations and distinguish diploid from 
haploid sets (Hömig-Hölzel and Savola 2012, Alhourani et al. 2014). 
 
1.1.3.2.  New high throughput approaches  
DNA sequencing is considered to be the gold standard tool for detection of point mutations 
associated with inherited and acquired genetic disease. Full sequencing of genes or genomes 
was not involved in routine cancer diagnostics until to date. Currently, next generation 
sequencing (NGS) technology (also known as “massively parallel” sequencing) allows to 
sequence the whole human genome (WHG), exome or transcriptome within a few days. It is 
based on sequencing of millions of DNA molecules simultaneously, after library preparation 
with production of sequence reads of 30-400 base pairs (bp) (Ilyas et al. 2015, Koboldt et al. 
2013). 
 
1.1.3.3.  Quantitative Real-time polymerase chain reaction (qRT-PCR) 
PCR provides a method for amplifying and studying alleles of specific genes or the mRNA 
transcribed from those genes. qRT-PCR is an in vitro method for reverse transcription of 
RNA followed by amplification of complementary DNA (cDNA). qRT-PCR is also very 
useful in detecting of the recurrent chromosomal translocations and rearrangements that 
generate oncogene fusion transcripts. For example, translocations t(4;11), t(8;21), t(9;22), 
t(12;21) and t/inv(16) can be simultaneously screened. Moreover, this technique is an efficient 
and highly sensitive in diagnostic that assist in selection of appropriate therapy and monitor 
the minimal residual disease (MRD) (Murphy and Bustin 2009, Olesen et al. 2004). 
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Figure 1.3. Principle of MLPA reaction including: 1) DNA denaturation and hybridization of MLPA 
probes; 2) ligation reaction; 3) PCR reaction; 4) separation of amplified products by electrophoresis 
and data analysis [adapted from Hömig-Hölzel and Savola 2012]. 
 
 
1.2.  The biology of leukemia 
All lineages of blood cells originate from a pool of self-renewing hematopoietic stem cells 
(HSCs) that resides in the bone marrow (BM). They can differentiate into two main lineages: 
lymphoid and myeloid progenitor cells (Longo 2013). Lymphoid progenitors can differentiate 
into B-lymphocytes, or T-lymphocytes. B-lymphocytes (or B-cells) differentiate in BM, while 
T-lymphocytes (or T-cells) proliferate and differentiate in the thymus (Hardy and Hayakawa 
2001, Rothenberg et al. 2008). Mature B- and T-cells leave to peripheral lymphoid organs 
through the bloodstream. The myeloid progenitors can give rise to bipotent granulocyte-
monocyte progenitors, whose final progeny are nucleated cells (monocytes and granulocytes); 
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besides they can differentiate into megakaryocyte-erythroid progenitors, which give rise to 
mature thrombocytes and erythrocytes. Mature granulocytes and monocyte are released into 
the bloodstream. Abnormalities in the normal blood cells differentiation and/or proliferation 
program result in hematological diseases, particularly leukemia.  
Leukemia is a neoplastic proliferation of hematopoietic precursor cells, arises from a mutated 
myeloid progenitor or lymphoid progenitor cell. These cells infiltrate the blood-forming 
tissues and circulate in the bloodstream. Commonly, leukemia is divided into two main 
classes: acute and chronic leukemia, which are further classified into lymphoid and myeloid 
types, depending on the cell lineage represented by the leukemic clone.  
Numerous transcription factors are involved in expression of genes during the progression of 
lymphoid cell precursors from the immature stage till they migrate into periphery. Though, 
mutations in transcription factors and/or overexpression of genes are tightly connected to 
lymphoid malignancies; for example mutations in the PAX5, IKZF1 and EBF1 genes which 
are important for B-cell development and differentiation, and thus associated with B-cell 
acute lymphoblastic leukemia (B-ALL) (O'Brien et al. 2011, Mullighan 2013). In contrast, 
somatic mutations leading to overexpression or acquired deletions in transcription factors 
have been described for myeloid cell development. In most of these cases they lead to 
inhibition of proliferation, block of differentiation and/or lead to altered lineage commitments. 
For example, mutation in C/EBP alpha which regulates proliferation and controls terminal 
granulocytic differentiation is associated with AML (Ho et al. 2009).   
 
1.3.  Acute leukemia (AL) 
AL is an aggressive and heterogeneous disease characterized by uncontrolled clonal 
proliferation and accumulation of poorly differentiated blast cells in the BM. AL shows a fast 
clinical pattern in comparison to chronic leukemia which is generally less aggressive. Without 
treatment AL can result in death within a few months. AL constitutes 95% of all childhood 
leukemias (Coebergh et al. 2006, Estey and Döhner 2006, Inaba et al. 2013). The severity of 
AL depends on leukemic cells infiltrating the BM and extramedullary organs and on the 
extent to the BM failure. Typical signs and symptoms of AL are fever, fatigue, pallor, bruises, 
bleeding, hepatosplenomegaly, lymphadenopathy, thrombocytopenia, coagulopathy, 
hyperleukocytosis and bone pain. In addition, central nervous system (CNS) involvement is 
possible (Reman et al. 2008, Nowak-Gottl et al. 2009). Overall, classification of AL plays an 
essential role in determining both treatment options and prognosis.   
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1.4.  Acute lymphoblastic leukemia (ALL) 
ALL is a malignant disease with clonal proliferation of lymphoid progenitor cells. It arises 
from recurrent genetic alterations that block precursor B and T cell differentiation and affect 
children (Teitell and Pandolfi 2009). ALL represents ~80% of childhood AL and ~25% of all 
childhood cancers (ages 0-15 years) but only ~20% of adult AL (Bassan et al. 2004, Inaba et 
al. 2013, ACS 2015). Worldwide, a sharp peak in incidence is observed among ALL children 
aged 2 to 5 years. In other words in Western Europe and in USA ALL appears in up to 40 
cases / million  and year, while in Eastern Europe and Japan the rate is only around 30 cases/ 
million and year; in sub-Saharan Africa, India, and in the Middle East the rate is only 20 
cases/million and year. This suggests either that in the industrialized Western countries there 
are higher exposures to environmental leukemogenes or that the genetic backgrounds are 
different (Stiller 2004, Howard et al. 2008, Hrusak et al. 2002, Linabery and Ross 2008).  
 
1.4.1. Classification of ALL 
ALL was initially classified into three major subgroups: L1 (80%), L2 (15%), and L3 (5%) 
based on French-American-British (FAB) Cooperative Group criteria using morphological 
features of lymphoblasts. L1 was correlated with the best prognosis, higher relapse rates were 
found for L2 and for L3 cases an adverse prognosis was given (Bennett et al. 1981). As 
mentioned ALL also classified into B and T cell ALL according to the expression of specific 
antigens easily identifiable by flow cytometry (appendix Tab. 1.1). B-ALL constitutes 80-
85% and T-ALL the remainder of ALL cases. B-ALL patients have a favorable prognosis 
with an overall complete remission (CR) rate of 95% for children between 1-15 years, and of 
60% for adults. Adverse prognosis in T-ALL was correlated with male gender, older age, 
leukocytosis and mediastinal mass (Perez-Andreu et al. 2015, Faderl et al. 2010, Goldberg et 
al. 2003). Hence, immunophenotype (Benter et al. 2001) and genetic and cytogenetic 
classifications of ALL are important aspects of diagnosis, risk assessment, treatment and 
prognosis in ALL (Vardiman 2010). Nowadays, around 80% of ALL patients can be readily 
classified into therapeutically relevant subgroups based such data (appendix Tab. 1.2).  
 
1.4.2. Clinical prognostic factors in ALL  
Prognostic factors to be assessed during ALL diagnostics are:   
Age: Children between 1 and <10 years of age with B-ALL tend to have favorable prognosis, 
while infants, adolescents, and adults are considered high-risk for treatment failure. For T-
ALL patients no effect of age for clinical outcome is know, yet (Hilden et al. 2006, de Bont et 
al. 2004). WBC count is a crucial variable for describing the nature of leukemia. Children 
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who have WBC counts more than 50,000/µl are classified as a high risk of relapse and need 
more intensive treatment (Vaitkevičienė et al. 2011).  
 
1.4.3. Cytogenetic aberrations in ALL 
Cytogenetic chromosomal abnormalities are detected in 50-60% of ALLs and may be 
structural or numerical (Fig. 1.4). Such aberrations are prognostic factors, too. Chromosome 
numbers: High hyperdiploidy (51-65 chromosomes) has been connected with good survival 
and excellent outcome in B-ALL, while hypodiploidy (<44 chromosomes) has worse 
prognosis (Chilton et al. 2014, Holmfeldt et al. 2013). Chromosomal translocations: 
Patients with a translocation t(12;21)(p13;q22)/ETV6/RUNX1 are more likely to be excellent 
cured, while those with a translocation t(9;22) or t(4;11) tend to have unfavorable outcomes 
(Bhojwani et al. 2012, Woo et al. 2014, Pui et al. 2003). In appendix Tab. 1.2 summarized the 
most common cytogenetic prognostic marker in ALL subtypes.  
 
 
 
Figure 1.4. Summary of the frequency of cytogenetic and molecular genetic aberrations frequently 
detected in ALL. Left side refers to childhood ALL and right side to adulthood ALL; B-ALL 
aberrations are indicated in black letters while T-ALL in blue ones [adapted from Downing et al. 
2012]. 
 
In ALL hyperdiploid karyotypes, the translocation t(9;22)(q34;q11), 11q23 (MLL gene) 
rearrangements, translocations t(12;21)(p13;q22), t(1;19)(q23;p13) and t(8;14)(q24;q32) are 
the most frequent structural cytogenetic abnormalities, while the genetic alterations associated 
with ALL hypodiploidy are: deletion in/of the genes TP53, RB1, and IKZF1 (Paulsson et al. 
2003, Chilton et al. 2014, Nachman et al. 2007, Holmfeldt et al. 2013). The most recurrent 
structural chromosomal aberrations in ALL are summarized in appendix Tab. 1.3.  
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1.4.3.1. Cytogenetically normal ALL (CN-ALL)  
CN-ALL represent up to ~50% of ALL cases. T-ALL- showed a normal karyotype more 
frequently than B-ALL patients and accordingly here cytogenetic markers cannot be 
determined. Based on the knowledge that chromosomes in ALL show a low banding 
resolution and that a good part of ALL cases present with a normal karyotype, it is not far to 
seek, that small aberration can easily be missed when analyzing ALL derived chromosomes 
by banding cytogenetics (Karst et al. 2006, Mrózek et al. 2009).  
 
1.4.3.2. Complex karyotypes in ALL 
Complex karyotypes are also well known and typical for approximately 5% of ALL cases. 
Such complex karyotypes include more than three to five chromosomal abnormalities. This 
group has been reported to indicate a significantly increased risk of treatment failure. Still, 
this prognostic marker has been incorporated in the definition of high-risk ALL groups 
(Moorman et al. 2007). 
 
1.4.4.  Molecular genetics of ALL 
CNAs are changes that alter the genome structure. They can be simple abnormal numbers of 
chromosomes (losses or gains) or, smaller, down to submicroscopic deletions or duplications. 
CNAs can be detected by technologies like MLPA, array-CGH, SNP-array-CGH and FISH 
using LSP. As submicroscopic CNAs have been revealed focal deletions, but also less 
frequently duplications or sequence/point mutations in genes that primarily serve as 
transcriptional regulators of the lymphoid development pathway (Mullighan 2012, Van 
Vlierberghe and Ferrando 2012, Inaba et al. 2013, Woo et al. 2014, Faderl et al. 2010). 
Common CNAs in ALL are listed in appendix Tab. 1.4. Numerous new genetic alterations 
have been discovered in ALL by using high throughput technologies such as NGS. 
Appreciation of these genomic abnormalities and mutations led to redefining 
subclassifications of ALL, recently (Pui et al. 2012, Mullighan 2013). For a number of target 
genes that play a key role in lymphoid development (e.g., PAX5, IKZF1, EBF1, LMO2) 
somatic mutations have been identified in B and T-ALL. For instance, deletion of PAX5 has 
been detected in 30% of B-ALL (Mullighan et al. 2007). JAK2 is a member of a family of 
tyrosine kinases involved in cytokine receptor signaling. Mutations in JAK2 were identified in 
10% of high-risk childhood B-ALL and frequently associated with other abnormalities, 
including deletions or mutations of IKZF1 and overexpression the CRLF2 gene (Mullighan et 
al. 2009a). In T-ALL, NOTCH1-activating gene mutation have been found in 60% and 
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FBXW7-inactivating gene mutation occurs in 20% of pediatric T-ALL (Gallo Llorente et al. 
2014). Less commonly, mutations in PTEN, WT1, amplification of MYB and sequence 
mutations in ras signaling (NRAS, KRAS, and NF1) and tumor suppression (TP53) have been 
identified in ALL (Mullighan 2013). 
 
1.5.  Acute myeloid leukemia (AML) 
AML is clinically and biologically a heterogeneous disease, characterized by clonal 
proliferation of myeloid precursors. These immature cells accumulated in BM or can escape 
into the peripheral blood, and infiltrate other organs (Ferrara and Schiffer 2013, Estey 2013). 
AML accounts for ~20% of childhood AL and is the most common AL type in adults over 60 
years of age. AML represents ~80% of all adult AL. The frequency of AML remains stable 
throughout childhood with a slight increase during adolescence age can be observed. 4-10 
cases per million children develop an AML annually (Stiller 2004, Belson et al. 2007). In 
advanced ages, the frequencies dramatically change: 3-10 cases per 100,000 per individuals 
over 65 years old per year are diagnosed with AML (Yamamoto and Goodman 2008, Dores et 
al. 2012).  
1.5.1. Classification of AML 
AML has been classified as to FAB into eight different subtypes (M0–M7) which depend on 
morphological and cytochemical evaluation. Some subtypes of AML tend to have a better 
outcome than others. For example, M3 subtype has a more favorable outcome, while 
undifferentiated AML-M0 and M7 are harder to treat effectively and have poorer outcome 
(Craig and Foon 2008, Vardiman et al. 2009). Cell surface and cytoplasmic expressed 
antigens help in diagnosis and classification of AML (appendix Tab. 1.5) (Vardiman et al. 
2009). Recently, WHO classified seven subtypes of AML with recurrent (cyto)genetic 
abnormalities (appendix Tab. 1.6). Each of these translocations or inversions results in a 
fusion gene encoding a chimeric protein that participates in leukemogenesis (Vardiman et al. 
2009, Dores et al. 2012). 
 
1.5.2. Clinical prognostic factors in AML 
Age: Children younger than 2 years suffering from AML have better prognosis than older 
children, while adult less than 60 years have favorable outcome with higher rates of achieving 
CR compared to those older than 60 years (Shah et al. 2013, Creutzig et al. 2008).  WBC 
count: AML patients with WBC counts higher than 100,000/µl are classified as having a high 
risk of relapse and need more intensive treatment (Löwenberg et al. 1999).  
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1.5.3. Cytogenetic aberrations in AML 
Abnormal karyotypes can be detected in 50-60% of AML patients. To date, many specific 
translocations and inversions have been described in AML (appendix Tab. 1.7).  AML 
patients who have translocations t(15;17), t(8;21), t(16;16)/or inv(16) have better chances to 
become cured and receive a CR, whereas patients with monosomies of chromosomes 5 or 7, 
with 11q23 rearrangements, monosomic and/or complex karyotypes are associated with poor 
prognosis, and require hematopoietic stem cell transplantation (HSCT) during their first 
remission (appendix Tab. 1.8) (Grimwade et al. 2010, Kayser et al. 2012, Ferrara and Schiffer 
2013).  Gain of chromosome 8 (trisomy 8) and loss of chromosomes 5 and 7 (monosomy 5 or 
7) are the most frequent numerical chromosomal abnormalities observed in different subtypes 
of AML. The recurrent loss of chromosome material proposes the existence of a putative 
tumor suppressor gene in these regions, as well the gain of chromosome result from the 
presence of potential oncogene that regulates myeloid precursor cells in proliferation and 
differentiation. Thus, loss of function or overexpression may leads to leukemic transformation 
(Braoudaki and Tzortzatou-Stathopoulou 2012, Schoch et al. 2006).  
 
1.5.3.1. Cytogenetically normal AML (CN-AML) 
CN-AML accounts 40-50% of de novo AML and up to 10% of sAML (secondary, therapy 
related AML). It is a very heterogeneous group of patients with variable age, morphological 
features, clinical course, and response to therapy. In this group patients are thought to have 
cryptic (cyto)genetic changes and categorized in the intermediate risk group  (Gross et al. 
2009, Grimwade et al. 2010, Walker and Marcucci 2012). 
 
1.5.3.2. Complex karyotypes in AML 
Complex karyotypes with three or more numerical and/or structurally altered chromosomes 
have been well recognized in AML, too with a high degree of genomic complexity with an 
average of 14 aberrations per case. Complex karyotypes occur in ~10% of AML patients. 
Noticeably, complex karyotypes may involve TP53 deletions and/or mutations. Indeed, this 
subgroup does not appear to be associated with age, gender, or WBC count, and particularly 
abnormalities of 17p or TP53 are predictive of a high risk of treatment failure in AML 
(Mrózek 2008, Rücker et al. 2012, Middeke et al. 2014).   
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1.5.4. Molecular genetics of AML 
Mutations in certain genes include FLT3, NPM1, IDH1/2, KIT, BAALC and CEBPA have 
significant impact on the prognosis in adult AML, particularly in CN-AML (Walker and 
Marcucci 2012). Point mutations or amplification of oncogenes provided new insight into the 
pathogenesis of CN-AML and also are important for further clarifying prognosis (Ilyas et al. 
2015). E.g. NPM1 gene mutations were identified in ~35 and 50% of de novo AML and CN-
AML, respectively. Sole mutation in NPM1 has been found as well as accompanied with 
other gene mutations including FLT3 and IDH1/2 (Ferrara and Schiffer 2013, Schneider et al. 
2012, Port et al. 2014).  
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1.6.  Aim of study/Questions worked on  
 
Normal karyotypes can be observed in AL in 40-50% of all cases studied by routine GTG-
banding analysis. According to what was outlined in the introduction part, unknown cryptic 
changes must be suggested to be present in the leukemic cells of these patients. The 
aberrations to be expected are suggested to be on the submicroscopic level. Previous studies 
have found such so-called cryptic aberrations when using high resolution FISH approaches. 
The observed aberrations fall into two groups: a) such cases which were only detectable by 
FISH and b) such which would have been also possible to be picked up, if more or better 
metaphases would have been analyzed in routine cytogenetics (Karst et al. 2006, Gross et al. 
2009). Besides, identification of additional aberrations (like point mutations or epigenetic 
changes) can be expected when using other, more molecular oriented approaches.  
 
Thus, the aims of the present work were: 
1 to identify overlooked and unknown cryptic chromosomal rearrangements in both CN-
ALL (61 cases) and CN-AML (42 cases); 
2 to characterize in detail here new identified tumor-associated acquired chromosomal 
breakpoints in CN-ALL and CN-AML cases; 
3 to characterize in detail the tumor-associated acquired breakpoints also in complex 
aberrant karyotypes of one ALL and seven AML cases; 
4 to detect submicroscopic structural CNAs in ALL and AML cases using MLPA and 
array-CGH; 
5 to correlate the new tumor-associated acquired rearrangements with diagnostic, 
prognostic and therapeutic relevance.  
 
Overall, the present work led to the numerous publications, 10 of which were selected for this 
thesis, which all deal with answering the questions raised before.  
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Even though they have been called outdated
for decades [1], cytogenetics and molecular
cytogenetics still are and will stay in future
indispensable tools in diagnostics. This state-
ment is true for clinical aspects of prenatal and
postnatal patient care but also for patients suf-
fering from neoplasia, in particular leukemia,
lymphoma and solid tumors, as well. In this
review, the development of cytogenetics and
molecular cytogenetics is summarized, the
basic technique of molecular cytogenetics is
outlined together with an overview on the dif-
ferent kinds of probes available for fluores-
cence in situ hybridization (FISH) and the
current state of molecular cytogenetics in can-
cer diagnostics is given. This includes espe-
cially the commercially available probe sets
applied in routine neoplasia diagnostics and
those multicolor FISH (mFISH) tools used in
research to identify new tumor-associated criti-
cal genomic regions.
Cytogenetic & molecular cytogenetics
The history of human cytogenetics started not
before the year 1879. At this time, micro-
scopes of a certain quality were available,
which were prerequisite to localize and identify
chromosomes in a cell. All chromosomal
studies between 1879 until approximately
1970 were retrospectively summarized as hav-
ing been performed in the ‘pre-banding era’.
Only so-called ‘classical cytogenetic studies’
were possible in that time, that is, chromo-
somes could exclusively be distinguished by
size and centromere index [2]; nowadays classi-
cal cytogenetics is still essential in animal [3]
and plant cytogenetics [4]. However, the
determination of the correct modal human
chromosome number in 1956, the first charac-
terization of inborn numerical chromosome
aberrations (like Down syndrome) as well as
the detection of first tumor-associated aberra-
tions were all achieved during the early days of
classical cytogenetics [2]. As summarized by
E Gebhart (1989) [5], tumor-associated chro-
mosomal anomalies were indeed already recog-
nized by the first observer of human
chromosomes, J Arnold in 1879. In 1890, it
was D von Hansemann who highlighted that
unusual, asymmetric mitosis can be observed
only in cancer cells. Partially based on this,
T. Boveri established in 1914 a ‘chromosome
theory of cancer development’ [5], which
turned out to be basically true many years
later [6]. Between 1927 and 1956, there were
multiple attempts to characterize chromosome
content and numbers of tumor cells, which
were basically hampered by the fact that the
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constitutional chromosome number in human was not deter-
mined (correctly) at that time. It is noteworthy that the chro-
mosomal aberration being typical for chronic myelogenous
leukemia, so-called Philadelphia chromosome, was already
detected in the ‘pre-banding era’ (in 1960). The same holds
true for characterization of monosomy 22 as being typically
observed in meningioma (in 1967), and double minutes (in
1962) later being identified as one of the cytogenetic equiva-
lents of oncogene amplification [5]. Interestingly, even
G Mendel, the ‘father of modern genetics’ postulated the exis-
tence of linkage groups (in German ‘Kopplungsgruppe’) for the
features he studied in peas [7]; and these linkage groups were
nothing else than chromosomes.
Logically, after ‘pre-banding era’ came the ‘pure banding era’,
starting with the invention of the Q-banding method by Lore
Zech (Uppsala) in 1968 [8]. Based on this, the GTG-banding
approach (G-bands by trypsin using Giemsa) was established in
1971, which remained the gold standard of all cytogenetic tech-
niques until now [2,5]. Using banding cytogenetics, more chro-
mosomal abnormalities, like translocations, inversions, deletions
and insertions, could be detected and precisely characterized,
which was impossible before. Many tumor-specific aberrations
were clearly identified since then, like the aforementioned Phila-
delphia chromosome which was characterized to be the result of
a reciprocal translocation t(9;22)(q34;q11) in 1973. Also the
acquired translocation t(8;14)(q24;q32) detected in Burkitt’s
lymphoma in 1976 and the characterization of homogeneously
staining regions in 1978 were important findings enabled due to
banding cytogenetics [5].
As black and white banding pattern together with chromo-
some morphology are the only two parameters that can be evalu-
ated in GTG-banding, origin of additional material in a
derivative chromosome often remains unclear. In order to over-
come this kind of limitations, molecular cytogenetic approaches
were and are necessary. In situ hybridization allows for examina-
tion of nucleic acid sequences inside cells or on chromosomes
and was first described in 1969 as a radioactive approach. As
nonradioactive probe labeling was not invented before 1981,
non-radioactive FISH was needed until 1986, until it was ready
to be used in human cytogenetics. Apart from avoidance of
health-threatening radioactivity, FISH speeds up analysis time
and comprises the possibility to detect several targets simulta-
neously (see below in section “FISH-techniques”) [2].
Thus, ‘pure banding era’ finished in 1986 with the first suc-
cessful molecular cytogenetic experiment on human chromo-
somes by D Pinkel and colleagues. The period since then may
be denominated ‘banding and molecular cytogenetic era’ as
banding cytogenetics and molecular cytogenetics complemented
each other and became important tools on an equal footing in
many fields of human diagnostics, including the care of cancer
patients. Initially, there were two basic approaches in molecular
cytogenetics: FISH and primed in situ hybridization (PRINS).
However, the latter never acquired the importance of FISH, as
it is much less robust and was never developed in a multicolor
variant [2,9].
Especially important for tumor cytogenetics was inventing a
molecular cytogenetic approach called comparative genomic
hybridization (CGH). In CGH, two genomes are analyzed for
gains and losses of genomic material at a low resolution of
5–10 Mb. Even though a main feature of many solid tumors is
their abnormal rapid in vivo growth, corresponding tumor cells
often refrain from growing in cell culture. Thus, originally
CGH gave first insights into chromosomal imbalances of many
previously not cytogenetically analyzed solid tumor types.
Indeed, CGH was applied more in research rather than as a
diagnostic tool [10]. An advancement of this chromosome-based
CGH approach is the so-called array-CGH, providing much
higher resolution of approximately 50 kb or even less, and
being used routinely in clinical rather than cancer diagnostics,
however, applied in cancer research [2,11,12].
Before discussing molecular cytogenetic applications in can-
cer diagnostics, some aspects about how the FISH technique
itself is performed need to be stressed.
FISH – technical aspects
DNA probes applied in FISH can be grouped in different
ways; here we suggest doing it as follows:
. locus-specific, single-copy probes;
. probes specific for repetitive sequences;
. whole chromosome painting probes (wcp);
. partial chromosome painting probes (pcp) (FIGURE 1).
Unstained Probe 1 Probe 2
A B
C D
Figure 1. Schematic drawing depicting the four different
kinds of fluorescence in situ hybridization-probes as
differentiated in this review. (A) Locus-specific, single-copy
probes, including subtelomeric probes. (B) Probes specific for
repetitive sequences like telomeric (probe 1) and centromeric
regions (probe 2). (C) A whole chromosome painting probe and
(D) partial chromosome painting probes.
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All four kinds of probes may be used in diagnostics and
should be applied at least in two-color FISH experiments: one
probe as specific for the region of interest, the second one as a
control. Most commercially available probes are locus- and/or
centromere-specific ones (see TABLES 1–3) [2].
Besides, mFISH probe sets can be of importance in molecu-
lar tumor-cytogenetic diagnostics, and they are even more con-
siderable in research. mFISH is defined as the simultaneous use
of at least three different ligands or fluorochromes for the spe-
cific labeling of DNA, excluding the counterstain. The first
commercially available and still diagnostically relevant mFISH
probe sets were put together in 1996 by M Speicher and col-
leagues and E Schro¨ck and coworkers, respectively, enabling
the staining of each of the 24 human chromosomes in different
colors using wcp probes. This kind of probe set was developed
in parallel, with slight modifications and described under dif-
ferent names as mFISH (=multiplex FISH), SKY (=spectral
karyotyping), multicolor FISH, COBRA-FISH (=COmbined
Binary RAtio labeling FISH) or 24-color FISH [2]. A summary
on possible applications besides cancer diagnostics can be
found elsewhere [13].
As mFISH methods applying wcp probes are not suited for
exact chromosomal breakpoint characterization, different
approaches summarized as ‘FISH banding methods’ were
developed. The latter ‘are any kind of FISH technique, which
provide the possibility to characterize simultaneously several
chromosomal subregions smaller than a chromosome arm with
resolution down to 5 Mb (excluding the short arms of the
acrocentric chromosomes). FISH banding methods fitting that
definition may have quite different characteristics, but share the
ability to produce a DNA-specific chromosomal banding’ [14].
The most often applied FISH-banding approach is the
microdissection-based multicolor banding (MCB or m-band).
Other mFISH probe sets such as for all subtelomeric regions
(M-Tel-FISH) or variants of centromere-specific multicolor
FISH (=cenM-FISH) are commonly not applied in cancer
diagnostics [2]. Array-CGH and next-generation sequencing
(NGS) methods are not considered as ‘molecular cytogenetic’
approaches, even though some authors surprisingly do this [15].
The latter may be warranted by the recent description of chro-
mothripsis based on NGS [16]. However, it has to be empha-
sized that complex chromosomal rearrangements and even
conditions like ‘chromosome-pulverization’, which may be one
step of chromothripsis, are known for decades already from
pre-banding era of cytogenetics [5].
Molecular cytogenetics in cancer diagnosis
It goes without saying that in neoplasia the identification
of cytogenetic markers1 is of high clinical significance for diag-
nostics, follow-up studies and prognosis [5,17,18]. In the first
years after introduction of molecular cytogenetics into cancer
Table 1. List of most important commercially available
fluorescence in situ hybridization-probes for leukemia.
Leukemia subtype Target region Gene
Myelodysplastic
syndrome
3q26
4q24
5q31.2
6p22 and 9q34
7q22 and 7q31
11q21
16p13 and 16q22
20q12 and 20q13.12
EVI1
TET2
EGR1
DEK/NUP214
RELN/TES
MAML2
MYH11/CBFB
PTPRT/MYBL2
Chronic myeloid
leukemia
4q12
5q32~33
9p24
9q34 and 22q11
11q22
17p13
FIP1L1/CHIC2/PDGFRa
PDGFRB
JAK2
BCR/ABL
ATM
P53
Acute myeloid
leukemia (AML)
3q26
4q12
5q31.2
5q32
5q35
6p22 and 9q34
6q23
6q27
7q22 and 7q31
9p24
9p21.3
11p15
11q23
15q24 and 17q21.2
16p13 and 16q22
20q12 and 20q13.12
21q22
22q22 and 8q21
EVI1
KIT
EGR1
CSF1R
NPM1
DEK/NUP214
MYB
MLLT4
RELN/TES
JAK2
MLLT3
NUP98
MLL
PML/RARa
MYH11/CBFB
PTPRT/MYBL2
ERG
RUNX1/RUNX1T1
Chronic lymphocytic
leukemia
3q26
5q32
6q21
6q23
11q22
11q13
11q22 and 18q21
12q13
13q14.3
14q32 and 11q13
17p13
19q13
TERC
CD74
SEC63
MYB
ATM
Cyclin D1
BIRC3/MALT1
GLI
DLEU2 or D13S25
IGH/CCND1
P53
BCL3
Acute lymphocytic
leukemia
Xp22.3
Xp22.3
1p32
1q23 and 19p13.3
4q21 and 11q23
5q35
6q23
7q34
8q24
9p21
9p13
9q34 and 22q11
10q23
10q24.3
11q23
12p13 and 22q22
14q11
14q32.13
14q32.3
19p13
22q22 and 8q21
CRFL2
P2RY8
SIL/TAL1
PBX1/TCF3
MLL/AFF1
TLX3
MYB
TCRB
C-MYC
P16 or CDKN2A
PAX5
BCR/ABL
PTEN
TLX1
MLL
TEL/AML1
TCR A/D
TCL1
IGH
E2A
RUNX1/RUNX1T1
1A ‘cytogenetic marker’ is a set phrase in tumor cytogenetics. It can
be, for example, a trisomy 8 as well as a translocation leading to onco-
gene activation or a deletion leading to tumor-suppressor gene loss.
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diagnostics, FISH was most often considered as a tool to con-
tinue and refine previous cytogenetic studies. This way to
choose and apply corresponding FISH-probes represents still a
major part of molecular cytogenetic diagnostics [19–21]. Besides,
molecular cytogenetics is more and more performed indepen-
dently from banding cytogenetic analyses in all kinds of
tumors, too [22]. This development was, among others, sup-
ported by the fact that every cytogenetic analysis is in need of
dividing cells to produce metaphase spreads. In other words,
time-consuming cell culture is necessary. Thus, interphase-
directed FISH (iFISH) analyses on tumor cell smear, touch
preparations or tissue sections are more and more in use with
the goal to achieve a quick result [23–25].
FISH approaches are especially suited to characterize chro-
mosomal and subchromosomal copy number changes and gene
fusions due to translocations or other rearrangements. All these
features are characteristically found acquired aberrations in
cancer [5,18,19].
In the following, different FISH-probe types and possible
applications in cancer diagnostics are summarized to the best
of our knowledge. Various FISH probes may be applied in a
specific case due to a finding in banding cytogenetics, indica-
tion specific and/or in follow-up studies.
Application of centromeric probes
Exclusive probes directed against the centromeric regions of one
specific human chromosome, each, are available for all human
gonosomes and most autosomes except for #5, #13, #14, #19,
#21 and #22 [26]. As centromeric probes provide dot-like signals
after FISH, they can be evaluated in metaphase and interphase
easily. They are commercially available and highly suited to
determine and/or confirm mono-, tri- or tetrasomies of single
chromosomes in tumor cells. Due to often low banding resolu-
tion of tumor chromosome, preparations such a metaphase-
directed FISH test may even be necessary in routine diagnostics,
for example, to determine or confirm the origin of a trisomic
chromosome derived from C-group. Numerical aberrations may
be observed for practically all human chromosomes in cancer.
So just three examples where these probes may be of importance
are given here as monosomy 7, trisomy 8 or tetrasomy 8, which
may all be present in acute leukemia [27,28]. Another important
field where especially gonosomal centromere-directed probes are
regularly applied is follow-up of sex-mismatched bone marrow
transplantation [29,30].
For application of all centromeric probes, one possible pitfall
has to be highlighted here: centromeric regions may be subject
to so-called chromosomal heteromorphisms. There are reports
on false-positive and false-negative results after pure iFISH
diagnostics using this kind of FISH-probes [26]. Thus, centro-
meric probes should only be applied if metaphase FISH was
done at least once with the corresponding probes. Nowadays,
locus-specific probes (see below) suited for iFISH are available
for all human chromosomes, which should preferably be
applied in all neoplastic samples of patients where no informa-
tion is available on potential centromeric heteromorphisms.
Table 2. List of most important commercially
available fluorescence in situ hybridization-probes
for lymphoma.
Lymphoma subtype Target region Gene
Anaplastic large-cell l 2p23
5q35
ALK
NPM1
Burkitt l 2p11
8q24
14q32.3
17p13
21q11
IGK
C-MYC
IGH
P53
IGL
Diffuse large B-cell l 2p16
2p11
3q27
8q24
9p21
14q32 and 18q21.33
17p13
19q13
21q11
REL
IGK
BCL6
C-MYC
P16 or CDKN2A
IGH/BCL2
P53
BCL3
IGL
Follicular l 3q27
6q23
9p21
14q32 and 18q21.33
17p13
BCL6
MYB
P16 or CDKN2A
IGH/BCL2
P53
Mantel cell l 5q32
9p21
11q22 and 18q21
13q14.3
14q32 and 11q13
17p13
19q13
CD74
P16 or CDKN2A
BIRC3/MALT1
DLEU2
IGH/CCND1
P53
BCL3
Multiple myeloma 1q21 and 1p36
1q21 and 8p21
4p16.3
5q32
6q23
11q22
13q14
14q32 and 4p16
14q32 and 11q13
14q32 and 16q23
14q32 and 20q12
15q22 and 9q34
17p13
c-MAF/SRD
c-MAF/n.a.
FGFR3
CD74
MYB
ATM
DLEU2
IGH/FGFR3
IGH/CCND1
IGH/MAF
IGH/MAFB
n.a. ! detection
of hyperdiploidy
P53
Others 2p23
3q12
3q27
5q35
6q23
10p11.2
11q21 and 18q21
11q22
13q14.3
14q32 and 18q21.33
17p13
ALK
TFG
BCL6
NPM1
MYB
KIF5B
API/MALT1
ATM
DLEU2
IGH/BCL2
P53
l: Lymphoma; n.a.: Not available.
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Table 3. List of most important commercially
available fluorescence in situ hybridization-probes
for solid tumors.
Tissue type probe
to cancer
Target region Gene
Bladder 9p21
17p13
P16 or CDKN2A
P53
Bone and soft tissue 1p36.2 and 3q25
1p36
2q33
2q36
3q12
6p21
7p21
9q22
11p15.5
11p13
11q24 and 22q12
12q13
12q13~q14
12q14
12q15
13q14
16p11
17q21 and 22q13
18q11.2
21q22
22q12
CAMTA1/WWTR1
PAX7
CREB1
PAX3
TFG
PHF1
ETV1
NR4A3
CARS
WT1
FLI1/EWSR1
DDIT3
CDK4
HMGA2
MDM2
FOXO1
FUS
COL1A1/PDGFB
SS18
ERG
EWSR1
Breast 1q32
1q41
3q26
5q31.2
6q23
6q25
7p12
8p11.2
8q24
10q23
10q26
11q13
11q22.3
12p12
12q14
15q25
17p13.1
17q11.2~12
17q21~22
20q13
MDM4
CENPF
SOX2
EGR1
MYB
ESR1
EGFR
FGFR1
C-MYC
PTEN
FGFR2
CCND1
ATM
KRAS
HMGA2
NTRK3
P53
HER2/NEU1/ERBB2
TOP2A
ZNF217
CNS 1p36.2 and 3q25
1p36
1q25
1q41
2p24
3p25
3q26
6q22
7p11.2
9p21
10q23
CAMTA1/WWTR1
MEGF6
ABL2
CENPF
NMYC
VHL
SOX2
ROS1
EGFR
CDNK2A
PTEN
Table 3. List of most important commercially
available fluorescence in situ hybridization-probes
for solid tumors (cont.).
Tissue type probe
to cancer
Target region Gene
12q13~q14
15q25
17p13
19p13
19q13
CDK4
NTRK3
P53
ZNF44/ZNF
CRX
Colorectal 3q26
6q23
6q24.3
7q34
10q23
12p12
17p13.1
18p11.32
SOX2
MYB
RREB1
BRAF
PTEN
KRAS
P53
TYMS
Esophagus 8q24
9p21
17p13.1
17q11.2~12
18p11.32
20q13
C-MYC
P16 or CDKN2A
P53
HER2/NEU1/ERBB2
TYMS
ZNF217
Eye 1q32
13q14
MDM4
RB1
Head and neck 1q41
3p25
5q32
11q21
12p13.3
19p13.2
CENPF
VHL
CD74
MAML2
FOXM1
BRD4
Kidney Xp11.23
3p25
3p14
6p21
7q31
10q23
17p13
TFE3
VHL
FHIT
TFEB
MET
PTEN
YWHAE
Liver 4q12
8q24
9p21
11q13.3
12p12
17p13.1
18q21
KIT
CMYC
P16
FGF3,4,19
KRAS
P53
BCL2
Lung 1q32
2p23 and 2p21
3p14
3q12
3q26
4q12
5q32
6q22
7p12
7q34
10p11.2
10q26
MDM4
ALK/EML4
FHIT
TFG
SOX2
PDGFRA
CD74
ROS1
EGFR
BRAF
KIF5B
FGFR2
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Application of locus-specific probes
In TABLES 1–3 major parts of the presently commercially available
locus-specific probes for metaphase FISH and iFISH applica-
tions in human cancer diagnostics are listed [31–37]. According
to tumor type, application of one or more of these probes may
be indicated.
The sheer amount of available locus-specific probes hampers
a detailed discussion of each of them in this review. Use of
locus-specific probes in neoplasia was reviewed before for leuke-
mia [29,38–44], lymphoma [44–46] and solid tumors [44,47], like
skin [44,47–49], lung [50] or breast cancer [51,52].
However, the commercially available probes can be catego-
rized as follows (FIGURE 2):
. dual-color break-apart probes, detecting oncogene activa-
tion [5] by disruption of the corresponding tested gene;
. dual-color (dual) fusion probes, which normally are separated
from each other in the human genome, but can come into
close proximity due to different kinds of rearrangements,
leading in the end also to oncogene activation [5];
. dual-color probes meant to detect deletion of tumor-
suppressor genes [5];
. dual-color probes for detection of copy number alterations of
parts of the genome – especially oncogene amplification [5];
. dual-color probes just for detection of copy number altera-
tions of major parts of or the entire genome (hypo- or hyper-
diploidy [5]) localized at different chromosomes.
The same probe may be suited to detect oncogene disruption,
translocation and amplification or hyper-/hypodiploidy.
Table 3. List of most important commercially
available fluorescence in situ hybridization-probes
for solid tumors (cont.).
Tissue type probe
to cancer
Target region Gene
Skin (melanoma) 6q23
6p25
7p21
7q34
9p21
10q23
11q13
22q12
MYB
RREB1
ETV1
BRAF
P16
PTEN
CCND1
EWSR1
Stomach 3q26
4q12
4q12
7q31
8q24
10q23
10q26
11q22 and 18q21
17p13.1
17q21
18p11.32
SOX2
KIT
PDGFRA
MET
CMYC
PTEN
FGFR2
BIRC3/MALT1
TP53
ERBB2
TYMS
Ovary 3q26
8q24
9p21
10q26
11q13
12p12
17p13.1
19q13
20q13
PIK3CA
CMYC
P16
FGFR2
CCND1
KRAS
P53
CRX
NCOA3(AIB1)
Pancreas 5q32
6q24.3
7q34
9p21
10q23
11q22.3
12p12
17q13
CD74
RREB1
BRAF
P16
PTEN
ATM
KRAS
P53
Prostate Xq12
3p14
3q27
7p21
8q24
9p21
10q23
12p13.3
12q13q14
17p13.1
21q22
AR
FHIT
ETV5
ETV1
C-MYC
P16
PTEN
FOXM1
CDK4
P53
ERG
Thyroid gland 1q22~q23
2q13
3q12
7q34
10q11.2
10q23
NTRK1
PAX8
TFG
BRAF
RET
PTEN
Table 3. List of most important commercially
available fluorescence in situ hybridization-probes
for solid tumors (cont.).
Tissue type probe
to cancer
Target region Gene
Uterus 3q26
5q32
6p21.3
7p15
8q24
9p21
10q23
10q26
12p12
17p13
17p13.1
17q12
PIK3CA
CSF1R
PHF1
JAZF1
CMYC
P16
PTEN
FGFR2
KRAS
YWHAE
P53
HER2/NEU1/ERBB2
Others 1p36
1p32 and 1q21
3p14
3q26
5p15
6q22
7q31
12p13.3
SRD
CKS1B/CDKN2C
FHIT
TERC
TERT
MET
ROS1
FOXM1
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Here it must especially be stressed that molecular cytogenetic
methods (except for CGH) are single-cell-directed tests. Thus,
low-level mosaics can be detected that may be missed by
molecular genetic approaches [53]. On the other hand, molecu-
lar approaches have the advantage of being inexpensive and
able to cover more targets at once. An approach that could the-
oretically have the potential to partially replace (molecular)
cytogenetics in tumor diagnostics is multiplex ligation-
dependent probe amplification. This PCR-based technique can
be used to screen for fusion genes, point mutations and copy
number variations [54]. However, it has to be checked carefully
when information on low-level mosaics can be renounced, and
it is necessary for accurate patient care. This statement is true
for all molecular approaches testing millions of cells at a time.
Best may be to combine the available approaches in a tumor-
specific scheme such as, for example, recently suggested for
chronic lymphocytic leukemia [39].
Application of whole chromosome painting probes
Metaphase-directed two- or three-color FISH using wcp probes
may be necessary in cancer diagnostics regularly, especially after
derivative chromosomes were detected during banding cyto-
genetic analyses [55]. Still banding cytogenetics and/or the
tumor-subtype need to provide clear hints that correct wcp
probes are chosen for further characterization of an acquired
derivative chromosome; otherwise, if available, mFISH using all
wcp probes in different fluorochrome combinations may be
indicated [56,57]. Of course, wcp probes may also be combined
with other probes like pcp-, locus-specific or centromeric ones.
Finally, it is a truism that wcp- and pcp-probes are not suited
for routine iFISH studies [58].
Application of mFISH probe sets
In neoplasia, characterization of complex rearrangements (CCR)
may also be necessary in routine diagnostics [57]. However, as
CCR are considered to implicate an adverse diagnostics, often no
further analyses are performed [5,17,18]. Besides, it is a matter of
financial issues and of the technical possibilities available in the
laboratory executing the diagnostics if expensive mFISH studies
can be applied in a specific case. In a worldwide perspective, the
majority of laboratories and oncologists will not be able to per-
form mFISH studies on a routine bases. Some countries in West-
ern Europe, Northern America and some other more wealthy
places around the world may be able to apply them on a routine
base at present; these may be the same which can offer array-
CGH and NGS as a routine setting [59–62].
In majority of cases, mFISH approaches (as well as array-
CGH and NGS) will be applied only in individual cancer cases
in research-associated settings [63–67]. Besides mFISH using wcp
probes, also FISH-banding approaches and other probes will be
used to resolve the individual case [68].
Clinical genetic aspects of molecular cytogenetics
diagnostic performed in cancer diagnosis
Any kind of FISH study performed in a case with diagnosis can-
cer needs to be done according to the results of tumor cytogenet-
ics and/or the input of the referring clinician. Genetic counseling
will not be necessary in most of neoplastic cases. However, excep-
tions are the hereditary cancers, like breast cancer [69–71].
Moreover, one has to consider that during cytogenetic and
molecular cytogenetic analysis incidental findings are possible.
Mosaic Turner or Klinefelter syndrome or carriers of small super-
numerary marker chromosomes may be detected [71,72]. Such
findings, even though being rare, also should be expected by the
clinician when a tumor-cytogenetic analysis has been requested.
Expert commentary
Molecular cytogenetics, together with cytogenetics provided, pro-
vides and will provide in future major input into the characteriza-
tion of molecular defects in neoplasia. Morphological and
clinical data, together with (molecular) cytogenetics and, as far as
available, data from more sophisticated molecular approaches,
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Figure 2. Schematic depiction of how locus-specific probes are normally combined in commercially available probe sets; the
signal distribution as observed in an normal interphase cell is shown in the upper, the abnormal situation in the lower row.
(A) Dual-color break-apart probe; (B) dual-color dual fusion probe; (C) dual-color probe-set for detection of a tumor-suppressor gene
deletion; (D) dual-color probe-set for detection of an oncogene-amplification – in D1 a gene amplification due to double minutes and in
D2 a corresponding amplicon due to a homogeneously staining region is shown; and (E) dual-color probe-set for detection hypo- or
hyperdiploidy – here a triploidy is detected.
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should all be considered to obtain correct diagnoses of studied
malignancies. However, as in majority of the world, banding
cytogenetics supplemented by the use of locus-specific probes is
that what routine malignancy diagnostics consists of we clearly
disagree with the statement of others [44] that FISH and mFISH
approaches are ‘early methods’ for routine cancer diagnostics and
‘recent high throughput genomic methods’, that is, array-CGH
and NGS are the new routine ‘molecular cytogenetic’ methods.
Array-CGH and NGS are wonderful research tools. They will for
sure lead in future to more insights into altered genome structure
of malignancies. And maybe in some wealthy ‘Western’ countries
these approaches, together with expensive mFISH techniques,
may reach routine diagnostic status. The main importance of
these sophisticated approaches in terms of implementation, and
especially interpretation, will be the identification of new tumor-
relevant genetic markers. The latter will be accessible by targeted
and simpler tests, later.
Five-year view
In future, cytogenetics and molecular cytogenetics still will be a
standard approach in cancer diagnostics. Specifically, the
impact of metaphase as well as interphase-directed locus-specific
FISH-probes will increase, especially as it can also be combined
with immunohistochemistry [73]. This is among others
highlighted by the fact that more and more companies enter
the market offering increasing portfolios of tumor-related
FISH-probes [31–37]. Thus, we expect molecular cytogenetics to
remain a stable field in terms of necessity and application in
cancer diagnostics. Thus, we suggest that not only for the next
5 years but for definitely longer, molecular cytogenetics would
be a key diagnostic, prognostic and follow-up tool in routine.
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Key issues
. Molecular cytogenetics evolved in 1986 from cytogenetics.
. Cytogenetics started to gain major relevance in cancer diagnostics after identification of the first tumor-associated chromosomal
aberration in 1960.
. Molecular cytogenetics uses different kinds of probes, such as locus-specific ones, whole and partial chromosome painting probes and
probes specific for repetitive sequences.
. Two-color fluorescence in situ hybridization (FISH) is applied in routine cancer diagnostics, while multicolor FISH (mFISH) methods are
applied more in research-associated settings.
. Locus-specific probes are routinely applied for the detection of tumor-suppressor gene deletion, oncogene amplification and/or gene
fusions, as well as hypo- and hyperdiploidies.
. Molecular cytogenetics routine applications are used in leukemia, lymphoma and solid tumor diagnostics.
. Cytogenetics and molecular cytogenetics is single cell directed and thus able to detect even acquired low-level mosaics.
. One has to be prepared to meet also in cancer diagnostics from time to time hereditary cases, which need special attention.
. mFISH as well as array-comparative genomic hybridization and next-generation sequencing are highly suited for research settings, able
to identify new tumor-relevant genetic markers.
. mFISH, array-comparative genomic hybridization and next-generation sequencing are and will in the near future be too expensive to
become routine cancer diagnostic tools from a worldwide perspective.
. Cytogenetics and molecular cytogenetics are and will stay in the future indispensable tools in cancer diagnostics.
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Article
Introduction
B cell acute lymphoblastic leukemia (B-ALL) is a heteroge-
neous disease accounting for approximately 20% of adult 
leukemia. B-ALL is also the most common leukemia in 
pediatrics, representing up to 80% of childhood leukemia, 
with a peak of prevalence between the ages of 1 and 6 years 
(Zuckerman and Rowe 2014; Pui et al. 2008).
One of the most common recurrent chromosomal rear-
rangements in B-ALL (observed in approximately 50% of 
the rearrangements) is the balanced translocation t(4;11)
(q21;q23), which leads to fusion of the MLL (mixed-lin-
eage-leukemia) gene on 11q23 to the AFF1 gene in 4q21 
(Woo et al. 2014). MLL encodes for a protein with histone 
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Summary 
MLL (mixed-lineage-leukemia) gene rearrangements are typical for acute leukemia and are associated with an aggressive 
course of disease, with a worse outcome than comparable case, and thus require intensified treatment. Here we describe 
a 69-year-old female with adult B cell precursor acute lymphoblastic leukemia (BCP-ALL) with hyperleukocytosis and 
immunophenotype CD10- and CD19+ with cryptic MLL rearrangements. G-banding at the time of diagnosis showed 
a normal karyotype: 46,XX. Molecular cytogenetics using multitude multicolor banding (mMCB) revealed a complex 
rearrangement of the two copies of chromosome 11. However, a locus-specific probe additionally identified that the 
MLL gene at 11q23.3 was disrupted, and that the 5′ region was inserted into the chromosomal sub-band 4q21; thus the 
aberration involved three chromosomes and five break events. Unfortunately, the patient died six months after the initial 
diagnosis from serious infections and severe complications. Overall, the present findings confirm that, by far not all MLL 
aberrations are seen by routine chromosome banding techniques and that fluorescence in situ hybridization (FISH) should 
be regarded as standard tool to access MLL rearrangements in patients with BCP-ALL.
Keywords
array-comparative genomic hybridization, B-cell precursor acute lymphoblastic leukemia, cryptic rearrangements, 
fluorescence in situ hybridization, MLL, mixed-lineage-leukemia gene
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methyltransferase activity, which plays a critical role in the 
hematopoietic regulation of HOXA as well as embryonic 
development (Ansari and Mandal 2010). The translocation 
t(4;11) or MLL/AFF1 gene fusion is almost exclusively 
seen in infant B-ALL (<1 year of age) and in highest fre-
quency in childhood B-ALL. Up to 93% of affected infants 
under the age of 90 days harbor MLL rearrangements such 
as translocations t(4;11), t(11;19), or t(1;11), and most of 
these children cannot be rescued with the currently avail-
able therapies. These MLL rearrangements are also approxi-
mately four times more common in children than in adults 
(Braoudaki and Tzortzatou-Stathopoulou 2012; van der 
Linden et al. 2009), and the most frequently observed trans-
location t(4;11), has a dismal prognosis (Pui et al. 2002; 
Biondi et al. 2000).
Cryptic structural abnormalities often remain undetected 
by routine chromosomal banding techniques in acute leuke-
mia. However, molecular (cyto)genetics has been proven to 
be a reliable tool for identification of such cryptic aberra-
tions. Well known examples are the recurrence of cryptic 
translocation t(12;21)(p13;q22), which is solely associated 
with childhood B-ALL, and the cryptic translocation t(5;14)
(q35;q32), which is known to be present in children and 
adolescents with T-ALL (Lazic et al. 2010; Su et al. 2006). 
Overall, chromosomal translocations found in childhood 
and/or adult B-ALL may result in the production of chime-
ric fusion proteins with leukemogenic potential.
Here, we report the case of a patient with adult BCP-ALL 
with a novel cryptic submicroscopic balanced translocation 
and an additional cryptic insertion of 5’MLL region into the 
AFF1 locus at 4q21, with an unfavorable prognosis.
Materials & Methods
Clinical Description
A 69-year-old female presented in 2008 with hyperleukocy-
tosis (white blood cell (WBC) count of 259.7×109/l; hemo-
globin of 14.2 mmol/l and platelets of 103×109/l). The bone 
marrow (BM) aspiration showed hypercellularity, with 98% 
blasts. Immunophenotyping identified a variety of B-cell-
specific antigens, with 96% of cells positive for CD15, 
CD19, CD22, CD34, CD45 and HLA-DR and all cells neg-
ative for CD10, CD13, CD20, and CD117. These findings 
were consistent with a diagnosis of BCP-ALL. It is note-
worthy that the immunophenotypes CD10- and CD19+ as 
seen here are associated with MLL rearrangements in BCP-
ALL. The patient was treated by induction therapy: Epi 
(4-epi-doxorubicin)/ VCR (vincristine)/ PEGAsp (polyeth-
yleneglycole asparaginase)/ PDN (prednisone), two courses 
of consolidation and maintenance treatment (Mercaptopurin, 
Metotrexat). Unfortunately, she died six months after the 
initial diagnosis from serious infections and severe 
complications.
Diagnosis
Banding cytogenetic anaylsis was performed using an 
unstimulated bone marrow aspiration obtained at diagnosis 
and according to standard procedures (Claussen et al. 2002). 
A total of 20 metaphases were available for cytogenetic 
evaluation and analyzed on a level of 300 bands per haploid 
karyotype (Shaffer et al. 2013). Standard G-banding revealed 
a normal female karyotype as 46,XX and FISH test for a 
cryptic translocation t(9;22)(q34;q11.2) was negative.
Retrospective Analyses
Molecular Cytogenetics. FISH was performed according to 
standard procedures and/or to manufacturer’s instructions. 
The probes and probe sets were made in-house. FISH-
banding probe-sets were created using genome-wide mul-
titude multicolor banding (mMCB) and chromosome 
specific array-proven multicolor-banding (aMCB) (Weise 
et al. 2003, 2008; Liehr et al. 2002). BAC (bacterial artifi-
cial chromosome) clones of interest were identified 
through the Human Genome Browser Database of the 
Genome Bioinformatics Group at the University of Cali-
fornia at Santa Cruz (http://genome.ucsc.edu/) and 
Ensembl Genome Data Resources of the Sanger Institute 
Genome Database (http://www.ensembl.org/). DNA 
probes (Table 1) obtained from the Resources Center 
(Oakland, USA) were labeled by PCR with Spec-
trumGreen, SpectrumOrange or TexasRed-dUTP and 
applied in two- or three-color FISH-approaches.
Additionally, the following commercially available probes 
were used: LSI MLL (11q23 Break probe, Abbott Molecular/
Vysis, Mannheim, Germany), POSEIDON NUP98 (11p15 
Break probe, Kreatech Diagnostics, Amsterdam, The 
Netherlands), SPEC TFG Break probe (TFG in 3q12.2, 
Zytovision, Bremerhaven, Germany), Centromere 4 (CEP4: 
4p11-q11 Alpha Satellite DNA, Abbott Molecular/Vysis), 
and subtelomeric probes for 11p, and 11q (11p in D11S2071; 
11q in D11S1037, Abbott Molecular/Vysis).
A total of 10–15 metaphase spreads were analyzed, 
using a fluorescence microscope (AxioImager.Z1 mot; 
Zeiss, Oberkochen, Germany) equipped with appropriate 
filter sets to discriminate between a maximum of five 
fluorochromes and the counterstain DAPI 
(Diaminophenylindol). Image capturing and processing 
were carried out using an ISIS imaging system 
(MetaSystems; Altlussheim, Germany).
DNA Isolation. Genomic DNA was extracted from cells fixed 
in acetic acid:methanol (1:3) by Puregene DNA Puriﬁcation 
Kit (Gentra Systems; Minneapolis, MN). DNA concentra-
tion was determined using a Nanodrop spectrophotometer 
(NanoDrop Technologies, Inc., Thermo Scientific; Wilm-
ington, DE). The quality of DNA was checked using agarose 
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gel electrophoresis. DNA samples extracted from fixed cells 
of two healthy males and two healthy females by the same 
method were used as reference samples.
Multiplex Ligation-dependent Probe Amplification (MLPA). The 
P377-A1 Hematologic malignancies probemix and SALSA 
reagents were used for this study (MRC-Holland; Amster-
dam, The Netherlands). Ampliﬁed probes and Genescan 
500 ROX standard were separated by capillary electropho-
resis using a 4-capillary ABI-PRISM 3130XL Genetic Ana-
lyzer (Applied Biosystems; Foster City, CA). Sizing of 
peaks and quantification of peak areas and heights were 
performed using GeneMarker v1.9 software (Applied Bio-
systems). A minimum of four healthy control samples were 
included in each run.
Array-Comparative Genomic Hybridization (aCGH). aCGH 
was performed using the Agilent SurePrint G3 Human 
Genome microarray 180 K (Agilent Technologies, Santa 
Clara, CA), an oligonucleotide microarray containing 
approximately 180,000 probes 60-mer with a 17 kb aver-
age probe spacing. Genomic DNA from the patient was co-
hybridized with a male control DNA (Agilent Technologies). 
Labeling was performed using the Agilent Genomic DNA 
enzymatic labeling kit according to the manufacturer’s 
instructions. After hybridization, the aCGH slide was 
scanned on an Agilent scanner, processed with Feature 
Extraction software (v10.7) and results were analyzed 
using Cytogenomics (v2.9.1.3) using ADM2 as aberration 
algorithm.
Results
At diagnosis, banding cytogenetics at low resolution did not 
show any chromosomal aberrations. However, after sub-
jecting the cytogenetic preparations in retrospective to 
FISH-banding probe-sets, mMCB identified a complex 
rearrangement for chromosome 11 involving reciprocal 
translocation and inversion (data not shown). The break-
points were determined in more detail by further FISH 
experiments, such as aMCB, using a chromosome 11 spe-
cific probe set (Fig. 1) and by locus-specific FISH probes at 
11p15.4 and 11q24.2 as shown in Table 1.
Additionally, dual-color FISH using a commercially avail-
able Break Apart Rearrangement probe specific for the MLL 
locus (LSI MLL) revealed an insertion of the 5′MLL gene into 
chromosome 4q21. According to the manufacturers of LSI 
MLL, a 350-kb portion (5’ region) centromeric of the MLL 
gene breakpoint cluster region was labeled in SpectrumGreen 
and includes exons 1–6, whereas the ~190-kb portion of the 3’ 
MLL region is labeled by SpectrumOrange; the latter remained 
on one of the two derivative chromosomes 11, while the 
green-labeled part of LSI MLL went to the der(4) (Fig. 2). 
This cryptic insertion was observed as signal splitting of the 
probe LSI MLL in 6/6 metaphases and 158/200 interphase-
nuclei. Thus, the 5′ MLL region was inserted most likely into 
the AFF1 gene in chromosome 4q21.
Table 1. Results of Locus-Specific Probes Used for Breakpoint Characterization.
Cytoband Location [hg18] Probe Result
3q12:2 Chr3:101,910,850-101,950,501 SPEC TFG signal on der(3); no split signal
4p11q11 Chr4:48,200,001-52,700,000 CEP4 signal on der(4); no split signal
11p15.4 Chr11:2,907,721-3,231,290 SHGC-84145 to RH75370 signal on der(11p) and (11q); split signal
11p15.4 Chr11:3,193,128-3,312,588 RP11-11A9 signal on der(11p) and (11q); split signal
11p15.4 Chr11:3,652,816-3,775,468 NUP98 n.a.
11p15.4 Chr11:3,573,461-3,758,006 RP11-120E20 signal on both der(11)
11p15.4 Chr11:3,694,708-4,295,038 D11S4525 to SHGC-79113 signal on both der(11)
11p15.5~p15.4 Chr11:2,755,275-2,927,014  RP11-81K4 signal on both der(11q); no split signal
11p15.5 Chr11:872,364-1,051,564 RP11-401C19 signal on both der(11q); no split signal
11p15.5 Chr11:135,611-335,808  D11S2071 signal on der(11p) and (11q); no split signal
11q23.3 Chr11:117,812,415-117,901,146  LSI MLL split signal on der(4) and der(11)
11q24.1 Chr11:120,790,892-120,960,991 RP11-142I2 signal on both der(11)
11q24.1 Chr11:121,326,327-121,516,640 RP11-166D19 signal on both der(11)
11q24.2 Chr11:123,265,105-123,469,312 RP11-485A5 signal on both der(11)
11q24.2 Chr11:124,585,478-124,761,531 RP11-100P11 signal on der(11q) and (11p); split signal
11q24.2 Chr11:125,827,475-126,006,340 RP11-432I22 signal on der(11q) and (11p); no split signal
11q24.3 Chr11:127,930,598-128,090,778 RP11-264E20 signal on der(11q) and (11p); no split signal
11q25 Chr11:133,964,875-134,130,595 RP11-267D5 signal on der(11q) and (11p); no split signal
11q25 Chr11:134,125,133-134,325,470 D11S1037 signal on der(11q) and (11p); no split signal
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The karyotype can be described as follows:
46,XX,der(4)(4pter->4q21.3::11q23.3->11q23.3::4q21.3-> 
4qter),
der(11)(11pter->11q23.3::11q23.3->11q24.2::11p15.4-> 
11pter), der(11)(11qter->11q24.2::11p15.4->11qter).
In summary, the present case presents genetic changes 
involving three chromosomes and five break events.
The breakpoints in 11q24.2 and 11p15.4 were further 
delineated by locus-specific probes, as summarized in Table 
1. The positions are given according to NCBI36/hg18, as a
number of the used BAC-probes could not be found in later 
genomic browser versions.
For 11q24.2, the break was narrowed down to lying 
between the positions 124,585,487 and 124,761,531; one 
OMIM gene is located there: PKNOX2 (PBX/KNOTTED 1 
HOMEOBOX 2). The breakpoint in 11p15.4 was found to 
be spanned by a probe from locus SHGC-84145 to locus 
RH75370 that was part of a dual color/Break Apart probe 
from Kreatech (The Netherlands) flanking the NUP98 gene 
(Fig. 3). Additionally, BAC RP11-11A9 showed a split sig-
nal and the position of the break event can be given between 
3,193,128 and 3,231,290; two OMIM genes are located 
there: MRGPRE and MRGPRG.
MLPA analysis showed no copy number variants; how-
ever, the array-CGH revealed an amplification of 83.4 Kb in 
the region of 3q12.2, which involves two genes, GPR128 
and TFG; the latter result was confirmed using locus-spe-
cific FISH probes, which showed intrachromosomal ampli-
fication in 12% of the interphase nuclei (data not shown).
Discussion
Structural chromosomal abnormalities can be readily 
detected by metaphase analysis or FISH in B-ALL. The 
most common balanced or unbalanced translocations have 
been correlated with variable prognostic significance. Here, 
included aberrations such as translocations t(4;11) (MLL/
AFF1), t(12;21) (ETV6/RUNX1), t(1;19) (E2A/PBX1), and 
t(9;22) (BCR/ABL) (Zhou et al. 2012; Pui et al. 2008). These 
alterations can be found in different incidences in childhood 
and adult B-ALL (Lazic et al. 2010).
In the present B-ALL case, a normal karyotype was ini-
tially reported, since the here-described translocation and 
insertion events were submicroscopic and only identifiable by 
a combination of different molecular (cyto)genetic approaches. 
Figure 1. Result of the aMCB probesets for chromosome 11. 
Characterization of the complex rearrangements occurring in 
the derivative chromosomes. A normal chromosome 11 pattern 
(topmost) is provided as a comparison to the two derivative 
patterns of chromosome 11.
Figure 2. LSI MLL Break Apart probe showed one yellow fusion 
signal, and split of green signal and orange signal. Surprisingly the 
5’MLL probe signal was inserted in a derivative chromosome 4.
Figure 3. POSEIDON NUP98 (11p15 Break probe) revealed a 
split of green signal upstream of the NUP98 gene (see Table 1) 
and translocation to 11q24 due to an inversion (see Table 1). 
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The main problems hampering banding cytogenetics are the 
well-known difficulties in obtaining evaluable metaphases 
with well-spread chromosomes instead of clumsy ones or 
those that appear fuzzy with indistinct margins (Othman et 
al. 2014; De Braekeleer et al. 2011).
The patient whose case is presented here had high counts of 
WBC and blast cells, with a pre-B phenotype (CD19+, CD10-) 
-hallmarks of patients carrying a translocation t(4;11). 
Unfortunately, these hints were not further followed initially.
The MLL gene plays an important role in normal hema-
topoietic growth and differentiation. Abnormalities to this 
region can occur very early in hematopoietic stem cell 
development (Ansari and Mandal 2010; Ferrando et al. 
2003). The translocation t(4;11)(q21;q23) is solely observed 
in B-ALL patients and presents in ~50% of MLL rearrange-
ments as well as in the ins(4;11)(q21.3;q23.3) insertion as a 
typical variant of this translocation. In addition, an absence 
or low expression of CD10- in BCP-ALL and a very high 
WBC count are particularly common with the translocation 
t(4;11)(q21;q23) (Woo et al. 2014; De Braekeleer et al. 
2011; Burmeister et al. 2009). MLL is well known to be 
rearranged in myeloid and lymphoid leukemia and can be 
classified into two groups. The first group includes MLL 
rearrangements, such as translocations or insertions, some 
of which are cryptic. These rearrangements result in the 
generation of in-frame fusion transcripts with various part-
ner genes, with more than 120 loci already identified. The 
second group comprises amplification of 11q23, leading to 
the presence of multiple copies of the MLL gene located 
either intrachromosomally as a homogeneously staining 
region (hsr), or extrachromosomally in double minutes 
(dmin) (Meyer et al. 2013; De Braekeleer et al. 2011). The 
prognosis of MLL rearrangements in infants (<1 year of 
age) is extremely poor due to a high risk of treatment fail-
ure. Young children (1 to <10 years) have a better response 
to therapy than infants. Finally, for adults, event-free sur-
vival (EFS) is seen in 80% of cases. In general, the out-
comes for adolescents and adults have improved 
significantly over time (van der Linden et al. 2009; Bassan 
2005; de Bont et al. 2004; Pui et al. 2002; Morel et al. 2003). 
The present case, which involves 3 chromosomes and 5 
break events in connection with an MLL gene rearrange-
ment, is more complex than other comparable cases, but 
still belongs to the aforementioned first group.
Interestingly, it is considered that the fusion product of 
MLL-AFF1 is transcribed from the der(4) and not from the 
der(11), which supports the idea that the MLL-AFF1 is a 
protein with oncogenic potential. A review of the literature 
revealed that 10 cases with an insertion of chromosome 11 
material in chromosome 4 have been identified in six chil-
dren (all females) and four adult (3 elderly females and one 
male) B-ALL patients (Mitelman et al. 2014). Still, no other 
comparable cases have shown an additional reciprocal 
translocation between the two homologous chromosomes 
11 and amplification in 3q12.2.
The chromosomal breakpoint 11p15 is recurrently 
involved in translocations in acute leukemia. The gene 
NUP98 can fuse with DOX10 in 11q22 or with MLL in 
11q23 in acute myeloid leukemia (AML) (Kaltenbach et al. 
2010; Romana et al. 2006). In the present case, the break-
point at 11p15.4 involved two other genes MRGPRE and 
MRGPRG, which are related to the MAS1 oncogene and 
mainly expressed in sensory neurons. The proteins derived 
from the MRG gene contain transmembrane, extracellular, 
and cytoplasmic domains that regulate nociceptor function 
(Dong et al. 2001). In the second breakpoint observed here, 
11q24.2, there is only one OMIM gene located: PKNOX2. 
PKNOX2 belongs to a homeodomain protein superfamily 
comprising a large number of sequence-specific transcrip-
tion factors that share a highly conserved DNA-binding 
domain; they play fundamental roles in cell proliferation, 
differentiation, and death (Imoto et al. 2001). Thus, it can be 
speculated that MRGPRE and/or MRGPRG fused with 
PKNOX2 may lead to gene expression with oncogenic 
potential.
In the present case, it remains rather unclear which of the 
rearrangements—MLL with MRGPRE and/or MRGPRG, 
fusion of MLL with AFF1 or 3q12.2 amplification—were 
causative in the adverse outcome. In terms of the latter 
alteration, the TFG gene located at 3q12.2 is known to play 
a role in the NF-κB pathway and, thus, multiple copies of 
the gene may have contributed to oncogenic potential of the 
tumor cells. Indeed, translocations involving this gene have 
been observed in hematological malignancies (Chase et al. 
2010).
Overall, this case shows that it is necessary to screen 
for further unbalanced submicroscopic abnormalities by 
molecular approaches such as MLPA and aCGH in acute 
leukemia. The present report highlights that MLL gene 
rearrangements should be considered and tested by molec-
ular approaches in case of a normal cytogenetic result. 
This holds especially true for such patients with a BCP-
ALL who are diagnosed as a result of high WBC counts 
and CD10-negative staining. However, if, in such cases, 
MLL rearrangements are detected, further cryptic aberra-
tions with potential influence on the disease may be pres-
ent. Overall, a normal routine chromosome banding 
karyotype in acute leukemia needs to be considered as a 
stimulus and reason for more detailed molecular (cyto)
genetic analyses.
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Abstract. Cytogenetic classiication of acute lymphoblastic leukemia (ALL) is primarily based on numerical and struc-tural chromosomal abnormalities. In T-cell ALL (T-ALL), chromosomal rearrangements are identiied in up to 70% of the patients while the remaining patients show a normal karyotype. In the present study, a 16-year-old male was diag-nosed with T-precursor cell ALL and a normal karyotype after standard GTG-banding, was studied retrospectively (>10 years after diagnosis) in frame of a research project by molecular approaches. In addition to molecular cyto-genetics, multiplex ligation-dependent probe ampliication (MLPA) and high resolution array-comparative genomic hybridization (aCGH) were also applied. Thus, the following yet unrecognized balanced chromosomal aberrations were detected: der(3)t(3;5)(p23;q31.1), der(5)t(3;5)(p23;q35.3), der(5)t(5;10)(q31.1;p12.3) and der(10)t(5;10)(q35.3;p12.3). The oncogene MLLT10 was involved in this rearrangement as was the IL3 gene; in addition, trisomy 4 was present. All of these clonal aberrations were found in 40% of the cells. Even if this complex karyotype would have been identiied at the time of diagnosis, most likely no other protocol of anticancer therapy (ALL-BFM 95) would have been applied. Three months after the end of a successful 2-year treatment, the patient suffered from isolated bone marrow relapse and died of sepsis during ALL-REZ-BFM protocol treatment.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia derived from malignant transformation of T cell progenitors and is more common in males than in females. T-ALL affects mainly older children and adolescents and represents 10-15% of pediatric and 25% of young adult ALL cases (1). Hyperdiploidy (>46 chromosomes) is found in 30% of childhood and 10% of adulthood ALL cases. Notably, high hyperdiploidy (51-65 chromosomes) has been connected with high survival rates and excellent outcome (2,3), while low hyperdiploidy (47-50 chromosomes) has been associated with worse prognosis (4). The most commonly gained chromosomes in ALL are #4, #6, #10, #14, #17, #18, #21 and X (5). Trisomy 4 is rarely observed as a sole cytogenetic abnormality in T-ALL (6). However, the mechanism for chromosomal gains in ALL and their role in leukemogenesis are still ambiguous (7,8). In hyperdiploid karyotypes, the t(9;22)(q34;q11), 11q23 (MLL gene) rearrangements, t(12;21)(p13;q22), t(1;19)(q23;p13) and t(8;14)(q24;q32) are the most common structural cytogenetic abnormalities in ALL. However, in T-ALL, involvement of the T cell receptor (TCR) gene in 14q11 in rearrangements such as t(1;14)(p31;q11), t(10;14)(q24;q11) or t(8;14)(q24;q11) are frequently observed; also del(6)(q15) and del(1)(p32) have been described (3,9-11).Still, cryptic structural chromosomal abnormalities were and are a challenge in the cytogenetics of T-ALL. For example, as the cryptic t(5;14)(q35;q32) is known to be present in ~20% of childhood and in 13% of adult T-ALL cases, this aberra-tion is currently routinely tested by molecular (cyto)genetics, addressing the breakpoint on the TLX3 (HOX11L2) gene in 5q35 and to the promoter of the BCL11B gene in 14q32 (12). In addition, recent reports on newly detected cryptic chromo-somal rearrangements such as the MLLT10 gene (previously 
AF10, in 10p13), and MLL (in11q23) or PICALM (in 11q14) highlight the necessity to further study clinical cases as detailed as possible (13,14). The goal of these studies must be, on the one hand, to provide the most accurate diagnosis to each 
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individual patient and, on the other hand, to achieve insights into the biology and pathogenesis of T-ALL.In the present study, an adolescent T-precursor cell ALL case with an MLLT10 and IL3 gene rearrangement together with trisomy 4 in complex four-way translocation is character-ized in detail retrospectively using molecular cytogenetics and molecular genetics. This leukemia subtype would currently be classiied as early T-cell precursor ALL (15-17).
Case report
Clinical description. A 16-year-old male presented in 1998 for diagnostics due to fever and unclear symptoms of malaise. Immunophenotypic analysis of bone marrow cells revealed the following results: HLA-dR+, TdT+, cyCd3+, Cd5 weak, Cd7+, Cd8+, Cd10+, Cd13+, Cd33+ and Cd34+. This supported a diagnosis of early T-ALL; at present, it would be classiied as early T-cell precursor ALL (Fig. 1A).The patient was treated according to the ALL-BFM 95 protocol; the continuation therapy was completed 24 months after the initial diagnosis. Three months later an isolated bone 
marrow relapse with acute thrombocytopenia was diagnosed, and treatment according to the ALL-REZ-BFM protocol was initiated. one month later the patient died due to an Aspergillus sepsis and still with 100% blasts in the bone marrow.
Tests conducted at diagnosis. Banding cytogenetic analysis was performed on an unstimulated bone marrow aspirate according to standard procedures. A total of 20 metaphases were available for cytogenetic evaluation and analyzed on a banding level of 300 bands per haploid karyotype (22). GTG-banding revealed a normal male karyotype in our labora-tory, and also a second cytogenetic analysis on 25 metaphases performed 4 months after the initial diagnosis in another labo-ratory conirmed this test result. Molecular diagnostic PCR tests for gene fusions BCR/ABL, MLL/AF4 and TEL/AML1 were negative (data not shown).
Test conducted in retrospect
Molecular cytogenetics. Fluorescence in situ hybridization (FISH) was performed according to standard procedures and/or according to the manufacturer's instructions.
Figure 1. (A) Early T-cell precursor ALL cells of the presented patient depicted after Pappenheim staining. (B) Application of M-FISH revealed derivative chromosomes 3, 5, 5 and 10 (arrows). (C) mMCB results are shown as an overlay of three of the six used color channels. Evaluation was carried out as previ-ously reported (21) using all 6 color channels and pseudocoloring. Breakpoints were determined as 3p23, 5q31.1, 5q35.3X and 10p12.3. (d) aMCB probesets for chromosomes 3, 5 and 10 conirmed the observed breakpoints after mMCB application. The breakpoint in 5q35.5 was conirmed by a subtelomeric probe 5qter. 
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The following homemade probes and probe sets were used: i) 24-color-FISH using all human whole chromosome painting (WCP) probes (19); ii) FISH-banding probe sets as follows: genome-wide multitude multicolor banding (mMCB) and chromosome-specific high resolution array-proven multicolor banding (aMCB) (20-22); iii) dNA from bacterial artiicial chromosome (BAC) probes (Table I) obtained from Resources Center (oakland, CA, uSA) were labeled by PCR with SpectrumGreen, Spectrumorange or TexasRed-duTP and applied in two- or three-color FISH approaches.
Additionally, the following commercially available probes were used: LSI EGR1/d5S23, d5S721 (EGR1 in 5q31; d5S23, d5S721 in 5p15.2; Abbott Molecular/Vysis, Mannheim, Germany), PoSEIdoN PdGFRB (5q33 Break probe; Kreatech diagnostics, Amsterdam, The Netherlands), and subtelomeric probes for 3p, 5p, 5q and 10p (3p in d3S4559; 5p in C84c11/T3, 5q in d5S2907; 10p in Z96139; Abbott Molecular/Vysis).A total of 10-15 metaphase spreads were analyzed, using a luorescence microscope (Axio Imager Z1 mot; Carl Zeiss AG) equipped with appropriate ilter sets to discriminate between 
Table I. Results of the locus-speciic probes used for breakpoint analyses in metaphase FISH are listed.
Cytoband Position [hg18] Genes/locus Probe Results (signals on…)
3pter chr3:131,486-331,767 d3S4559 3pTEL (Vysis) der(5)t(3;5)
3p24.1 chr3:30,275,517-30,447,565 n.d. RP11-69K20 der(5)t(3;5)
3p24.1 chr3:30,541,893-30,705,070 STT3B RP11-7I16 der(5)t(3;5)
3p22.3 chr3:32,453,732-32,650,841 GPD1L RP11-524o15 der(5)t(3;5)
GADL1
OSBPL10
CMTM7
CMTM8
3p22.2 chr3:38,928,115-39,088,251 n.d. RP11-159A17 der(3)t(3;5)
5q22.2 chr5:112,073,070-112,236,540 n.d. RP11-107C15 der(5)t(5;10)
5q23.1 chr5:117,308,035-117,479,091 n.d. RP11-567A12 der(5)t(5;10)
5q23.3 chr5:126,045,879-126,232,850 n.d. RP11-434d11 der(5)t(5;10)
5q23.3~q31.1 chr5:130,306,745-130,460,728 5' of IL3 RP11-114H7 der(5)t(5;10)
5q31.1 chr5:131,424,246-131,426,795 IL3 n.a. n.a.
5q31.1 chr5:131,817,004-131,977,063 3' of IL3 RP11-729C24 der(3)t(3;5)
5q31.1 chr5:135,739,999-135,916,051 n.d. RP11-114H21 der(3)t(3;5)
5q31.2 chr5:137,829,080-137,832,903 EGR1 LSI EGR1 der(3)t(3;5)
5q32.1 chr5:149,473,595-149,515,615 PdGFRB PoSEIdoN der(3)t(3;5)
PdGFRB
(Kreatech)
5q35.1 chr5:170,996,421-171,159,856 n.d. RP11-20o22 der(3)t(3;5) and der(5)t(3;5)
5q35.2 chr5:173,985,900-174,153,222 n.d. RP11-47J7 der(3)t(3;5) and der(5)t(3;5)
5q35.2 chr5:175,502,694-175,558,904 n.d. RP11-844P9 der(3)t(3;5) and der(5)t(3;5)
5q35.3 chr5:176,550,923-176,735,050 n.d. RP11-265K23 der(3)t(3;5) and der(5)t(3;5)
5q35.3 chr5:178,243,600-178,455,573 5' HNRNPH1 RP11-281o15 der(3)t(3;5) and der(5)t(3;5)
5q35.3 chr5:178,973,785-178,983,328 HNRNPH1 n.a. n.a.
5q35.3 chr5:179,360,362-179,524,360 3' HNRNPH1 RP11-39H3 der(5)t(5;10) and der(5)t(3;5)
5q35.3 chr5:180,142,710-180,335,838 n.d. RP11-516K1 der(5)t(5;10) and der(5)t(3;5)
5qter chr5:180,510,748-180,711,420 d5S2907 5pTEL (Vysis) der(5)t(5;10) and der(5)t(3;5)
10pter chr10:292,280-292,670 Z96139 10pTEL (Vysis) der(5)t(3;5)
10p12.31 chr10:20,782,567-20,938,614 n.d. RP11-51E20 der(5)t(3;5)
10p12.31 chr10:21,321,413-21,495,264 5' MLLT10 RP11-165o3 der(5)t(3;5)
10p12.31 chr10:21,863,580-22,072,560 MLLT10 n.a. n.a.
10p12.31 chr10:22,399,352-22,575,929 3' MLLT10 RP11-108B14 der(5)t(5;10)
n.d., not determined; n.a., not available.
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a maximum of ive luorochromes and the counterstain dAPI (diaminophenylindol). Image capturing and processing were carried out using an ISIS imaging system (MetaSystems, Altlussheim, Germany).
DNA isolation. Genomic dNA was extracted from cells ixed in acetic acid-methonal (1:3) using the Puregene dNA puriication kit (Gentra Systems, Inc., Minneapolis, MN, uSA). dNA concentration was determined by a Nanodrop spectrophotometer. The quality of dNA was checked using agarose gel electrophoresis. dNA samples extracted from ixed cells of 2 healthy males and 2 healthy females by the same method were used as reference samples.
Multiplex ligation-dependent probe ampliication (MLPA). The P377-A1 hematologic malignancies probemix and SALSA reagents were used for the present study (MRC-Holland, Amsterdam, The Netherlands). Ampliied probes and 
GeneScan 500 RoX standard were separated by capillary electrophoresis using a 4-capillary ABI PRISM 3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA, uSA). Sizing of peaks and quantiication of peak areas and heights were performed using the GeneMarker v1.9 software (Applied Biosystems). A minimum of 4 healthy control samples were included in each run.
High resolution array-comparative genomic hybridization (aCGH). aCGH was performed using the Agilent SurePrint G3 Human Genome Microarray 180K (Agilent Technologies, Santa Clara, CA, uSA), an oligonucleotide microarray containing ~180,000 probes 60-mer with a 17-kb average probe spacing. Genomic dNA of the patient was co-hybridized with a male control dNA (Agilent Technologies). Labeling was performed using the Agilent Genomic dNA Enzymatic Labeling kit (Agilent Technologies) according to the manufac-turer's instructions. After hybridization, the aCGH slide was scanned on an Agilent scanner, processed with the Feature Extraction software (v.10.7) and results were analyzed using Cytogenomics (v2.9.1.3) using AdM2 as aberration algorithm.
Results of the retrospective analyses. Genome-wide 24-color FISH using all human WCP probes and FISH-banding anal-ysis using the mMCB probe set were applied as initial tests in this retrospective case. Thereby, a previously unrecognized numerical aberration, trisomy 4, and balanced translocations were identified between one chromosome 3 and 10, each, and both chromosomes 5. overall, an abnormal karyotype was characterized as 47,Xy,+4,der(3)t(3;5)(p23;q31.1),der(5)t(3;5)(p23;q35.3), der(5)t(5;10)(q31.1;p12.3),der(10)t(5;10)(q35.3;p12.3)[8]/46,Xy[13] (Fig. 1B and C).Chromosome-specific aMCB confirmed these results (Fig. 1d) and locus-specific probes narrowed down the breakpoints according to NCBI36/hg18 as follows (Table I). i) The breakpoint in 3p23 was determined between the posi-tions 30,705,070 and 32,453,732; 6 oMIM genes are located there: STT3B, GPD1L, GADL1, OSBPL10, CMTM7 and 
CMTM8. ii) The breakpoint 5q31.1 locates between positions 130,460,728 and 131,817,004 and those lank the gene IL3 (interleukin 3 precursor) in 131,424,246-131,426,795. iii) The second breakpoint on chromosome 5 in subband q35.3 was 
mapped to positions 178,455,573 to 179,360,362; here the 
HNRNPH1 (heterogeneous nuclear ribonucleoprotein H1) gene is included in 178,973,785-178,983,328. iv) Finally, the breakpoint in 10p12.3 was narrowed down to localize between positions 21,495,264 and 22,399,352, where the MLLT10 (myeloid/lymphoid or mixed-lineage leukemia) gene has been mapped to 21,863,580-22,072,560.No submicroscopic changes were detected by MLPA and aCGH; only the trisomy 4 was observed in aCGH (data not shown).
Discussion
Chromosomal translocations in ALL may be missed in banding karyotyping due to several reasons. They may be cryptic, as they are not resolvable due to a similar or identical GTG-banding pattern; an example is the t(12;21)(p13;q22) in childhood ALL (23). In addition, known aberrations may be masked in a complex karyotype (24). Finally, it may simply be dificult to obtain evaluable metaphases where chromosomes are well-spread and not clumsy or appearing as fuzzy with indistinct margins (25). In the present case the latter was the major problem. In the reanalyses, all well-spread metaphases were normal and all aberrant metaphases were clumsy and not evaluable in standard GTG-banding. Thus, cytogenetic analyses in two different laboratories missed the aberra-tions present in this case. otherwise gross structural and a numerical aberration would not have been overlooked like in this case which were detected in retrospect by molecular cytogenetics.Trisomy 4 as a sole abnormality is rare in acute myeloid leukemia (AML) (26) but is scarce in ALL and is not asso-ciated with a clear prognosis (6,27,28). In pediatric ALL, trisomy 4 has been reported to be associated with a favorable outcome suggesting that children who have trisomies of both chromosomes 4 and 10 may have a particularly low risk of treatment failure (3,5). Here, trisomy 4 was observed together with additional structural chromosomal aberrations. Most likely the oncogene MLLT10 in 10p12.31 was activated by the strong promoter of HNRNPH1 in 5q35.3. In addition, the translocation of 5q31.1 to 3p23 brought in close proximity the 
gene IL3, which has been shown to have an oncogenic effect on hematopoietic cells (29), to 6 oMIM genes listed in Table I, which could also potentially lead to overexpression of IL3.
MLLT10 gene. Rearrangements have previously been identiied in both child and adulthood acute leukemia (30). The t(10;11) is a recurrent reciprocal translocation present in two common variants: t(10;11)(p12;q23) and t(10;11)(p12;q21); the latter tending to be more frequent in T-ALL patients (31). In addi-tion, the t(10;11)(p12;q23) mainly found in childhood AML is rarely observed in B-ALL and T-ALL (32). The MLLT10 gene encodes a leucine zipper protein that functions as a transcrip-tion factor. MLLT10 gene rearrangements are associated with a poor outcome due to the poor response to therapy (33,34). 
HNRNPH1 gene. While unbalanced structural aberration of chromosome 5 are common in myelodysplastic syndrome or AML (35,36), they are less common in ALL. Still Brandimarte et al (14) previously identiied the HNRNPH1 
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gene as a new MLLT10 fusion partner in pediatric T-ALL, as we observed in our case of T-precursor cell ALL.
IL3 gene. Located in 5q31.1, the IL3 gene is a multipotent hematopoietic growth factor produced by activated T cells (37). Its involvement in malignancies was previously reported in B-ALL cases due to a t(5;14)(q31;q32). overexpression of IL3 was associated with unfavorable outcome in such cases (38).
3p23 region. Six oMIM genes are located in the breakpoint region of chromosome 3 in subband p23. These include: STT3B (source of immunodominant MHC-associated), 
GPD1L (glycerol-3-phosphate dehydrogenase 1-like), GADL1, (glutamate decarboxylase-like 1), OSBPL10 (oxysterol-binding protein-like protein 10), CMTM7 (CKLF-like MARVEL transmembrane domain containing 7) and CMTM8 (CKLF-like MARVEL transmembrane domain containing 8). It is dificult to determine which one might have provided a strong promoter for IL3 gene expression.In conclusion, the study in particular of ALL cases with unexpectedly adverse outcome in retrospect and in detail by high resolution molecular approaches is warranted. In the present case the combination of FISH-banding, FISH with locus-speciic probes and aCGH revealed trisomy 4 but apart from that a balanced aberrant karyotype, explaining the severe course of the disease in this case with adverse outcome. Even if this complex karyotype would have been identiied at the time of diagnosis most likely no additional therapy other than the applied protocol (ALL-BFM 95) would have been used. yet, the recurrence may have been detected much earlier in the case of available cytogenetic markers. Thus, the most compre-hensive molecular (cyto)genetic analyses should be offered to each individual ALL case. Even though aCGH would not have detected the balanced translocations, the detectable trisomy 4 would have hinted at the malignant clone missed by banding cytogenetics. In conclusion, the present case is the irst one presenting with combined trisomy 4 with a four-way transloca-tion activating IL3 together with MLLT10.
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An adult B-cell precursor acute lymphoblastic
leukemia with multiple secondary cytogenetic
aberrations
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Abstract
Background: We report a clinically diagnosed acute lymphoblastic leukemia (ALL) with yet unreported secondary
chromosomal aberrations.
Results: A complete cytogenetic and molecular cytogenetic analysis, using GTG banding, fluorescence in situ
hybridization (FISH) and array-proven multicolor banding (aMCB), for a female patient with clinically diagnosed
ALL and immunophenotypically confirmed pre-B ALL (FAB classifications), revealed the presence of a complex
structural rearrangement, der (2) (20qter- > 20q13.33::2q21- > 2p14::2q21 > 2qter) along with t (9;22) (q34;q11),
t (12;14) (q12;p12) and a monosomy of chromosome 7.
Conclusions: Molecular cytogenetic studies are suited best for identification and characterization of chromosomal
rearrangements in acute leukemia. Single case reports as well as large scale studies are necessary to provide further
insights in karyotypic changes taking place in human malignancies.
Keywords: Acute lymphoblastic leukemia, Secondary chromosomal abnormalities, Philadelphia chromosome,
Fluorescence in situ hybridization, Array-proven multicolor banding, Prognostic factors
Background
Acute lymphoblastic leukemia (ALL) is a heterogeneous
disease characterized by multiple subtypes [1]. To date,
several structural and numerical chromosomal abnor-
malities have been characterized in ALL and according
to the WHO classification the following, seven genetic
subtypes are defined for B lymphoblastic leukemia, t
(9:22) (q34;q11.2), 11q23 traslocations, t (12;21) (p13;q22),
t (1;19) (q23;p13.3), t (5;14) (q31;q32), hyperdiploidy and
hypodiploidy [2]. Among the genetic subtypes, Philadel-
phia (Ph) chromosome, which results from a reciprocal
translocation between Abelson (ABL1) from chromosome
9 and breakpoint cluster region (BCR) from chromosome
22, is the most frequent cytogenetic aberration which is
found in ~ 25% of adult ALL cases, and in more than 50%
of patients, aged 50 years or more [3,4]. The presence of
the BCR-ABL1 rearrangement worsens the prognosis of
ALL and represents the most significant adverse prognos-
tic marker that influences the disease outcome [5]. Ph
positive (Ph+) ALL is a more aggressive disease than
chronic myeloid leukemia (CML), indicating that other
factors than BCR-ABL1 are involved in its development
and progression [5,6]. Ph + precursor-B-ALL is highly ag-
gressive, frequently resistant to chemotherapy and with a
short survival time [6,7]. Here, we are presenting a Ph +
pre-B-ALL case with yet unreported translocation events
involving six different chromosomes and a monosomy 7.
These chromosomal rearrangements appeared after un-
successful chemotherapy treatment.
Case presentation
A 31-year-old woman was diagnosed as suffering from
ALL in September 2011. Anemia, thrombocytopenia, diar-
rhea, fatigue and weight loss were the indicative symp-
toms. She was treated as follows: after the first GM-ALL
protocol (phase I and II) failed, Flag-IDA protocol was
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used, which also did not succeed. Then again GM-ALL
protocol (phase I and II) was applied and after being un-
successful hyper-CVAD was applied. At this point the first
cytogenetics and hematology were determined. The
patient's hematologic parameters were white blood cells
(WBC) at 123×109/l, consisting of 12% neutrophils, 75%
lymphocytes, 11% monocytes and 1% basophiles. Red
blood cell (RBC) count was 3.26×106/mm3, hemoglobin
level 9.7 g/dl and the platelet count 34×109/l. Serum lac-
tate dehydrogenase (LDH) value was 2,712 U/l (normal
value up to 480 U/l), serum alkaline phosphates value 208
U/l (normal value up to 128 U/l), serum alanine amino-
transferase 198 U/l (normal value up to 40 U/l) and serum
aspartate aminotransferase value 139 U/l (normal value
up to 40 U/l). The patient was treated further according
to standard ALL chemotherapy protocols for fourteen
months, however, without clinical success of chemother-
apy. Unfortunately she died under the treatment.
Results
A sample of a female patient diagnosed as pre B-ALL,
according to FAB classifications, was received after the
completion of three different protocols of chemotherapy.
The conventional cytogenetics analysis by GTG banding
revealed the karyotype as 45, XX, -7, der (2) t (2;20)
(?;?), t (9;22) (q34;q11), t (12;14) (q?;p?) [12] / 46, XX, t
(12;14) (q?;p?) [10] (Figure 1). The dual color FISH using
the probe specific for BCR and ABL and WCP probes
specific for chromosomes 2, 7, 12, 14 and 20 confirmed
the presence of BCR/ABL fusion on der (22) (data not
shown), and the presence of the other rearrangements.
To further characterize the breakpoints, aMCB was
performed, as previously reported [8] (Figure 2) and the
final karyotype was redefined as: 45, XX,-7, der (2)
(20qter- > 20q13.33::2q21- > 2p14::2q21 > 2qter), t (9;22)
(q34;q11), t (12;14) (q12;p12) [12] / 46, XX, t (12;14)
(q12;p12) [10].
The abnormal cell population showed the following
immunophenotype, which was consistent with pre-B-
ALL (FAB classifications): CD45+, HLADr+, CD117+,
CD34+, CD19+, CD10+, CD38+ and expressed CD123
and CD11c (52%) heterogeneously. The abnormal cells
negatively reacted with antibodies to CD5, CD64 and
CD3.
Conclusions
We characterized a Ph + adult pre-B-ALL case with a
complex secondary chromosomal abnormality, a trans-
location and a monosomy 7. According to the literature,
not a single case of ALL showed a der (2) (20qter- >
20q13.33::2q21- > 2p14::2q21- > 2qter) plus a t (12;14)
(q12;p12) [9]. Moreover, a t (12;14) (q12;p12) was ob-
served only in two cases of mantle cell lymphoma [9]
and in a case of acute myeloid leukemia [10]. On the
other hand, the chromosomal bands, 2p14, 2q21, 12q12,
and 14p12 are listed in 5, 32, 20, and 4 cases, respect-
ively, in other rearrangements involving different chro-
mosomes than the ones which are involved in the
present case, in previously reported ALL cases [9]. In
addition, inv (2) with 2q21 as one of the breakpoints has
also been reported in 3 cases of ALL [9].
Till date, several chromosomal aberrations such as t
(9;22), t (4;11), t (1;9), and hyperdiploid or hypodiploid
karyotype have been associated with the prognostic
Figure 1 GTG-banding revealed a 45, XX-7, der (2) t (2;20), t (9;22), t (12;14). All derivative chromosomes are shown with arrows.
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outcome in ALL cases. Apart from t (9;22) (q34;q11)/
BCR-ABL and t (4;11) (q21;q23)/MLL-AF4, an elevated
white blood cell count, age over 40 and non-responders/
slow responders to chemotherapy are commonly
regarded as high risk criteria in ALL [11]. Monosomy 7,
as a sole secondary abnormality, is also related with a
poor prognosis and shorter survival in adult ALL cases
[12,13]. In addition, deletions of 7p confer with an infer-
ior outcome in children with ALL, regardless of the
presence of other poor prognostic features, whereas de-
letions of 7q are not associated with an adverse outcome
[14]. The tendency for an adverse prognosis in patients
with secondary loss of chromosome 7 or 7p in Ph + ALL
may be the cumulative result of these events. Mullighan
et al. [15] recently described a deletion of IKZF1 gene
which encodes the transcription factor Ikaros, located
on 7p12 in 83.7% of Ph + ALL cases but not in chronic-
phase CML, suggesting that loss of Ikaros, a prototypical
member of the Krüppel-like zinc finger (ZnF) transcrip-
tion factor subfamily, which is required for normal
hematopoietic differentiation and proliferation, particu-
larly in lymphoid lineages, [16-18] is an important step
in the progression of Ph + ALL. Recently, two of seven
myeloproliferative neoplasms patients with loss of IKZF1
due to monosomy 7 have also been reported which sug-
gests that IKZF1 may represent an important tumor-
suppressor gene affected by monosomy 7 [19].
The presence of the underlying BCR/ABL gene re-
arrangement in CD10 B-cell precursor ALL has been
reported previously [20] and it has already been demon-
strated that the occurrence of BCR-ABL positive ALL in
comparison to BCR-ABL negative disease represents a
subgroup with a worse prognosis within the CD10+ B-
lineage ALL [21].
In conclusion, the present case is a de novo case of
adult pre-B-ALL with yet unreported translocation
events involving six different chromosomes in addition
to monosomy 7.
Materials and methods
Chromosome analysis
Chromosome analysis using GTG-banding was performed
according to standard procedures [22] 12 months after ig-
nition of the chemotherapeutic treatment. A minimum
of 20 metaphase cells derived from unstimulated bone
marrow culture were analyzed. Karyotypes were de-
scribed according to the International System for Hu-
man Cytogenetic Nomenclature [23].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using LSI
BCR/ABL three-color dual-fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA) was
applied according to manufacturer's instructions together
Figure 2 Array-proven multicolor banding (aMCB) was applied to characterize the breakpoint locations. Each image shows the results of
MCB analysis using probe sets for chromosomes 2, 9, 12, 14, 20 and 22. The normal chromosomes are shown in the left side of each image and
the derivative chromosomes on the right. The MCB-probes unstained regions on the derivative chromosomes are shown in gray. Abbreviations:
# = chromosome; der = derivative chromosome; Ph = Philadelphia chromosome.
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with a whole chromosome painting (WCP) probe for chro-
mosomes 2, 7, 12, 14 and 20 (MetaSystems, Altlussheim,
Germany) [22]. FISH using the corresponding chromosome
specific array-proven multicolor banding (aMCB) probe
sets based on microdissection derived region-specific librar-
ies was performed as previously reported [8]. A minimum
of 20 metaphase spreads were analyzed, using a fluores-
cence microscope (AxioImager.Z1 mot, Carl Zeiss Ltd.,
Hertfordshir, UK) equipped with appropriate filter sets to
discriminate between a maximum of five fluorochromes
plus the counterstain DAPI (4',6- diamino-2-phenylindole).
Image capture and processing were performed using an
ISIS imaging system (MetaSystems).
Flow cytometric immunophenotype
Flow cytometric analysis was performed using a general
panel of fluorescent antibodies against the following an-
tigens typical for different cell lineages and cell types:
CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD138, CD209,
CD235a and CD243; In addition to antibodies to Kappa
and Lambda light Chains, IgD, sIgM, and HLADr. All
antibodies were purchased from BD Biosciences. Sam-
ples were analyzed on a BD FACSCalibur™ flow cyt-
ometer. Autofluorescence, viability, and isotype controls
were included. Flow cytometric data acquisition and
analysis were conducted by BD Cellquest™ Pro software.
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Acute leukemia oten presents with pure chromosomal resolution; thus, aberrations may not be detected by banding cytogenetics.
Here, a case of 26-year-old male diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) and a normal karyotype ater
standard GTG-banding was studied retrospectively in detail by molecular cytogenetic and molecular approaches. Besides
luorescence in situ hybridization (FISH), multiplex ligation-dependent probe ampliication (MLPA) and high resolution array-
comparative genomic hybridization (aCGH) were applied. hus, cryptic chromosomal aberrations not observed before were
detected: three chromosomes were involved in a cytogenetically balanced occurring translocation t(2;9;18)(p23.2;p21.3;q21.33).
Besides a translocation t(10;14)(q24;q11) was identiied, an aberration known to be common in T-ALL. Due to the three-way
translocation deletion of tumor suppressor genes CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, andMTAP/ARF/p14 in 9p21.3 took
place. Additionally RB1 in 13q14 was deleted. his patient, considered to have a normal karyotype ater low resolution banding
cytogenetics, was treated according to general protocol of anticancer therapy (ALL-BFM 95).
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is a quite rare
and heterogeneous disease, more common in males than in
females. It accounts for 15% of childhood and 25% of adult
ALL cases [1]. Underlying genetic causes of T-ALL are poorly
understood and this is highlighted by the fact that T-ALL is
associated with a normal karyotype in 30–50% of the cases [2,
3]. In abnormal karyotypes recurrent chromosomal aberra-
tions are reported [4]. Regularly, promoter and enhancer ele-
ments of genes involved in T-cell development are juxtaposed
with translocations in close proximity of oncogenes [5, 6].he
most common structural chromosomal abnormalities in T-
ALL are TCR (T-cell receptor) loci rearrangements. Break-
points in 14q11 (TCRA/D) and 7q34 (TCR�) are observed
frequently. Besides, deletions in the long arm of chromosome
6 may be found; the common deleted region involves mainly
subband 6q16; however, candidate gene(s) have not been
formally identiied yet [7, 8]. Also tumor suppressor genes
have been seen to be involved in T-ALL [9].
Cryptic structural chromosomal abnormalities are still
a challenge in cytogenetic standard diagnostics of acute
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leukemia. However, many cryptic aberrations have been
identiied by molecular cytogenetics already. Examples in
T-ALL are cryptic deletions in 9p21 involving the genes
CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, and MTAP/
ARF/p14 leading to loss of G1 checkpoint control of the cell
cycle or the RB1 locus in 13q14, which also plays a role as
tumor suppressor gene in cell cycle regulation [9].
Here, a case of a young adult T-ALL patient with a novel
cryptic three-way translocation, a reciprocal translocation,
and submicroscopic deletions is reported.
2. Material and Methods
2.1. Clinical Description. A 26-year-old male presented in
1998 initially with a total white blood cell count of 20.2 ×
109/L, hemoglobin of 9.2mmol/L, and platelets of 126 ×
109/L. Bone marrow examination was consistent with T-ALL
having 91% blast cells. According to low cytometry the
immunophenotype of bone marrow lymphocytes was as
follows: the cells were positive for CD2 (96%), CD8 (96%),
CD4 (92%), CD7 (92%), CD1A (89%), CD10 (87%), CyCD3
(86%), and TdT (85%) and negative for �F1, �F1, CD3, CD13,
CD19, CD20, CD24, CD33, CD34, HLA-DR, MPO-7, slg,
TZR-�/�, and TZR�/�. he patient was treated according
to ALL-BFM 95 protocol and died eight months ater initial
diagnosis from serious infections and severe complications
while being in complete hematological remission.
2.2. Test Done at Diagnosis. GTG-banding was done accord-
ing to standard procedures. A total of 7 metaphases were
available for cytogenetic evolution derived from unstimu-
lated bone marrow of the patient and were analyzed on
a banding level of 180–250 bands per haploid karyotype
[11] and determined as 46,XY [7, 12]. RT-PCR performed
for TEL/AML1 and BCR/ABL fusion genes was reported to
be negative and luorescence in situ hybridization (FISH)
analysis carried out according to manufacturer’s instructions
for the same loci was negative (probes used: LSI BCR/ABL
and LSI TEL/AML1, Abbott Molecular/Vysis, Mannheim,
Germany).
2.3. Test Done in Retrospective
2.3.1. Molecular Cytogenetics. FISH was done according to
standard procedures and manufacturer’s instructions for the
following commercially available probes: LSI 13 in 13q14.2
(RB1, Abbott Molecular/Vysis, Mannheim, Germany), LSI
IGH/BCL2 (IGH in 14q32; BCL2 in 18q21, Abbott Molec-
ular/Vysis, Mannheim, Germany), SPEC ALK/2q11 (ALK
in 2p23, Zytovision GmbH, Bremerhaven, Germany), SPEC
p16/CEN9 (p16 in 9p21.3, Zytovision GmbH, Bremer-
haven, Germany), SPEC BIRC3/MALT1 (BIRC3 in 11q22.2,
MALT1 in 18q21.32, Zytovision, Bremerhaven, Germany), and
POSEIDONMLL/MLLT3 (MLL in 11q23.3,MLLT3 in 9p21.3;
Kreatech Diagnostics, Amsterdam, Netherland).
Whole chromosome painting (WCP) probe for chromo-
somes 2, 9, 10, 14, and 18 and bacterial artiicial chromo-
some probes (BACs) for chromosomes 2 and 9 (Table 1)
were homemade [13]. he homemade multitude multicolor-
banding (mMCB) and chromosome speciic high resolution
array-proven multicolor-banding (aMCB) probe sets were
also applied as previously reported [10, 14, 15].
A total of 10–15 metaphase spreads were analyzed,
using a luorescence microscope (AxioImager.Z1 mot, Zeiss)
equipped with appropriate ilter sets to discriminate between
amaximumof ive luorochromes and the counterstain DAPI
(Diaminophenylindol). Image capturing and processing were
carried out using an ISIS imaging system (MetaSystems,
Altlußheim, Germany).
2.3.2. DNA Isolation. GenomicDNAwas extracted from cells
ixed in acetic acid :methanol (1 : 3) by Puregene DNA Purii-
cation Kit (Gentra Systems, Minneapolis, MN, USA). DNA
concentration was determined by a Nanodrop spectropho-
tometer. he quality of DNA was checked using agarose gel
electrophoresis. DNA samples extracted from ixed cells of 2
healthymales and 2 healthy females by the samemethodwere
used as reference samples.
2.3.3. Multiplex Ligation-Dependent Probe Ampliication
(MLPA). he P377-A1 hematologic malignancies probemix
and SALSA reagents were used for this study (MRC-Hol-
land, Amsterdam, he Netherlands). Ampliied probes and
Genescan 500ROX standardwere separated by capillary elec-
trophoresis using a 4-capillary ABI-PRISM 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, USA). Sizing of
peaks and quantiication of peak areas and heights were
performed using GeneMarker v1.9 sotware (Applied Biosys-
tems). A minimum of 4 healthy control samples were includ-
ed in each run.
2.3.4. High Resolution Array-Comparative Genomic Hybridi-
zation (aCGH). aCGH was performed using Agilent Sure-
Print G3 Human Genome microarray 180K (Agilent Tech-
nologies, Santa Clara, CA, USA), an oligonucleotidemicroar-
ray containing approximately 180,000 probes 60-mer with a
17 kb average probe spacing. Genomic DNA of patient was
cohybridized with a male control DNA (Agilent Technolo-
gies, Santa Clara, CA, USA). Labeling was performed using
Agilent Genomic DNA enzymatic labeling kit (Agilent)
according to the manufacturers’ instructions. Ater hybridi-
zation, the aCGH slide was scanned on an Agilent scanner
and processed with Feature Extraction sotware (v10.7) and
results were analyzed using Cytogenomics (v2.9.1.3) using
ADM2 as aberration algorithm.
3. Results of Retrospective Analysis
As an initial test of retrospective analysis a genome wide
FISH-banding applying mMCB was performed. hereby, a
previously unrecognized reciprocal and apparently balanced
translocation between the three chromosomes 2, 9, and
18 was identiied. Besides a known recurrent translocation
of chromosomes 10 and 14 was recognized and the kary-
otype was suggested as 46,XY,t(2;9;18)(p23.2;p21.3;q21.33),
t(10;14)(q24;q11) (Figure 1). aMCB and WCP probes as
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Table 1: (a) Probes used for characterization of the three-way translocation, their location, and obtained results. (b) Probes used for
characterization of the in aCGH detected deletions, their location, and obtained results.
(a)
Cytoband Location [hg19] Probe Result for derivative chromosomes
2p24.3
chr2:
RP11-119F22 Signal on der(9); no split signal
16,014,784–16,140,647
2p23.3
chr2:
RP11-106G13 Signal on der(9); no split signal
26,967,697–27,136,688
2p23.2
chr2:
SPEC ALK Signal on der(9); no split signal
29,415,640–29,447,593
9p22.1
chr9:
RP11-503K16 Signal on der(18); no split signal
18,717,972–18,718,524
9p22.1
chr9:
RP11-513M16 Signal on der(18); no split signal
19,371,384–19,371,943
9p21.3
chr9:
RP11-15P13 Signal on der(18); no split signal
20,182,493–20,361,132
9p21.3
chr9:
MLLT3 MLLT3-gene signal on der(18); no split signal
20,344,968–20,621,872
9p21.3
chr9:
SPEC p16 Deletion on der(9) and/or der(18)
21,967,751–21,975,132
9p21.3
chr9:
RP11-946B6 Deletion on der(9) and/or der(18) ish 9p21.3(RP11-946B6x0)[8]
23,608,612–23,790,449
9p21.2
chr9:
RP11-438B23 Signal on der(9); no split signal
27,937,615–27,944,495
18q21.32
chr18:
MALT1 MALT1-gene signal on der(18); no split signal
56,338,618–56,417,370
18q21
chr18:
BCL2 BCL2-gene signal on der(2); no split signal
60,985,282–60,985,899
(b)
Cytoband Location [hg19] Probe Result for derivative chromosomes
9p21.3
chr9:
21,967,751–21,975,132
SPEC p16
ish 9p21.3(p16x1)[4]
nuc ish 9p21(p16x0)[64]/9p21(p16x1)[83]/
9p21(p16x2)[53]
13q14.2
chr13:
48,920,000–49,140,000
LSI 13 = ��1
nuc ish 13q14.2(��1x0)[36]/
13q14.2(��1x1)[43]/
13q14.2(��1x2)[121]
shown in Figure 2 conirmed these suggestions. Locus
speciic probes narrowed down the breakpoints as shown
in Table 1(a). Unfortunately there was no suicient cell
pellet available to characterize the breakpoints in more
detail than listed in Table 1(a). Even though closely located
to the observed chromosomal breakpoints, direct involve-
ment of the following oncogenes was excluded using
locus speciic FISH-probes for ALK in 2p23.2, MLLT3 in
9p21.3, and MALT1 and BCL2 in 18q21.33. However, MLPA
(result not shown) and aCGH (Figure 3) revealed that the
t(2;9;18) is not really balanced: a deletion in 9p21.3 includ-
ing CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, andMTAP/
ARF/p14 could be found as chr9: 21,252,517–21,798,676x1
and 21,817,082–23,515,821x0 (hg19) (Figure 3; Table 1(b)).
Moreover, a deletion in 13q14.2 was detected as chr13:
48,982,000–49,062,000x1 (hg19, Figure 3). FISH showed a
mosaic condition of mixed heterozygous and homozygous
deletion of 9p21.3 and 13q14.2 (Table 1(b)).
4. Discussion
Chromosomal translocations are considered to be the pri-
mary cause of leukemia for both acute and chronic phase. In
this study, we retrospectively identiied previously undetected
balanced and unbalanced chromosomal and subchromoso-
mal changes by application of molecular cytogenetics includ-
ing FISH-banding, locus-speciic FISH-probes, and aCGH
plus MLPA. FISH-banding, especially mMCB, allows the
identiication of balanced and unbalanced inter- and intra-
chromosomal rearrangements of the whole human karyotype
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Figure 1: Application of mMCB showed no normal karyotype
but derivative chromosomes 2, 9, 10, 14, and 18 (arrows). mMCB
results are shown as overlay of three of the six used color channels.
Evaluation was done as previously reported [10] using all 6 color
channels and pseudocoloring. Breakpoints were determined as
2p23.2, 9p21.3, 10q24, 14q11, and 18q21.33.
in one single experiment [10]. It might be indicated to apply
mMCBor comparable FISH-banding approaches routinely in
T-ALL cases exhibiting poor quality of the metaphase, that
is, not well spreading ones with chromosomes appearing as
fuzzy with indistinct margins [16, 17].
In this study one well-known and one yet unreported
balanced translocation event were identiied for a T-ALL
as t(10;14)(q24;q11) and t(2;9;18)(p23.2;p21.3;q21.33), respec-
tively. While a direct involvement of the cancer-related
oncogenes ALK in 2p23.2, MLLT3 in 9p21.3, and BCL2 in
18q21.33 could be excluded, loss of two tumor suppresser gene
loci in 9p21 and in 13q14 was found.
Data from the literature conirmed that the oncogenes
tested and located nearby the chromosomal breakpoints of
the three-way translocation were not yet found to be involved
in T-ALL: ALK located in 2p23.2 was previously detected in
a variety of B- and T-cell lymphomas and nonhematopoietic
solid tumors [18–23], the BCL2 gene is overexpressed in
lymphomas [24, 25], and theMLLT3 genewas one of themost
highly upregulated transcripts and the most common fusion
partner of MLL in de novo acute myeloid leukemia (AML)
subtype M5 and therapy-related AML [26–28]; however,
Meyer et al. [29] found that MLLT3 also plays a role in
pediatric rather than adult ALL.
In the present case, an additional chromosomal translo-
cation t(10;14)(q24;q11), known as sole abnormality in 10%
of T-ALL patients, was identiied. Also it is present in 5% of
pediatric and 30% of adult T-ALL [20, 30, 31]. he TLX1 gene
at 10q24 is a transcription factor becoming overexpressed as
oncogene due to its juxtaposition to a strong promoter and
enhancer elements of the TCR loci at 14q11 [5, 32–34]. A
favorable outcome was reported in pediatric and adult T-ALL
MCB 2
MCB 9
MCB 18
Normal der(2) der(9) der(18)
(a)
wcp10
wcp14
der(14)der(10)#10 #14
(b)
Figure 2: (a) Results of aMCB probe sets for chromosomes 2, 9, and
18 are shown in pseudocolor depiction, which conirmed the char-
acterization of these three chromosomes involving rearrangement
as t(2;9;18)(p23.2;p21.3;q21.33). (b)Whole chromosomepaints (wcp)
for chromosomes 10 and 14 conirmed that the t(10;14)(q24;q11) was
independent of the t(2;9;18).
to be associatedwith the t(10;14) or TLX1 gene overexpression
[5, 20, 35].
Even though balanced rearrangements are known to be
typical for hematopoietic malignancies to date, only a limited
number of studies have used whole genome directed FISH
approaches to identify cryptic chromosomal abnormalities
in ALL patients [36–38]. Still, in ALL it is uncommon to
see three-way translocations. However, due to lowmetaphase
resolution in ALL the real incidence of three-way transloca-
tions is currently unknown.
he present report highlights that ater identiication
of apparently balanced chromosomal aberrations, it is still
necessary to screen for further unbalanced submicroscopic
abnormalities by molecular approaches such as MLPA and
aCGH. However, also a conirmation of the results by molec-
ular cytogenetics is necessary, as aCGH was partially mis-
classiied a mix of homo- and heterozygote deletions as pure
homozygote ones.
9p21.3 deletions, which lead to the loss of CDKN2A/
INK4A/p16, CDKN2B/INK4B/p15, and MTAP/ARF/p14
tumor suppressor genes expression, are the most predomi-
nant aberrations seen in precursor B-cell ALL (∼20% of the
cases) and T-ALL (>60% of the case) [39–42]. Besides also
a deletion of RB1 gene resulting in inactivation of another
tumor suppressor gene expression was identiied. RB1 is
rarely reported to be deleted in T-ALL. In contrast, deletion
of RB1 has been detected in 30% of B-ALL and nearly to 60%
in B-CLL cases [43, 44]. hus, RB1 pathway was identiied as
potential targets for therapy of ALL [45, 46].
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Figure 3: aCGH conirmed deletions in 9p21.3 and 13q14.2 (arrows) detected initially byMLPA (result not shown). FISH conirmed presence
of these deletions in metaphase and/or interphase. Examples for heterozygote deletions of 9p21.3 and 13q14.2 are depicted; probes speciic for
the corresponding tumor suppressor genes were labeled in red; centromeric probe for chromosome 9 (D9Z3) was labeled in green.
5. Conclusion
In conclusion, we report a case of T-ALL with complex chro-
mosomal aberrations. Even if at time of diagnosis the deletion
on 9p21.3 would have been detected and accordingly treated,
it remains unclear what inluence the other tumor suppres-
sors and oncogenes (possibly) activated by the complex rear-
rangements would have had for the clinical outcome. Overall,
the present case stresses the necessity to study hematological
malignancies by diferent means to get a comprehensive pic-
ture of the genetic changes in connection with the acquired
disease, as aCGH or MLPA alone would only have identiied
the imbalanced rearrangements, while molecular cytogenet-
ics predominantly gave hints on the presence of balanced
rearrangements.
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Abstract 
Acquired copy number changes are common in acute leukemia. They are reported as 
recurrent amplification or deletion and may be indicative for involvement of oncogenes or 
tumor suppressor genes in the acquired disease and can serve as potential biomarkers for 
prognosis or even as a target for molecular therapy. Here, we report a gain of copy 
numbers of 14q13 to 14q32 leading to an IGH@ locus splitting in a young adult female, 
present as a yet unreported rearrangement in B-cell acute lymphoblastic leukemia (B-
ALL). Low resolution banding cytogenetics at the time of diagnosis revealed a normal 
karyotype. However, retrospective application of fluorescence in situ hybridization- 
(FISH-) banding, locus specific FISH-probes, as well as multiplex ligation-dependent 
probe amplification and high resolution array-comparative genomic hybridization revealed 
previously cryptic aberrations. Overall a karyotype 46,XX,del(9)(p21.3p21.3),der(14)(pter-
>q32.33::q32.33->q13::q32.33->qter) was determined. The patient was treated according 
to PALG 5-ALL7-3 protocol and achieved complete remission. These findings indicate 
that a favorable prognosis is linked to these aberrations under the mentioned treatment. 
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Introduction  
B-cell acute lymphoblastic leukemia (B-ALL) is a malignant neoplasm derived from B-cell 
progenitors. It is the most common malignancy in pediatric patients, accounting for up to 
80% of childhood leukemia. Thus, it is the leading cause of cancer-related death in 
children and young adults (1-2).  
Rearrangements involving the immunoglobulin heavy chain (IGH@) locus on 
chromosomal band 14q32.33 are rare in B-ALL, occurring in <5% of the childhood cases 
and detected in approximately 10% of adult patients (3-4). IGH@ rearrangements occur 
more frequently in adolescent and appear to have a favorable clinical outcome. The same 
holds true for such cases of B-ALL associated with genetic aberrations like deletion in 
9p21.3 (CDKN2A/B) and 9p13.3 (PAX5) (5). In B-ALL, the most common IGH@ 
rearrangement is translocation to partner genes like C-MYC in 8q24 as the well 
characterized translocation t(8;14)(q24.1;q32). Another possible partner is the inhibitory 
transcription factor ID4 in 6p22 being cytogenetically visible as translocation 
t(6;14)(q32;p22). The translocation t(14;19)(q32;q13) leads to overexpression of the CEBP 
(CCAAT/enhancer binding protein) gene family, the translocation t(5;14)(q31;q32) 
involves IL3 in 5q31, and the translocation t(X;14)(p22;q32) or translocation 
t(Y;14)(p11.2;q32) result in deregulated expression of CRLF2 (cytokine receptor-like 
factor 2). Translocations between IGH@ and EPOR (erythropoietin receptor) in 19p13 
have also been reported together with other translocations appearing less frequently (6-8). 
In all of these translocations an oncogene located near the breakpoint of the translocation 
partner is activated by juxtaposing to IGH@ regulatory sequences (4). Interestingly, all 
rearrangements involving IGH@ at 14q32.33 have unique biological characteristics and 
correlate with clinical, morphological, and immunophenotypic features.  
Cryptic deletions in chromosomal band 9p21.3 involve the CDKN2A gene which encodes 
for two transcripts: p16/INK4A and p14/ARF, and the CDKN2B gene (p15/INK4B). Their 
functions in cell cycle are to control the transition of G1 phase to S phase. The size of 
9p21.3 deletions in ALL patients seem to vary substantially, but in most cases CDKN2A is 
co-deleted with CDKN2B and MTAP (9-11). 
We report here a new IGH@ rearrangement in a young adult of B-ALL associated with 
deletion in CDKN2A/B. The way how the chromosome 14 rearrangement may have been 
evolved is also discussed.  
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Material and Methods  
Clinical description 
A 20-year-old female presented in 2008 with white blood cell (WBC) count of 3.7x109/l, 
hemoglobin of 11.0 mmol/l and platelets of 334 x109/l. In bone marrow about 93% of blast 
cells were observed. Immunophenotype was characterized by the expression of a variety of 
B-cell-specific antigens being positive for CD10, CD19, CD22, CD34, CD38, CD45, 
CD52, CD79a, TdT, HLA-DR, and being negative for CD2, CD15, CD20, CD33, CD56, 
CD66c, and cIgM. These findings were consistent with common acute B-cell 
lymphoblastic leukemia (B-ALL).  
The patient was treated by induction therapy according to PALG 5-ALL7-3 (Epirubicin, 
Vincristine, PEG Asparaginaza, steroids), two courses of consolidation and maintenance 
treatment. From December 2011 till to date patient is under the observation in out-patient 
clinic with complete remission 1 (CR) and without signs for mininal residual disease 
(MRD). 
 
Cytogenetic results at diagnoses 
Banding cytogenetic analyses was performed on unstimulated bone marrow aspirate 
according to standard procedures (12). A total of 25 metaphases were available for 
cytogenetic evaluation and analyzed on a banding level of 300 bands per haploid karyotype 
(13). GTG-banding revealed a normal female karyotype as 46,XX. 
 
Retrospective analyses 
Molecular cytogenetics 
Fluorescence in situ hybridization (FISH) was done according to standard procedures 
and/or according to manufacturer’ s instructions.  
Homemade were the following probes and probe sets:  
- BAC (bacterial artificial chromosome) clones of interest were identified through the 
Human Genome Browser Database of the Genome Bioinformatics Group at the University 
of California at Santa Cruz (http://genome.ucsc.edu/) and Ensembl Genome Data 
Resources of the Sanger Institute Genome Database (http://www.ensembl.org/). DNA 
probes (Table 1) obtained from Resources Center (Oakland, USA) were labeled by PCR 
with SpectrumGreen, SpectrumOrange or TexasRed-dUTP and applied for two- or three-
color FISH-approaches. 
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- FISH-banding probe-sets as follows: genome wide multitude multicolor banding 
(mMCB) and chromosome specific high resolution array-proven multicolor-banding 
(aMCB) (14-16).  
Additionally, commercially available probes were used: LSI IGH (14q32 Break probe, 
Abbott Molecular/Vysis, Mannheim, Germany), POSEIDON p16 (9p21 and 9q21 Control 
probe, Kreatech Diagnostics, Amsterdam, Netherland), SPEC ERG/TMPRSS2 TriCheck™ 
Probe (ERG in 21q12.13-q22.3, TMPRSS2 in 21q22.3 Zytovision, Bremerhaven, 
Germany), and subtelomeric probe for 14q (14q in D14S1420, Abbott Molecular/Vysis, 
Mannheim, Germany). 
A total of 10-15 metaphase spreads were analyzed, using a fluorescence microscope 
(AxioImager.Z1 mot, Zeiss) equipped with appropriate filter sets to discriminate between a 
maximum of five fluorochromes and the counterstain DAPI (Diaminophenylindol). Image 
capturing and processing were carried out using an ISIS imaging system (MetaSystems, 
Altlussheim, Germany). 
 
DNA isolation  
Genomic DNA was extracted from cells fixed in acetic acid-methonal (1:3) by Puregene 
DNA Puriﬁcation Kit (Gentra Systems, Minneapolis, MN, USA). DNA concentration was 
determined by a Nanodrop spectrophotometer. The quality of DNA was checked using 
agarose gel electrophoresis. DNA-samples extracted from fixed cells of 2 healthy males 
and 2 healthy females by the same method were used as reference samples. 
 
Multiplex ligation-dependent probe amplification (MLPA)  
The P377-A1 Hematologic malignancies probemix and SALSA reagents were used for this 
study (MRC- Holland, Amsterdam, The Netherlands). Ampliﬁed probes and Genescan 500 
ROX standard were separated by capillary electrophoresis using a 4-capillary ABI-PRISM 
3130XL Genetic Analyzer (Applied Biosystems, Foster City, USA). Sizing of peaks and 
quantification of peak areas and heights were performed using GeneMarker v1.9 software 
(Applied Biosystems). A minimum of 4 healthy control samples were included in each run. 
 
High resolution array-comparative genomic (aCGH)  
aCGH was performed using Agilent SurePrint G3 Human Genome microarray 180 K 
(Agilent Technologies, Santa Clara, CA, USA), an oligonucleotide microarray containing 
approximately 180,000 probes 60-mer with a 17 kb average probe spacing. Genomic DNA 
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of patient was co-hybridized with a male control DNA (Agilent Technologies, Santa Clara, 
CA, USA). Labeling was performed using Agilent Genomic DNA enzymatic labeling kit 
(Agilent) according to the manufacturers’  instructions. After hybridization, the aCGH slide 
was scanned on an Agilent scanner, processed with Feature Extraction software (v10.7) 
and results were analyzed using Cytogenomics (v2.9.1.3) using ADM2 as aberration 
algorithm. 
 
Results  
G-banding at a low resolution did not show any chromosomal aberrations. Retrospective 
application of mMCB revealed only one gross chromosomal alteration, an inverted 
duplication on a chromosome 14. To characterize the rearrangement in more detail further 
FISH experiments like aMCB for chromosome 14 (Fig. 1A) and locus-specific FISH 
probes (Tab. 1) were applied revealing a which der(14)(pter->q32.33::q32.33-
>q13::q32.33->qter). 
Dual-color-FISH using a commercial available break apart rearrangement probe specific 
for IGH, both interphase nuclei and metaphases studies revealed splitting of IGH variable 
region (IGHV) and 3′ flanking region, both located downstream to the IGH locus (results 
not shown). MLPA analysis showed heterozygous deletion of p16/INK4A, p15/INK4B and 
p14/ARF and confirmed by interphase FISH (iFISH – results not shown).  
aCGH revealed two large genomic imbalances: a gain of 70.6 Mb in the region of 14q13.2-
q32.3 between the positions (GRCh37/hg19) 35,918,265 and 106,513,022 and loss of 3 Mb 
in the region of 9p21.3 between the positions 21,252,517 and 24,289,720. Both findings 
are compatible with FISH and MLPA result (Fig. 1C).   
Besides, aCGH revealed five small genomic imbalances with loss of copy number variants 
in: 
- 3q26.32 between the positions 176,825,586 and 177,697,157; 1 OMIM gene is 
located there: TBL1XR1;  
- 10p15.3 between the positions 1,491,986 and 1,582,072; 2 OMIM genes are located 
there: ADARB2 and NCRNA00168; 
- 16q13 between the positions 57,275,940 and 57,331,381; 2 OMIM genes are 
located there: ARL2BP and PLLP; 
- 21q22.2 between the positions 39,764,621 and 39,865,171; 1 OMIM gene is located 
there: ERG; 
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- Xq13.3 between the positions 47,330,212 and 47,335,227; 1 OMIM gene in is 
located there: ZNF41 (results not shown). 
 
Discussion  
Copy number variants of specific target genes are important in the development and 
progression of acute leukemia and may serve as potential biomarkers for prognosis and/or 
as targets for molecular therapy. Gene amplification is an important mechanism of 
oncogene activation in acute leukemia. However, it is difficult to identify or resolve 
genomic imbalances less than 10 Mb in size by banding cytogenetics due to poor quality of 
chromosomes being often not well-spread and clumsy or appearing as fuzzy with indistinct 
margins. Thus, molecular cyto(genetic) approaches such as FISH, MLPA, and aCGH have 
been shown to be potent means for detection of previous cryptic genomic imbalances (7; 
17). Consequently, application of aforementioned approaches unraveled here a yet 
unreported genomic imbalance in a B-ALL case as 46,XX,del(9)(p21.3p21.3),der(14)(pter-
>q32.33::q32.33->q13::q32.33->qter). The characterization of that aberration revealed the 
involvement of the cancer-related oncogene IGH@ at 14q32.33 being critical in 
leukaemogenic process (4). 
Inversions (inv) within the long arm of a chromosome 14 are common karyotypic 
abnormalities in T-cell lymphoid malignancies like T-chronic lymphocytic leukemia 
(CLL) and adult T-cell leukemia. In contrast, in B-cell lineage ALL inv(14)(q11q32) 
involving CEBPE and IGH@ is an exceedingly rare phenomenon associated with better 
prognosis and repeatedly reported with complete remission (4; 18-19). The good outcome 
of the present cases thus fits in that line. 
To the best of our knowledge a derivative chromosome 14 like the here reported one has 
not been seen in ALL yet. In Fig. 1B a suggestion is depicted how the rearrangement might 
have happened. As it is a rearrangement involving an interstitial part of the long arm of 
chromosome 14, U-type exchange mechanisms as reported in comparable cases from 
clinical genetics (20) can be discarded. 
Homozygous deletions of tumor suppressor genes p16/INK4A, p15/INK4B and p14/ARF at 
9p21 represent a marker of unfavorable outcome. Thus the heterozygote deletion seen in 
the present case may be a hint for a careful follow-up of the patient, especially as there are 
hints that the prognosis is here closely linked to and depend on the treatment received (6-
10).  
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Finally, the present patient showed copy number changes of five regions with yet unclear 
clinical significance. The identification of new copy number change can lead to 
identification of functional important genes in leukemogenesis:  
• Deletion of TBL1XR1 gene on 3q26.32 has been recently detected in ETV6-RUNX1 
positive ALL, primary central nervous system lymphomas and diffuses B large cell 
lymphoma. Remarkably, TBL1XR1 is widely expressed in hematopoietic tissues 
and may play a key regulatory role in the NF-kappaB pathway, hence suggesting 
that TBL1XR1 could have a potential biological role in ALL pathogenesis (21-22).  
• ADARB2 at 10p15.3 encodes a member of the double-stranded RNA adenosine 
deaminase family of RNA-editing enzymes and may play a regulatory role in RNA 
editing and function as tumor suppressor gene. Overall, reduction of RNA level of 
ADARB2 due to a deletion may favor cancer development and progression (23-24).  
• Also a recurrent deletion was found on 21q22.22 targeting exclusively ERG. ERG 
gene is a transcriptional factor which belongs to the erythroblast transformation-
specific (ETS) family. The latter has a key regulatory role in hematopoietic 
differentiation during early T and B cell development. Overexpression of ERG gene 
was shown in acute myeloid leukemia and T-ALL and was associated with poor 
prognosis. Currently, deletion of ERG gene associated with a very good outcome in 
older children and young patient with BCP-ALL, as also seen in our case with 
complete remission and without MRD (25-26).  
• Submicroscopic losses of ARL2BP, PLLP and ZNF41 genes were reported here for 
the first time in ALL. ARL2BP is a member of ARF family of RAS-related 
GTPases and has an essential role in photoreceptor maintenance and function. 
Homozygous mutation in ARL2BP gene was identified in retinitis pigmentosa with 
or without situs inversus (27). Overexpression of PLLP gene has been detected in 
malignant pleural mesothelioma (28). ZNF41 is a transcription factor belongs to a 
cluster of human zinc finger genes on chromosome Xp11.23. Mutations in ZNF41 
gene was identified in X-linked mental retardation (29). 
Overall, we found unbalanced acquired gross and submicroscopic rearrangements in a case 
of B-ALL not reported before in this unique combination. The clinical consequences of the 
individual changes remain to be determined in detail. However, it is noteworthy that 
treatment according to PALG 5-ALL7-3 protocol achieved complete remission. 
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Conclusion  
Molecular cyto(genetic) approaches are a helpful tool for identification of cryptic 
rearrangements and potential new target genes for leukemogenesis and progression of the 
disease as well as for clinical outcome and treatment options. Our results suggest that, the 
detection of submicroscopic alterations in B-ALL such as deletion of TBL1XR1, 
CDKN2A/B and ERG genes with a good outcome would be useful for diagnosis and risk 
stratification, especially in future protocols that include B-ALL patients. 
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Table 1 
Used probes, their location and obtained results are listed according to GRCh37/hg19. 
Cytoband Location [GRCh37/hg19] Probe  Result 
3q26.32 chr3: 177,272,863-177,430,308 RP11-114M1 
deletion on der(3)  
ish     3q26.3(RP11-114M1x1)[5] 
3q26.32 chr3: 177,488,843-177,646,481 RP11-91K9 
deletion on der(3)  
ish     3q26.3(RP11-91K9)[5] 
9p21.3/ 
 
9p11.1q11 
chr9: 
21,967,751-21,975,132 
chr9: 
47,300,001-50,700,000 
SPEC p16/ 
 
CEN9 
deletion on der(9)  
ish        9p21.3(p16x1)[8] 
nuc ish 9p21(p16x1)[147]/ 
9p21(p16x2)[53] 
14q11.2 chr14: 20,814,125-20,814,672 RP11-332N6 1 signal on der(14)  
14q11.2 chr14: 20,940,682-21,103,092 RP11-14J7 1 signal on der(14)   
14q12 chr14:  29,511,827-29,698,386 RP11-125A5 1 signal on der(14)   
14q13.1 chr14:  32,299,162-32,460,130 RP11-501E21 1 signal on der(14)   
14q13.2 chr14:  35,335,072-35,521,841 RP11-26M6 1 signal on der(14)   
14q13.3 chr14:  36,683,813-36,704,814 RP11-259K15 2 signals on der(14) 
14q21.1 chr14:  39,897,747-40,060,823 RP11-111A21 2 signals on der(14) 
14q21.1 chr14:  40,408,068-40,537,355 RP11-34O18 2 signals on der(14) 
14q21.3 chr14: 49,809,988-49,981,102 RP11-346L24 2 signals on der(14) 
14q21.3 chr14:  50,148,020-50,148,604 RP11-831F12 2 signals on der(14) 
14q23.1 chr14:  59,967,413-60,142,554 RP11-701B16 2 signals on der(14) 
14q24.2 chr14:  70,701,212-70,701,81 RP11-486O13 2 signals on der(14) 
14q31.1 chr14:  80,030,106-80,193,689 RP11-242P2 2 signals on der(14) 
14q32.3 chr14:  106,053,226-106,518,932 LSI IGH split signals on der(14) 
14qter chr14:  107,038,129-107,238,316 D14S1420 1 signal on der(14)   
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Figure 1 
A) Result of aMCB 14 probe set suggested the breakpoints of der(14) as 14q13 and 14q32.33; 
those were confirmed by locus-specific FISH probes as detailed in Tab. 1. For aMCB the 
normal (#14) and the derivative chromosome 14 (der(14)) is shown in pseudocolor banding 
pattern and the corresponding underlying fluorochrome profiles. Schematic depiction of 
the der(14)(pter->q32.33::q32.33->q13::q32.33->qter) is also shown. 
B) A mode of formation for the der(14) from Fig. 1A is suggested in this self-explaining 
schematic drawing.  
C) aCGH revealed substantial genomic imbalances; loss in 9p21.3 detected initially by 
MLPA (result not shown) and gain of 14q13.2-q32.33 (arrows).  
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Abstract
Background: Acute lymphoblastic leukemia (ALL) is not a single uniform disease. It consists of several subgroups
with different cytogenetic and molecular genetic aberrations, clinical presentations and outcomes. Banding
cytogenetics plays a pivotal role in the detection of recurrent chromosomal rearrangements and is the starting
point of genetic analysis in ALL, still. Nowadays, molecular (cyto)genetic tools provide substantially to identify
previously non-detectable, so-called cryptic chromosomal aberrations in ALL. However, ALL according to banding
cytogenetics with normal karyotype - in short cytogenetically normal ALL (CN-ALL) - represent up to ~50 % of all
new diagnosed ALL cases. The overall goal of this study was to identify and characterize the rate of cryptic alterations
in CN-ALL and to rule out if one single routine approach may be sufficient to detect most of the cryptic alterations
present.
Results: Sixty-one ALL patients with CN-ALL were introduced in this study. All of them underwent high resolution
fluorescence in situ hybridization (FISH) analysis. Also DNA could be extracted from 34 ALL samples. These DNA-samples
were studied using a commercially available MLPA (multiplex ligation-dependent probe amplification) probe set directed
against 37 loci in hematological malignancies and/or array-comparative genomic hybridization (aCGH). Chromosomal
aberrations were detected in 21 of 61 samples (~34 %) applying FISH approaches: structural abnormalities were
present in 15 cases and even numerical ones were identified in 6 cases. Applying molecular approaches copy number
alterations (CNAs) were detected in 27/34 samples. Overall, 126 CNAs were identified and only 34 of them were
detectable by MLPA (~27 %). Loss of CNs was identified in ~80 % while gain of CNs was present in ~20 % of the
126 CNAs. A maximum of 13 aberrations was detected per case; however, only one aberration per case was found in 8
of all in detail studied 34 cases. Of special interest among the detected CNAs are the following new findings:
del(15)(q26.1q26.1) including CHD2 gene was found in 20 % of the studied ALL cases, dup(18)(q21.2q21.2) with
the DCC gene was present in 9 % of the cases, and the CDK6 gene in 7q21.2 was deleted in 12 % of the here in
detail studied ALL cases.
Conclusions: In conclusion, high resolution molecular cytogenetic tools and molecular approaches like MLPA
and aCGH need to be combined in a cost-efficient way, to identify disease and progression causing alterations in
ALL, as majority of them are cryptic in banding cytogenetic analyses.
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Background
Acute lymphoblastic leukemia (ALL) is a malignant dis-
ease of the hematological system with clonal proliferation
of lymphoid progenitor cells. It arises from genetic alter-
ations that block precursor B and T cell differentiation
and predominantly affects children [1]. B-ALL constitutes
80-85 % of ALL cases and T-ALL the remainder ones. B-
ALL patients have a favorable prognosis with an overall
complete remission rate of 95 % for pediatric (children
and adolescent between 1–15 years) but of only 60 % for
adults. Adverse prognosis in T-ALL was correlated with
presence of hyperleukocytosis, enhanced mediastinal
mass, central neural system involvement, male gender and
advanced age [1–5]. Cytogenetically detectable structural
or numerical chromosomal abnormalities are detected
in ~50 % of ALL cases. Such aberrations have prognos-
tic significance [1, 6]. High hyperdiploidy (51–65 chro-
mosomes) has been connected with good survival and
excellent outcome in B-ALL, while hypodiploidy (<44
chromosomes) has an adverse prognosis [7–9]. Recur-
rent structural chromosomal abnormalities found in
ALL can also be reciprocal translocations. ALLs with a
translocation t(12;21)(p13;q22) leading to the ETV6/
RUNX1 gene-fusion are more likely to be cured, than
those with a translocation t(9;22) or t(4;11), which tend
to have unfavorable outcomes. Complex karyotypes, in-
cluding three to five or more chromosomal abnormalities,
are typically found in ~5 % of ALL cases and are also asso-
ciated with an adverse outcome [10]. Finally, ALL cases
with according to banding cytogenetics normal karyotype -
in short cytogenetically normal ALL (CN-ALL) - are classi-
fied into intermediate risk group [6, 11, 12]. Malignant bone
marrow of T-ALL patients shows a normal karyotype more
frequently than those of B-ALL patients. Accordingly in
those cases cytogenetic markers cannot be determined and
therapeutic decisions may be hampered.
Based on the knowledge that chromosomes in ALL
show a low banding resolution and that a good part of
ALL cases present with a normal karyotype, it is not far
to seek, that small aberration can easily be missed
when analyzing ALL derived chromosomes by banding
cytogenetics alone [6, 13]. Copy number alterations
(CNAs) at the microscopic or submicroscopic level, i.e.
focal deletions, but also duplications or sequence/point
mutations in genes that primarily serve as transcrip-
tional regulators of the lymphoid developmental pathway
can nowadays be detected by approaches like multiplex
ligation-dependent probe amplification (MLPA) or array-
comparative genomic hybridization (aCGH) [12, 14, 15].
The present study includes 61 CN-ALL cases, which
were retrospectively studied for the rate of cryptic (sub)-
chromosomal changes to rule out if one single molecular
(cyto)genetic routine approach may be sufficient to de-
tect most if not all of the cryptic alterations present.
Results
Standard cytogenetic analysis by G-banding revealed
normal karyotypes in 61 ALL cases included in this
study (Additional file 1: Table S1). In a first step all 61
cases were studied by the whole genome oriented fluor-
escence in situ hybridization (FISH)-banding based probe
set multitude multicolor banding (mMCB) [16]. For fur-
ther delineation of mMCB results appropriate FISH-
probes and probe sets were applied (Additional file 1:
Table S1). Based on these results 21/61 (34 %) cases were
not cytogenetically normal but had gross acquired
chromosomal aberrations: structural abnormalities were
found in 15/61 cases (24 %) and even numerical ones were
observed in 6/61 cases (10 %) (Table 1). Overall, in GTG-
banding cryptic balanced and unbalanced translocations,
derivative chromosomes, isochromosomes, interstitial de-
letions, inverted duplications and/or numerical aberrations
were identified in 34 % of the studied CN-ALL cases by
means of molecular cytogenetics. In Fig. 1 case P66 is ex-
emplified with a three-way translocation between chromo-
somes #10, #11 and #14, inversion of second chromosome
# 14 and insertion (11;10). The breakpoints of this P66
case were characterized as 10p12.3, 10q11.23, 11p15.3,
11q23.3, 14q11, 14q24.2, and 14q32.3.
34/61 studied CN-ALL cases (18 B-ALL, 8 T-ALL and
8 with undefined ALL) were studied further using MLPA
and aCGH. Overall, 126 CNAs were detected by MLPA
and aCGH in those cases. CNAs were identified in 27/
34 (80 %) of the studied cases. 1 to 13 CNAs per case
were detected (Table 1). The distribution of CNAs per
chromosome and frequencies of gains and losses are
summarized in Fig. 2; i.e. all chromosomes apart from 8
and Y were involved in CNAs in this study.
Deletions and duplications could be grouped accord-
ing to their sizes as follows:
– focal CNAs (e.g. deletion of CHD2 gene in 7 cases
or duplication of DCC gene in 3 cases – Table 1);
– CNAs involving variable numbers of genes (e.g.
deletion on 9p21.3 in 8 cases or amplification of
9q34.12q34.13 in one case – Table 1);
– CNAs involving large parts of whole chromosomal p
and/or q arms (e.g. deletion on 4p16.3p14 in one case
or duplication of 7p22.3p14.1 in one case – Table 1)
– CNAs of whole chromosomes (e.g. monosomy X in
one case or trisomy #14 in one case – Table 1).
Most frequently observed deletion was 9p21.3 in 8/34
ALL cases (3x in B-ALL, 4x in T-ALL and 1x in undefined
ALL); the CDKN2A/B genes were affected in all these eight
cases. Furthermore, PTEN in 10q23.31 (6/34) and IKZF1 in
7p12.2 (5/34) were the hit by deletions regularly. Besides,
deletion in 15q26.1 (CHD2 gene) was detected in 7/34
cases and duplication in 18q21.2 (DCC gene) in 3/34 cases.
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients
Case number Age [y] Metaphase directed FISH MLPA LSPs for genes aCGH – affected
cytobands
Localization acc. to
GRCH37/hg19
Size of imbalance
[bp]
B-ALLs
P1 1 46,XX normal normal dup(11)(p15.5p15.4) chr11:1,960,555-3,626,932 1,666,377
P8 30 47,XY,+21[5]/46,XY[2] dup of 21q22.12 RUNX1: dup (72 %) n.d. n.d. n.d.
P13 34 46,XY[8] del of 10q23.3 del(10)(q23.2q23.31) chr10:88,906,902-91,189,599 2,282,697
del of 17p13.1 TP53: del (9 %) del(17)(p13.1p13.1) chr17:7,579,695-8,281,928 702,233
P17 27 46,XX[7] n.d. normal normal n.d. n.d.
P23 59 del(3)(p25.3p25.3) chr3:10,179,706-10,385,195 205,489
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,337,405-50,482,274 144,869
del(10)(q23.3q23.3) chr10:89,570,600-89,676,741 106,141
del(11)(q14.2q14.2) chr11:85,683,188-85,944,362 261,174
47,XX,+14[2]/ IGH: dup (58 %) +14 +14 107,349,540
46,XX[3] del(15)(q26.1q26.1) chr15:93,390,484-93,463,312 72,828
del(17)(p13.1p13.1) chr17:7,581,198-7,922,308 341,110
del(17)(q11.2q11.2) chr17:30,259,053-30,271,653 12,600
del(18)(q21.32q21.32) chr18:57,517,756-57,718,190 200,434
del(21)(q22.3q22.3) chr21:45,527,941-45,565,198 37,257
P28 84 46,XY, del of 7p12.2 del(7)(p12.2p12.2) chr7:50,353,062-50,444,269 91,207
t(9;22)(q34;q11), del of 9p21.3 CDKN2A/B: del (75 %) del(9)(pterp11.2) chr9:0–47,212,321 47,212,321
del(11)(q13q25)[7] del of 9p13.2 del(9)(q34.2qter) chr9:136,917,580-141,213,431 4,295,851
del(10)(q23.3q23.3) chr10:89,619,806-89,731,258 111,452
del of 11q22.3 BIRC3: del (75 %) del(11)(q13.2qter) chr11:67,773,863-135,006,516 67,232,653
ATM: del (77 %) del(15)(q26.1q26.1) chr15:93,412,860-93,450,773 37,913
MLL: del (80 %) dup(20)(q11.23q12) chr20:37,305,876-39,130,131 1,824,255
del(20)(q12q13.12) chr20:39,245,111-45,524,952 6,279,841
dup(20)(q13.12q13.12) chr20:45,524,953-45,780,811 255,858
del(20)(q13.12q13.32) chr20: 45,780,812-58,067,678 12,286,866
del(21)(q22.2q22.2) chr21:39,764,621-39,807,169 42,548
BCR: del (94 %) del(22)(q11.23q11.23) chr22:23,584,037-23,592,537 8500
P43 69 46,XX, normal TFG: dup (15 %) dup(3)(q12.2q12.2) chr3:100,360,682-100,444,109 83,427
der(4)(4pter- > 4q21.3::11q23.3- del(7)(q21.2q21.2) chr7:92,252,341-92,475,197 222,856
>11q23.3::4q21.3- > 4qter), MLL: ins (75 %)
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients
(Continued)
der(11)(11pter- >
11q23.3::11q23.3- >
11q24.2::11p15.4- > 11pter),
der(11)(11qter- >
11q24.2::11p15.4- > 11qter)[5]
P48 39 46,XY, n.d. del(6)(q13q14.2) chr6:73,331,571-84,140,938 10,809,367
t(6;11)(q15;p12), del(6)(q16.2q21) chr6:99,282,580-109,703,762 10,421,182
ins(6;11)(q22.1;q13q14), del(6)(q22.31q22.33) chr6:124,125,069-128,841,870 4,716,801
inv(6)(q15q25.3), ESR1: del (89 %) del(6)(q25.1q25.3) chr6:151,725,897-157,531,913 5,806,016
del(11)(q21q23.2)[8] del(7)(p12.2p12.2) chr7:49,991,954-51,207,236 1,215,282
dup(11)(p15.5p15.4) chr11:1,925,114-3,143,116 1,218,002
WT1: del (91 %) del(11)(p15.1p12) chr11:20,546,133-37,403,781 16,857,648
BIRC3: del (90 %) del(11)(q14.1q14.3) chr11:85,157,088-88,557,421 3,400,333
ATM: del (77 %) del(11)(q22.1q22.3) chr11:100,992,179-114,667,959 13,675,780
del(13)(q14.2q14.2) chr13:48,980,623-49,148,073 167,450
P49 39 46,XX[10] n.d. normal dup(11)(p15.5p15.4) chr11:2,016,406-3,430,378 3,430,378
P51 59 46,XX[6] normal normal del(10)(p12.1p12.1) chr10:28,057,099-28,220,314 163,215
del(15)(q26.1q26.1) chr15:93,412,860-93,450,773 37,913
del(X)(q21.1q21.1) chrX:76,875,639-77,157,819 282,180
P52 21 46,XY[4] normal del(6)(p21.1p21.1) chr6:45,395,872-45,409,919 14,047
del(7)(q21.2q21.2) chr7:92,149,393-92,495,958 346,565
del of 10q23.3 del(10)(q23.3q23.3) chr10:89,610,886-89,722,948 112,062
del(11)(q14.2q14.2) chr11:85,683,188-85,944,362 261,174
del(15)(q26.1q26.1)) chr15:93,433,130-93,450,773 17,643
del(17)(q23.1q23.1) chr17:57,698,768-57,913,528 214,760
del(20)(q13.2q13.2) chr20:52,151,411-52,629,609 478,198
del(X)(p22.33p22.33) chrX:1,327,561-1,684,270 1,684,270
P53 34 46,XY[5] normal normal dup(22)(q11.21q11.21) chr22:18,706,001-21,561,514 2,855,514
P55 19 46,XY[6] del of 17p13.1 TP53: del (100 %) del(17)(pterp11.2) chr17:0–20,219,464 20,219,464
−20 −20 63,025,520
P56 47 45,XY,-21[2]/ normal normal del(12)(pterp11.21) chr12:0–31,260,891 31,260,891
46,XY[4]
P57 56 46,XY[3] normal normal normal n.d. n.d.
P58 20 46,XX, TBL1XR1: del (68 %) del(3)(q26.32q26.32) chr3:176,825,586-177,697,157 871,571
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients
(Continued)
der(14)(pter- > q32::q32- >
q13::q32- > qter)[10]
del of 9p21.3 CDKN2A/B: del (74 %) del(9)(p21.3p21.3) chr9:21,252,517-24,289,720 3,037,203
del(10)(p15.3p15.3) chr10:1,491,986-1,582,072 90,086
IGH: split (78 %) dup(14)(q13q32.33) chr14:35,918,265-106,513,022 70,594,757
del(16)(q13q13) chr16:57,275,940-57,331,138 55,198
del(21)(q22.2q22.2) chr21:39,764,621-39,895,171 130,550
P64 5 46,XX, n.d. del(5)(q31.3q32) chr5:142,096,863-145,891,069 3,794,206
t(16;19)(p11.2;q13.3),
der(5)t(5;9)(q31;p13.2), CDKN2A/B: del (86 %) del(9)(p21.3p21.3) chr9:21,218,548-23,002,377 1,783,829
der(9)t(5;9)(q31;p13.2),
der(9)t(9;9)(q34;p13.2)[10] FUS: split (75 %)
P66 0.5 46,XX, n.d. MLL: split (70 %) dup(11)(p15.5p15.4) chr11:1,008,688-3,669,161 3,669,161
der(10)(10pter- >
10p12.31::11q23.3- >
11q23.3::10p12.31- >
10q11.23::14q24.2- > 14qter),
IGH: inv (100 %)
der(11)(10qter- >
10q11.23::11p15.3- >
11q23.3::10p12.31- >
10p12.31::11q23.3- > 11qter),
der(14)t(11;14)(q15.3;q24.2),
inv(14)(q11q23)[8]
T-ALLs
P5 22 46,XX[12] normal normal normal n.d. n.d.
P6 16 47,XY, normal normal
+4, +4 +4 191,154,276
der(3)t(3;5)(p23;q31.1),
der(5)t(3;5)(p23;q35.3),
der(5)t(5;10)(q31.1;p12.3),
der(10)t(5;10)(q35.3;p12.3)[8]/
46,XY[13]
P7 26 46,XY, del of 9p21.3 CDKN2A/B: del (64 %) del(9)(p21.3p21.3) chr9:21,817,082-23,515,821 1,698,739
t(2;9;18)(p23.2;p21.3;q21.33), del of 13q14.2 RB1: del (25 %) del(13)(q14.2q14.2) chr13:48,982,463-49,062,316 79,853
t(10;14)(q24;q11)[10] del(16)(p13.3p13.3) chr16:3,154,954-4,568,792 1,413,838
P18 36 46,XY[5] dup of 18q21.2 DCC: dup (13 %) n.d. n.d. n.d.
P32 27 47,XX, del of 6q21 n.d. n.d. n.d.
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients
(Continued)
+21, del of 6q27
t(10;14)(q24;q11), del of 9p21.3 CDKN2A/B: del (89 %)
del(6)(q15q27)[6] del of 12p13.2 ETV6: del (78 %)
del of 13q14.3 DLEU1: del (15 %)
dup of 21q22.1 RUNX1: dup (78 %)
P35 40 46,XY,i(9)(q21.11)[2] del(2)(q34q34) chr2:213,811,279-214,150,984 339,705
dup(7)(pterp14.1) chr7:0–38,218,586 38,218,586
del(7)(q21.2q21.2) chr7:92,252,341-92,460,773 208,432
del(7)(q36.3qter) chr7:156,881,580-159,138,663 2,257,083
del of 9p21.3 CDKN2A/B: del (92 %) del(9)(pterp11.2) chr9:0–47,212,321 47,212,321
del of 9p13.2 dup(9)(q21.11qter) chr9:71,035,265-141,213,431 70,178,166
del(10)(q23.2q23.31) chr10:89,570,600-89,728,844 158,244
del(11)(q22.2q22.2) chr11:102,106,046-102,529,831 423,785
del(13)(q14.2q14.2) chr13:49,004,123-49,122,923 118,800
del(15)(q26.1q26.1) chr15:93,390,484-93,466,292 75,808
del(16)(p13.3p13.3) chr16:3,808,951-3,839,782 30,831
del(18)(q21.32q21.32) chr18:57,517,756-57,617,796 100,040
del(20)(q13.2q13.2) chr20:52,151,411-52,574,928 423,517
P38 22 46,XY[3] normal normal normal n.d. n.d.
P61 18 46,XX,der(2)t(2;7)(q37.3;q34),
t(7;10)(q34;q24.1 ~ 25.1) [4]/
del(1)(p36.31p36.23) chr1:5,958,728-7,238,618 1,279,890
del(4)(p16.3p14) chr4:3,072,509-38,882,925 35,810,416
46,XX[3] dup of 6q23.3 MYB: amp (90 %) dup(6)(q23.3q23.3) chr6:134,245,761-136,118,354 1,872,593
del of 9p21.3 CDKN2A/B: del (88 %) del(9)(p21.3p21.3) chr9:21,252,517-23,002,377 1,749,860
ABL1: amp (95 %) dup(9)(q34.1q34.1) chr9:133,658,293-134,092,544 434,251
FGFR2: del (57 %) del(10)(q25.1q26.3) chr10:112,392,101-135,534,737 23,124,636
B- or T ALLs (not clinically well defined)
P11 26 46,XY[8] n.d. normal normal n.d. n.d.
P16 17 46,XX[7] del(1)(q25.3q31.1) chr1:184,771,633-185,825,795 1,054,162
del(4)(p15.33p15.31) chr4:12,322,760-18,779,457 6,456,697
del(4)(q21.22q24) chr4:82,992,997-106,476,929 23,483,932
del(7)(pterp14.2) chr7:0–36,320,986 36,320,986
dup of 7q22.1 RELN: dup (61 %) dup(7)(q21.3q22.3) chr7:96,048,870-106,348,693 10,299,823
del(9)(p23p22.2) chr9:12,656,733-17,466,907 4,810,174
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients
(Continued)
del of 9p21.3 CDKN2A/B: del (81 %) del(9)(p21.3p21.3) chr9:20,279,653-22,555,566 2,275,913
del(10)(p14p13) chr10:6,889,266-12,484,159 5,594,893
del of 12p13.2 ETV6: del (91 %) del(12)(p13.2p13.1) chr12:11,761,018-12,934,870 1,173,852
del(18)(p11.32p11.31) chr18:2,741,687-3,231,531 489,844
P21 62 46,XY[11] n.d. normal normal normal normal
P24 23 46,XY[12] dup of 18q21.2 DCC: dup (18 %) n.d. n.d. n.d.
P30 46 46,XY[6] normal normal n.d. n.d. n.d.
P33 76 45,X,-X[8] del(4)(q24q24) chr4:106,036,993-106,601,946 564,953
del(7)(q21.2q21.2) chr7:92,080,855-92,475,197 394,342
dup(7)(q36.2q36.2) chr7:153,039,830-154,467,634 1,427,804
del of 10q23.3 del(10)(q23.3q23.3) chr10:89,610,886-89,698,312 87,426
del(15)(q21.2q21.2) chr15:51,826,924-51,919,665 92,741
del(15)(q26.1q26.1) chr15:93,433,130-93,450,773 17,643
del of 17p13.1 TP53: del (10 %) del(17)(p13.1p13.1) chr17:7,583,457-8,156,734 573,277
del(17)(q11.2q11.2) chr17:30,259,193-30,267,204 8011
dup of 18q21.2 DCC: dup (10 %) dup(18)(q21.2q21.2) chr18:49,105,579-51,431,815 2,326,236
del(20)(q13.2q13.2) chr20:52,151,411-52,554,455 403,044
del(21)(q22.12q22.12) chr21:36,253,465-36,426,708 173,243
-X -X 155,270,560
P46 63 46,XY[8] normal dup(6)(q25.3q25.3) chr6:157,944,961-158,033,908 88,947
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,452,798-50,492,798 40,000
dup(17)(q12q12) chr17:36,046,040-36,095,204 49,164
P47 59 46,XX[6] normal dup(1)(p13.3p13.3) chr1:107,921,895-107,970,781 48,886
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,356,873-50,465,376 408,503
del of 9p13.2 del(9)(p13.2p13.2) chr9:37,006,073-37,320,759 314,686
dup(9)(q31.1q31.1) chr9:104,126,808-104,167,077 40,269
del(15)(q26.1q26.1) chr15:93,390,484-93,450,773 60,289
del(18)(q21.32q21.32) chr18:57,517,756-57,718,190 200,434
del(19)(p13.3p13.3) chr19:0–2,787,457 2,787,457
bp basepairs, LSP locus-specific probes as specified in Additional file 2: Table S2, y year
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Conclusions
Cytogenetic analysis has been and still is the standard
method for detection of diagnostically relevant recurrent
chromosomal aberrations in ALL. It is well known that
when using banding karyotyping cryptic chromosomal
aberrations may be missed due to several reasons: (i)
sensitivity of chromosomal banding techniques is lim-
ited, even in case of good chromosomal morphology, to
aberrations being at least 10 Mb in size, (ii) aberrations
may be cryptic or masked, i.e. they are not resolvable
due to a similar or identical GTG-banding pattern and/
or poor chromosome morphology, and (iii) metaphases
may be difficult to obtain and to evaluated as chromo-
somes may not be well-spread, clumsy or appearing as
fuzzy with indistinct margins; thus even numerical aber-
rations may be missed [6, 13, 17].
In the past molecular cytogenetic approaches have
shown to be efficient to detect in banding cytogenetics
cryptic chromosomal aberrations [6, 13, 17]. Besides in
metaphase also interphase nuclei can be studied in case
of low mitotic (non-dividing) cells and also alterations
being at low mosaic level can be easily detected by that
approach [12, 14, 18]. In this study, we detected previ-
ously cryptic aberrations in 21/61 (34 %) cases with
ALL using metaphase directed FISH studies; even com-
plex aberrations were identified in some of these cases
(Table 1 and Additional file 1: Table S1).
For 34/61 cases DNA could be extracted from the cy-
togenetically worked up cell suspension. Thus, in those
cases besides FISH also MLPA and aCGH could be ap-
plied additionally, i.e. approaches which have much
higher resolution than FISH, but can only detect unbal-
anced aberrations and no low level mosaics. Using
these approaches cryptic CNAs were detected in ~80 %
of those ALL cases. All 126 CNAs detected by MLPA and
aCGH have been checked by UCSC genome browser to
exclude benign copy number variations (CNVs) (http://
genome-euro.ucsc.edu/cgi-bin/hgGateway?redirect=au-
to&source=genome.ucsc.edu). Thus, all of them most
likely are leukemia-related genetic changes, which were
recognized in 27/34 ALL cases.
Of special interest may be a novel recurrent submicro-
scopic CNA expressed as loss of 15q26.1: focal deletion of
CHD2 gene located there was found in 7 of the 34 (20 %)
studied ALL cases in this study. The CHD2 gene is a
member of the chromodomain helicase DNA-binding
(CHD) protein family, which are all characterized by a
chromatin-remodeling domain (the chromodomain) and
an SNF2-related helicase/ATPase domain [19]. Thus, in
future it may be of interest to study CHD2 gene deletions
also for presence of mutations in this gene and also to
screen ALL patients in general for CHD2 gene mutations.
Besides, duplication of DCC gene in 18q21.2 was
present in 3 of the 34 (9 %) studied cases. DCC is a mem-
ber of the immunoglobulin superfamily of cell adhesion
Figure 1 Result of aMCB probesets for chromosomes 10, 11, and 14
are shown, which characterized the breakpoints seen in case P66 as
10q11.23, 11p15.3, 14q11, 14q24.2, and 14q32.3. The final karyotype
after application of all approaches as summarized in Additional file 1:
Table S1 was 46,XX,der(10)(10pter- > 10p12.31::11q23.3- >
11q23.3::10p12.31- > 10q11.23::14q24.2- > 14qter),der(11)(10qter- >
10q11.23::11p15.3- > 11q23.3::10p12.31- > 10p12.31::11q23.3- >
11qter),der(14)t(11;14)(q15.3;q24.2),inv(14)(q11q23)
Figure 2 Distribution of CNAs as detected by aCGH in 27/34 studied cases. On X-axis the chromosome number is shown, while on Y-axis the
total number of CNAs for each chromosome is depicted (scale 2).
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molecules and acts as a transmembrane dependence
receptor for netrins, key factors in the regulation of axon
guidance during development of the central nerve system.
Amplification of DCC gene was previously reported in
chronic lymphocytic leukemia (CLL) [20, 21], however,
this is the first report for DCC gene amplification in ALL.
To evaluate the role of the DCC gene and to elaborate its
potential as a molecular marker in ALL still needs more
studies.
In general, submicroscopic CNAs were identified most
frequently in chromosomes #7 and #9. CNAs in #7 in-
volved deletion of IKZF1 at 7p12.2 that encodes IKAROS
protein and is required for the development of all lymph-
oid lineages in 5 of 34 (14 %) studied CN-ALL cases.
According to the literature deletions and/or sequence mu-
tations of IKZF1 are present in 15 % of pediatric B-ALL,
including ~70 % of BCR-ABL–positive ALL and with
high-risk of relapse ~30 % of BCR-ABL–negative B-ALL
[22]. However, deletions of IKZF1 are predominantly
monoallelic and involve the N-terminal zinc-finger do-
main of IKAROS protein and result in expression of
dominant-negative isoforms with cytoplasmic localization
and oncogenic activity as well as an association with very
poor outcome [23, 24]. Thus, IKZF1 has newly been con-
sidered as a prognostic marker for B-ALL and might be
useful for risk stratification [24, 25].
Cyclin dependent kinase 6 (CDK6) at 7q21.2, is the cata-
lytic subunit of a protein kinase complex that regulates cell
cycle G1 phase progression and G1/S transition. Deletion
of CDK6 was identified in this study in 4 of 34 (12 %) of
ALL cases. It has been shown recently that inhibition of
CDK6 may lead to overcome the differentiation block seen
in acute myelogenous leukemia (AML) with MLL translo-
cations [26]. Further studied for this gene may also be
recommended for better understanding of ALL biology.
The majority of #9 abnormalities is involving deletions
of cell cycle regulatory genes at 9p21.3. The main target
to deletions is CDKN2A which encodes for the two tran-
scripts p16/INK4A and p14/ARF (alternative splicing),
followed by CDKN2B gene (p15/INK4B); both are tumor
suppressor genes. Deletions of CDKN2A/B can be found
in 30 and 50 % of B-ALL and T-ALL cases, respectively
[23, 25, 27]. In the present study such deletions were
only found in 8/34 (24 %) of the studied ALL cases,
which is most likely due to low case numbers.
CDKN2A/B deletion can be detected at initial diagnosis
or acquired at relapse, suggesting that CDKN2A/B dele-
tion is a secondary genetic event. Also, the outcome of
cases with CDKN2A/B deletion depends on the status of
the second allele, as homozygous deletions are associ-
ated with poor outcome and heterozygous deletions
represent markers for favorable outcomes [27, 28]. T-
ALL-case P61 had such a prognostically adverse homo-
zygous deletion in 9p21.3 together with amplification of
9q34.12 to 9q34.13; the latter contains the ABL1 and
NUP214 genes (Fig. 3). NUP214-ABL1 fusion gene amp-
lification was previously mainly observed in T-ALL and
associated with poor outcome [6].
Figure 3 aCGH from case Nr. P61 showed two CNAs in chromosome 9; at 9p21.3 a homozygous deletion (arrowhead) and at 9q34.12 to 9q34.13
an amplification (arrow). a FISH confirmed presence of the homozygous deletion in 9p21.3 in interphase. b An amplification present as double
minutes was confirmed using a probe specific for the ABL-gene
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Another recurrent deletion in #9 in the studied ALL
cases involved the PAX5 gene located in 9p13.2, which
encodes for a protein with key roles in lymphoid devel-
opment. It was found to be deleted in B-ALL (n = 2) and
T-ALL (n = 1 showed short arm 9p deleted) in this study.
In the literature, deletion of PAX5 was reported in
31.7 % of B-ALL and also it has been involved in several
chromosomal translocations [29, 30]. In a recent report,
PAX5 deletion was observed in only 10 % and 18 % in
children and adult B-ALL, respectively; notably PAX5
deletion was frequently accompanied by deletion of
CDKN2A (83.3 % of children and 100.0 % of adults)
[28]. Also PAX5 was found to be a common target in
leukemogenesis of B-ALL, but not associated with ad-
verse outcome [15]. In future, PAX5 could be used as
one of the molecular markers in diagnosis and monitor-
ing of the disease, especially in B-ALL [28–30].
Besides, other CNAs have been identified here,
encompassing single or few genes, only. Many of CN
losses involve cell cycle regulatory and/or putative tumor
suppressor genes like 10q23.3 (PTEN; n = 6), 13q14.2
(RB1; n = 3), and 17p13.1 (TP53; n = 4), or transcrip-
tional regulators and co-activators like 3q26.32
(TBL1XR1; n = 1), 12p13.2 (ETV6; n = 2), 21q22.12
(RUNX1; n = 1) and 21q22.2 (ERG; n = 2), or regulators
of chromatin structure and epigenetic regulators like
16p13.3 (CREBBP; n = 2). Although, oncogene overex-
pression resulting from gene duplication is infrequent in
ALL, we found MYB duplication in one case, too. These
observations of gene loss of function or overexpression
being involved in leukemic transformation [15, 31]
underline the heterogeneity of different ALL cases and
the potential of molecular approaches to identify new
subgroups of this disease.
The present study also highlights, that most likely all
CN-ALL cases hold cryptic genomic alterations. DNA
sequencing and single-nucleotide polymorphism (SNP)
arrays have been used to detect mutations for a number
of target genes that are known to key roles in lymphoid
development. Thus, somatic mutations have been identi-
fied in both B and T-ALL patients [2]. For instance,
mutations in JAK2 were identified in 10 % of high-risk
childhood B-ALL and shown to be associated frequently
with other abnormalities, including deletions or muta-
tions of IKZF1 and overexpression the CRLF2 gene [23].
In T-ALL, NOTCH1-activating gene mutation has been
found in 60 % and FBXW7-inactivating gene mutation
occurs in 20 % of pediatric T-ALL [32]. Less commonly,
mutations in PTEN, WT1, amplification of MYB and
sequence mutations in RAS signaling (NRAS, KRAS, and
NF1) and tumor suppression (TP53) have been identified
in ALL [8, 31].
Overall, sensitive methods to detect cryptic chromo-
somal aberrations in CN-ALL are useful and necessary for
genetic risk–based classification and correct determin-
ation of treatment protocols. The present study highlights
that molecular cytogenetic approaches together with mo-
lecular methods are suited to identify cryptic rearrange-
ments and potential target genes that involved in
leukemogenesis and progression of the disease. Also it
could be demonstrated that aCGH is a highly efficient
tool for detection of CNAs in CN-ALL. However, while
aCGH (and MLPA) provide data on imbalanced genomic
alterations, (molecular) cytogenetics additionally detects
different leukemic subclones within one sample, as well as
balanced translocations leading to tumor-specific fusion
genes. It seems to be valid, that there is no leukemia clone
without genetic alterations; we just have to use the appro-
priate techniques to identify them. In conclusion, to obtain
a comprehensive picture of all relevant changes in each in-
dividual ALL case data from cytogenetics, FISH, MLPA
and aCGH needs to be considered and included in diag-
nostics; however, sometimes such investigations may be
hampered by lack of sufficient cellular material, as also in
this study, where only 34/61 cases could also be studied
on DNA level or other previous studies [16, 33].
Methods
Patients and sample preparation
Cell suspensions were obtained from bone marrow col-
lected from 61 patients diagnosed with ALL (31 with
B-ALL, 12 with T-ALL and 18 with undefined ALL;
Additional file 1: Table S1). The samples were obtained
under informed consent of the corresponding patients
and according to institutional ethical committee guide-
lines (ethical commission of the university clinic Jena,
Germany; code 1105-04/03).
GTG-banding
The bone marrow cells were unstimulated cultivated for
24 hours (with and without colchicin) and 48 h, and a
standard cytogenetic cell preparation following air drying
method was done [34]. GTG-banding was routinely done
in each sample following standard procedures. Twenty
metaphases were obtained for cytogenetic evolution on a
banding level of 250–300 bands per haploid karyotype
[35]. Apart from 4 all 61 studied cases had a normal
karyotype of 46,XX or 46,XY. In one case the karyotype
could not be determined due to low metaphase quality;
one case just had (most likely age associated) loss of an X-
chromosome in a subset of the cells, one case had a ques-
tionable der(19) in all cells, and another one a trisomy 14
in 6/20 studied cells.
Molecular cytogenetics
Fluorescence in situ hybridization was done according to
standard procedures and/or according to manufacturer’s
instructions.
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Homemade were the following probes and probe sets:
– 24-color-FISH using all human whole chromosome
painting (WCP) probes [36];
– FISH-banding probe-sets as follows: genome wide
multitude multicolor banding (mMCB) and
chromosome specific high resolution array-proven
multicolor-banding (aMCB) [16, 37, 38];
– WCP probes for all chromosomes were homemade
[36].
– The following commercially available locus-specific
probes (LSPs) (Additional file 2: Table S2) were used
to validate and possibly confirm the breakpoints
found in mMCB, aCGH and/or MLPA: from Abbott/
Vysis (Wiesbaden, Germany), Kreatech Diagnostics
(Amsterdam, Netherland), ZytoVision (Bremerhaven,
Germany), and DNA from bacterial artificial
chromosome (BACs) probes obtained from Resources
Center (Oakland, USA) were labeled by PCR with
SpectrumGreen, SpectrumOrange or TexasRed-dUTP
and applied in two- or three-color FISH-approaches.
For each interphase FISH analysis to determine the
percentage of specific aberrations, at least 200
interphase nuclei were examined per sample and
FISH-probe – the applied probes can be found in
Additional file 2: Table S2.
– Homemade and previously reported chromosome-
specific sub-CTM- (= subtelomere -/ subcentromere
oriented) probe-sets were applied in selected cases
[13] (Additional file 1: Table S1).
DNA isolation
Genomic DNA was extracted from cells fixed in acetic
acid-methonal (1:3) by Puregene DNA Purification Kit
(Gentra Systems, Minneapolis, MN, USA). DNA concen-
tration was determined by a Nanodrop spectrophotom-
eter. The quality of DNA was checked using agarose gel
electrophoresis. DNA-samples extracted from fixed cells
of 2 healthy males and 2 healthy females by the same
method were used as reference samples.
MLPA analysis
SALSA MLPA P377-A1 Hematologic malignancies
probemix was used for this study (MRC- Holland,
Amsterdam, The Netherlands). This probemix contains
probes for 37 genes covered by 54 probes, which have
diagnostic or prognostic significant role in hematologic
malignancies. MLPA was performed according to the
manufacturer’s protocol, which includes three reaction
phases: hybridization, ligation, and PCR amplification.
Amplified probes and GeneScan LIZ 500 (Applied
Biosystems, Foster City, USA) standard were separated
by capillary electrophoresis using a ABI-PRISM 3130XL
Genetic Analyzer (Applied Biosystems, Foster City, USA).
GeneMarker (SoftGenetics, USA) was used to analy-
zeMLPA data. Detection threshold was set at 0.65-1.35;
control samples of four healthy donors were included in
each run.
Array-comparative genomic Hybridization (aCGH)
aCGH was performed using Agilent SurePrint G3 Human
Genome microarray 180 K (Agilent Technologies, Santa
Clara, CA, USA), an oligonucleotide microarray contain-
ing 170,334 probes 60-mer with a ~13 kb overall median
probe spacing (11 kb in Refseq-genes). Genomic DNA of
patients was co-hybridized with a sex-mismatched control
DNA (G1471 or G1521; Promega, Mannheim, Germany).
Labeling was performed using Agilent Genomic DNA en-
zymatic labeling kit (Agilent) according to the manufac-
turers’ instructions. After hybridization and washing, the
aCGH slide was scanned on an Agilent scanner, processed
with Feature Extraction software (v12.0.2.2) and results
were analyzed using Cytogenomics (v3.0) using ADM2 as
aberration algorithm.
Additional files
Additional file 1: Table S1. All 61 CN-ALL cases studied; for each case
age, gender and subtype of ALL is given. Also all FISH-probes, probe sets
and approaches applied for each case are listed. Abbreviations: n.d. = not
determined, y = year.
Additional file 2: Table S2. List of locus specific probes used in the
present study for further characterization of acquired aberrations and/or
determination of the percentage of deletions or duplications as determined
by aCGH or MLPA.
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Acute myeloid leukemia (AML) is a heterogeneous disease characterized by themalignant transformation of he-
matopoietic precursors to a pathogenic cell clone. Chromosomal band 11q23 harboringMLL (=mixed lineage
leukemia) gene is known to be involved in rearrangements with variety of genes as activating partners ofMLL
in different AML subtypes. Overall, an unfavorable prognosis is associated with MLL abnormalities. Here we
investigated an 11-month-old male presenting with hyperleukocytosis being diagnosed with AML subtype
FAB-M5b. In banding cytogenetics a der(19)t(19;?)(q13.3;?) and del(Y)(q11.23)were found as sole aberrations.
Molecular cytogenetics revealed that the MLL gene was disrupted and even partially lost due to a
t(10;19;11)(p12.31;q13.31;q23.3), anMLL/MLLT10 fusion appeared, and the der(Y)was an asymmetric inverted
duplication with breakpoints in Yp11.2 and Yq11.23. The patient got hematopoietic stem cell transplantation
from his haploidentical mother. Still three months afterwards 15% of blasts were detected in bone marrow and
later the patient was lost during follow–up. The present case highlights the necessity to excludeMLL rearrange-
ments, even when there seems to be no actual hint from banding cytogenetics.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
Infant acute leukemia (AL) is deﬁned as malignancy of the blood oc-
curring in the ﬁrst years of life. Acutemyeloid leukemia (AML) accounts
15%–20% of childhood AL cases, while AML is themost frequent form of
adult AL providing ~80% of the cases (Rubnitz et al., 2010).
Chromosomal rearrangements involving the MLL (mixed lineage
leukemia or myeloid/lymphoid leukemia, also called ALL1 for acute
lymphoblastic leukemia 1 or KMT2A lysine (K)-speciﬁc methyltransfer-
ase 2A) gene located on chromosome 11 subband q23 are typically
found in 35%–50% of childhood and in 5% of adult AMLs (Balgobind
et al., 2011; Stasevich et al., 2006; De Braekeleer et al., 2005). The MLL
gene has been found to be “promiscuous”, being able to form fusion
genes with more than 120 different translocation partners (Meyer
et al., 2013). The t(9;11)(p22;q23) is themost frequent event involving
theMLL gene in pediatric AML (50%), and the t(10;11)(p12;q23) is the
second common one (13%) (Balgobind et al., 2011; Coenen et al., 2011;
Meyer et al., 2013; DiNardo et al., 2015).
This t(10;11) is most often found in AML French–American–
British (FAB) subtypes M4/M5; these patients present leukocytosis,
extramedullary disease, poor long-term outcomes and high risk of re-
lapse (Lillington et al., 1998; Balgobind et al., 2011; Meyer et al.,
2013). In most cases, the t(10;11) leads to fusion of the 5′ end of MLL
and 3′ of MLLT10. The mechanism of this rearrangement seems to be
more complex than a simple reciprocal translocation because of an op-
posite orientation of both genes on chromosomes 10 and 11. This impli-
cates that an inversion of one of the two genes is necessary to allow the
formation of the MLL–MLLT10 chimeric transcript (Stasevich et al.,
2006; Matsuda et al., 2006). Besides, the MLLT10 gene (previously
AF10) can also form a fusion gene with PICALM (11q14) in AL
(Brandimarte et al., 2013; Borel et al., 2012).
Overall, detection or exclusion of anMLL disruption or ampliﬁcation
is extremely necessary for treatment decisions, as well as for basic re-
search enabling new insights into possible fusion genes involvingMLL.
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Here we report a new case of childhood AML-M5b harboring a cytoge-
netically balanced translocation with break events in 10p12.31,
11q23.3, and 19q13.31 associated with a partial deletion of the MLL
gene. Besides, an unusual rearrangement of the Y-chromosome was
observed.
2. Material and methods
2.1. Clinical description
An 11-month-old male infant was presented in 2012 with
hyperleukocytosis (white blood cell (WBC) count of 43.6 × 109/l). Bone
marrow (BM) aspiration showed 95% blasts, being Sudan Black B stain-
ing negative and ANAE (alpha-naphthyl-acetate-esterase) stain positive.
Immunophenotyping revealed positivity for MPO (myeloperoxidase),
HLA-DR, CD4, CD33, CD45, CD15, CD11b and CD13 prompting a diagno-
sis of AML, and FAB classiﬁcation as AML type M5b.
The infant was enrolled in protocol AML-BFM 98 and after induction
therapy blasts in BM were only 5%. After one year of initial therapy the
patient had medullary and extramedullary relapse, 82% blasts in BM
being positive for HLA-DR, CD4, CD33, CD45, CD15, MPO, CD11b and
CD13. The patient was further treated according to protocol AML-BFM
2004 and after induction therapy blasts in BM were again down to 5%
but skin nodes being present. Hematopoietic stem cell transplantation
(HSCT) from haploidentical mother was performed after conditioning
with thiotepa, treosulfan and ﬂudarabine. Three months after HSCT,
15% of blasts were again detected in BM, being CD45 positive; also
skin biopsy showed extramedullary relapse. Unfortunately, later the pa-
tient was lost during follow-up.
2.2. Banding cytogenetic
Chromosome analyses were performed on unstimulated BM after
direct chromosome preparation, as well as after 24 h culture. GTG-
banding as well as C-banding were performed (Claussen et al., 2002).
A total of 30 metaphases were analyzed. Karyotype designation was
done according to International System for Human Cytogenetic Nomen-
clature (ISCN, 2009). A chromosome analysis was possible on a level of
300 bands per haploid karyotype.
2.3. Molecular cytogenetics
Fluorescence in situ hybridization (FISH) was done according to
standard procedures and according to manufacturers' instructions for
the following commercially available probes: LSI MLL (11q23 Break
probe, Abbott Molecular/Vysis, Mannheim, Germany), LSI SRY (Yp11.3,
Abbott Molecular/Vysis, Mannheim, Germany), SPEC ETV6/RUNX1
(ETV6 in 12p13, RUNX1 in 21q22, ZytoVision, Bremerhaven, Germany),
SPEC 19q13/19p13 (ZytoVision, Bremerhaven, Germany), Centromere
Y (CEPY (DYZ3): Yp11.1–q11.1 Alpha Satellite DNA; CEPY (DYZ1):
Yq12 Satellite III DNA, Abbott Molecular/Vysis, Mannheim, Germany),
and subtelomeric probes for Yp/Xp, and Yq/Xq (Yp in DXYS153, Xp in
DXYS129; Yq in D11S1037, Abbott Molecular/Vysis, Mannheim,
Germany).
Whole chromosome painting (WCP) probe for chromosomes 9, 10,
11, 19, and Y and BAC (bacterial artiﬁcial chromosome) clones of inter-
est were identiﬁed through the Human Genome Browser Database of
the Genome Bioinformatics Group at the University of California at
Santa Cruz (http://genome.ucsc.edu/) and Ensembl Genome Data Re-
sources of the Sanger Institute Genome Database (http://www.
ensembl.org/). DNA probes (Table 1) obtained from BAC/PAC Resources
Center (Oakland, USA) were labeled by PCR with SpectrumGreen,
SpectrumOrange or TexasRed-dUTP and applied in two- or three-color
FISH-approaches. The homemade multitude multicolor banding
(mMCB) and chromosome speciﬁc high resolution array-proven
multicolor-banding (aMCB) probe sets were also applied as previously
reported (Weise et al., 2003, 2008).
A total of 10–15 metaphase spreads were analyzed, using a ﬂuores-
cence microscope (Axio Imager.Z1 mot, Zeiss) equipped with appropri-
ate ﬁlter sets to discriminate between amaximumof ﬁve ﬂuorochromes
and the counterstain DAPI (Diaminophenylindol). Image capturing and
processingwere carried out using an ISIS imaging system (MetaSystems,
Altlussheim, Germany).
3. Results
Cytogenetic study performed at diagnosis on a bonemarrow cell cul-
ture revealed a 46,X,del(Y)(q11.23),der(19)t(19;?)(q13.3;?)[26]/
46,XY[4] without evidence for 11q23 rearrangement (Fig. 1). FISH
analysis using WCP probes for chromosomes 19 and Y revealed a
balanced translocation of 19q to another chromosome. mMCB probeset
showed that the rearrangement indeedwasmore complex: 46,X,der(Y)
(Ypter→Yq11.23::Yp11.2→Ypter),t(10;19;11)(p12;q13;q23). Chro-
mosome speciﬁc aMCB probesets for #10, #11, #19, and Y conﬁrmed
the mMCB result (Fig. 2A). Locus speciﬁc probes narrowed down the
breakpoints as shown in Table 1 to 10p12.31, 11q23.3, 19q13.31,
Yp11.2 and Yq11.23.
The LSIMLL break apart probe gave the following result (Fig. 2B): the
5′MLL probe was given a green split signal on derivative chromosomes
10 and 11. This probe includes exons 1 to 6 of theMLL gene, according to
http://www.vysis.com and based onMLL gene nomenclature available
from http://www.ensembl.org; transcript ID ENSG00000118058. Also
Table 1
Used probes, their location and obtained results are listed.
Cytoband Positions [hg18] Probe Result on derivative chromosomes
Yp11.31 chrY: 264,089–264,253 CTC-839D20 2 signals on der(Y)
Yp11.31 chrY: 2,714,896–2,715,792 LSI SRY 2 signals on der(Y)
Yp11.32 chrY: 317,555–517,715 DXYS153 2 signals on der(Y)
Yp11.2 chrY: 6,752,454–6,919,727 RP11-115H13 2 signals on der(Y)
Yp11.1–q11.1 chrY: 11,200,001–12,500,000 DYZ3 1 signal on der(Y)
Yq11.221 chrY: 15,173,440–15,173,599 RP11-71M14 1 signal on der(Y)
Yq11.221 chrY: 15,688,562–15,841,531 RP11-59K8 1 signal on der(Y)
Yq12 chrY: 27,200,001–57,772,954 DYZ1 Deletion on der(Y)
Yqter chrY: 57,719,381–57,727,828 EST Cdy 16c07 for SYBL1 Deletion on der(Y)
10p12.31 chr10: 20,782,567–20,938,614 RP11-51E20 Signal on der(19)
10p12.31 chr10: 21,321,413–21,495,264 RP11-165O3 Signal on der(19)
10p12.31 chr10: 22,399,352–22,575,929 RP11-108B14 Signal on der(10)
11q23.3 chr11: 117,812,415–117,901,146 LSI MLL Split signal on der(10) and der(11) and deletion of 3′ part of MLL
19q13.2 chr19: 47,022,914–47,206,527 RP11-688M4 Signal on der(19)
19q13.31 chr19: 48,171,290–48,356,279 RP11-313K22 Signal on der(19)
19q13.31 chr19: 49,097,834–49,247,766 RP11-143F10 Split signal on der(19) and der(11)
19q13.31 chr19: 49,726,602–49,900,222 RP11-21J15 Signal on der(11)
19q13.32 chr19: 52,803,265–53,038,398 SPEC GLTSCR1/R2/CRX Signal on der(11)
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the 3′ MLL region of ~190 kb in size (red signal in Fig. 2B) was deleted
due to the rearrangement.
Breakpoints on chromosomes 10 and 19were narrowed down using
the BAC-probes listed in Table 1. The breakpoint in 10p12.31 was
mapped between positions 21,495,264 and 22,399,352, where the
MLLT10 gene has been mapped to 21,863,580–22,072,560. The
breakpoint in 19q13.31 was mapped between positions 49,097,834
and 49,247,766; 2 OMIM genes are located there: ZNF45, and ZNF155
(Fig. 2C). The positions are given according to NCBI36/hg18, as numer-
ous of the used BAC-probes could not be found in later genomic browser
versions. The hybridization signals of the subtelomeric (Yp and Yq)
probes were revealed: duplication in Yp subtelomeric region and dele-
tion in Yq region (Fig. 3).
4. Discussion
In the present case two independent rearrangements were ob-
served, one involving three autosomes and one of a gonosome. Both
were already partially visible after GTG-banding analyses, however,
their real nature could only be resolved by molecular cytogenetics.
Structural abnormalities involving the Y-chromosome are rare
events in hematological malignancies. A der(Y)t(Y;1)(q12;q21) is
Fig. 2. A) Results for aMCB probesets for chromosomes 10, 11, and 19 are shown, which characterized the breakpoints as 10p12, 11q23 and 19q13 aftermMCB (results not shown). B) LSI
MLL break apart probe revealed a fusion signal on normal chromosome 11 and one green signal each on der(10) and der(11); still red signal was absent in whole metaphase spread. The
breakpoint in 11q23 could be narrowed down to 11q23.3. C) Further characterization of the breakpoints in derivative chromosomes 10 and 19 by BAC-probes revealed breakpoints as
10p12.31 and 19q13.31.
Fig. 1. G-banded karyogram from bone marrow cells at diagnosis, showing mos 46,X,del(Y)(q11.23),der(19)t(19;?)(q13.3;?)[26]/46,XY[4].
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described to be a recurrent but uncommon chromosomal rearrange-
ment in AML (Manabe et al., 2013); also a t(Y;11) involving the MLL
gene was reported once (Bernasconi et al., 1999). Besides inverted du-
plication shaped derivative Y-chromosomes have not been reported in
AML yet. The observed der(Y)(Ypter → Yq11.23::Yp11.2 → Ypter)
here was only present in the malignant cell clone and a normal Y-
chromosome was present in cells with normal male karyotype. Thus,
it is unlikely that the patient originally had a mosaic karyotype 46,
der(Y)(Ypter→ Yq11.23::Yp11.2→ Ypter)/46,XY even though such
cases are reported in the literature (for overview see (Liehr, 2014)).
Thus, this is to the best of our knowledge the ﬁrst asymmetric inverted
duplication shaped derivative Y-chromosome ever reported. It remains
to be determined if gain of Yp11.32–p11.2 and loss of Yq12, might be
implicated in leukemogenesis due to gene dosage effects.
Gene fusion, as a result of chromosomal translocation, is an impor-
tant event in leukemogenesis.MLL rearrangements are strongly associ-
ated with AMLM4/M5 and characterized by extreme leukocytosis, skin
involvement, and central nervous system disease (Coenen et al., 2011;
DiNardo et al., 2015). Two clinical subgroups of patients have a high fre-
quency of 11q23 aberration and M5 subtypes: one is AML in infants
(b1 year) with MLL rearrangement in about 50% of cases; the other
group is adult “secondary leukemia” potentially after treatment with
DNA topoisomerase II inhibitors. However, the patients with M5a sub-
type are more likely to have a t(9;11) than patients with M5b, while
other translocations are more frequent in M5b patients (Flandrin,
2002; De Braekeleer et al., 2005; Balgobind et al., 2011).
In the present childhood AML-M5b case a yet unreported (Mitelman
et al., 2014) cytogenetically balanced but molecular proven unbalanced
translocation t(10;19;11)(p12.31;q13.31;q23.3)was described. Only by
molecular cytogenetics resolvable ﬁndings were (i) the fusion of 5′MLL
(11q23.3) toMLLT10 (10p12.31) and (ii) the deletion of 3′MLL. The fu-
sion of 10p12with 19q13.31 and that of 11q23.3 and 19q13.31 could in-
volve the following genes:MLLT10, ZNF155, and MLL.
Only four AML cases were reported with three way translocations
before involving the same three chromosomes 10, 11 and 19, still all of
them involving other chromosomal breakpoints especially in chromo-
some 19, than the present case (Pui et al., 1994; La Starza et al., 2006;
Mulaw et al., 2012; Petković et al., 1992). Also a t(11;19)(q23;q13)
MLL–ACTN4 fusion was previously seen (Burmeister et al., 2009).
ACTN4 on chromosome 19q13 is an actin-ﬁlament cross-linking protein.
Mutations in ACTN4 or ACTN4 deﬁciency lead to focal and segmental
glomerulosclerosis.
MLLT10 gene rearrangements have been identiﬁed to a high percent-
age in pediatric AML cases; it encodes for a leucine zipper protein that
functions as a transcription factor (Dreyling et al., 1998). The t(10;11)
is a recurrent reciprocal translocation in AL and has two common vari-
ants; t(10;11)(p12;q21) and t(10;11)(p12;q23), the latter tending to
be more frequently observed in young children AML (Lillington et al.,
1998) and rarely seen in acute lymphatic leukemia (ALL) (Coenen
et al., 2011); the second variant is t(10;11)(p12;q21) identiﬁed mainly
in T-ALL patients, as well as reported in AML and myeloid sarcoma
(Bohlander et al., 2000; Mulaw et al., 2012).
Such t(10;11) rearrangements are often described as “cryptic” be-
cause in 10%of AML cases they are not detectable by banding cytogenet-
ics. As patients with t(10;11) are associated with unfavorable outcome
due to the less response to therapy their identiﬁcation is of high impor-
tance for therapy planning (DiMartino et al., 2002; Caudell and Aplan,
2008; Coenen et al., 2011). MLL and MLLT10 fusion may form due to
translocations, insertions, deletions or due to more complex rearrange-
ments (Stasevich et al., 2006; Matsuda et al., 2006). As in the present
case observed, translocations involving band 11q23 usually lead to a
breakage in the MLL gene where the 5′ part of the gene is retained on
the derivative chromosome 11. Therefore, the active fusion gene (5′
MLL–3′ partner) is almost always located on the der(11), except in
rare cases of insertion of the 5′ MLL to another chromosome. The
breakpoints within the MLL gene cluster in the 8.5 kb region, called
the breakpoint cluster region (bcr) are located between exons 5 and
11. MLL partner plays a critical role in determining the disease pheno-
type; for example: MLL–MLLT7 in T-ALL, MLL–MLLT2 in B lineage ALL,
MLL–MLLT3 and MLL–MLLT10 in AML-M5, MLL–MLLT1 in ALL/AML.
This suggests that the fusion protein affects the differentiation of the he-
matopoietic pluripotent stem cells or the lymphoid ormyeloid commit-
ted stem cells (De Braekeleer et al., 2005; Stasevich et al., 2006; Chaplin
et al., 2001). However, a deletion of 3′MLL in combination with a trans-
location is observed in approximately 20% of the cases with t(4;11) and
t(9;11),which leads toworse course of disease compared to thosewith-
out deletion (Corral et al., 1993; Kobayashi et al., 1993).
11q23 abnormalities occur predominantly in pediatric AML (FAB
type M5) and MLL rearrangements are frequently associated with
monoblastic leukemias. Abnormalities in this region can occur very
early in hematopoietic stem cell development. Due to strong prognostic
impact patients without known recurrent translocations, such as
t(8;21) and inv(16), should be investigated by FISH forMLL rearrange-
ments. We would also like to highlight that immunophenotyping is as
important as molecular (cyto)genetic analyses as both can complete
each other. The translocation partners for 11q23 are numerous and
markedly heterogeneous, thus, additional molecular methods may be
needed to further assess the partner genes forMLL. Also RT-PCR might
be suitable to detect the most frequently observed MLL fusion
transcripts.
Acknowledgments
This study was supported in part by the DAAD.
References
Balgobind, B.V., Zwaan, C.M., Pieters, R., Van den Heuvel-Eibrink, M.M., 2011. The hetero-
geneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25,
1239–1248.
Bernasconi, P., Cavigliano, P.M., Boni, M., Malcovati, L., Calatroni, S., Astori, C., Caresana, M.,
Bernasconi, C., 1999. A novel t(Y;11) translocation with MLL gene rearrangement in a
case of acute myelomonocytic leukemia (AML-M4). Leukemia 13, 487–489.
Bohlander, S.K., Muschinsky, V., Schrader, K., Siebert, R., Schlegelberger, B., Harder, L.,
Schemmel, V., Fonatsch, C., Ludwig, W.D., Hiddemann, W., Dreyling, M.H., 2000. Mo-
lecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid
leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leuke-
mia 14, 93–99.
Borel, C., Dastugue, N., Cances-Lauwers, V., Mozziconacci, M.J., Prebet, T., Vey, N., Pigneux,
A., Lippert, E., Visanica, S., Legrand, F., Rault, J.P., Taviaux, S., Bastard, C., Mugneret, F.,
Collonges Rames, M.A., Gachard, N., Talmant, P., Delabesse, E., Récher, C., 2012.
PICALM–MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk. Res.
36, 1365–1369.
Brandimarte, L., Pierini, V., Di Giacomo, D., Borga, C., Nozza, F., Gorello, P., Giordan, M.,
Cazzaniga, G., Te Kronnie, G., La Starza, R., Mecucci, C., 2013. New MLLT10 gene
recombinations in pediatric T-acute lymphoblastic leukemia. Blood 121,
5064–5067.
Burmeister, T., Meyer, C., Schwartz, S., Hofmann, J., Molkentin, M., Kowarz, E., Schneider,
B., Raff, T., Reinhardt, R., Gökbuget, N., Hoelzer, D., Thiel, E., Marschalek, R., 2009. The
MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leu-
kemia: results from the GMALL study group. Blood 113, 4011–4015.
Caudell, D., Aplan, P.D., 2008. The role of CALM–AF10 gene fusion in acute leukemia. Leu-
kemia 22, 678–685.
Fig. 3. FISH-probes as speciﬁed in the ﬁgure and detailed in Table 1 enabled conﬁrmation of
mMCB result for derivative Y-chromosome as der(Y)(Ypter→Yq11.23::Yp11.2→Ypter).
M.A.K. Othman et al. / Gene 563 (2015) 115–119
2.Results 82
Chaplin, T., Jones, L., Debernardi, S., Hill, A.S., Lillington, D.M., Young, B.D., 2001. Molecular
analysis of the genomic inversion and insertion of AF10 into MLL suggests a single-
step event. Genes Chromosomes Cancer 30, 175–180.
Claussen, U., Michel, S., Mühlig, P., Westermann, M., Grummt, U.W., Kromeyer-Hauschild,
K., Liehr, T., 2002. Demystifying chromosome preparation and the implications for the
concept of chromosome condensation during mitosis. Cytogenet. Genome Res. 98,
136–146.
Coenen, E.A., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvrignon, A.,
Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle,
H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Lo Nigro, L.,
Morimoto, A., Perot, C., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I.,
Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Pieters, R., Zwaan, C.M.,
van den Heuvel-Eibrink, M.M., 2011. Prognostic signiﬁcance of additional cytogenetic
aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of
an international study. Blood 117, 7102–7111.
Corral, J., Forster, A., Thompson, S., Lampert, F., Kaneko, Y., Slater, R., Kroes, W.G., van der
Schoot, C.E., Ludwig, W.D., Karpas, A., 1993. Acute leukemias of different lineages
have similar MLL gene fusions encoding related chimeric proteins resulting from
chromosomal translocation. Proc. Natl. Acad. Sci. U. S. A. 90, 8538–8542.
De Braekeleer, M., Morel, F., Le Bris, M.J., Herry, A., Douet-Guilbert, N., 2005. TheMLL gene
and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer
Res. 25, 1931–1944.
DiMartino, J.F., Ayton, P.M., Chen, E.H., Naftzger, C.C., Young, B.D., Cleary, M.L., 2002. The
AF10 leucine zipper is required for leukemic transformation of myeloid progenitors
by MLL–AF10. Blood 99, 3780–3785.
DiNardo, C.D., Tang, G., Pemmaraju, N., Wang, S.A., Pike, A., Garcia-Manero, G., Cortes, J.,
Bueso-Ramos, C., Kantarjian, H.M., 2015. Acute myeloid leukemia with t(10;11): a
pathological entity with distinct clinical presentation. Clin. Lymphoma Myeloma
Leuk. 15, 47–51.
Dreyling, M.H., Schrader, K., Fonatsch, C., Schlegelberger, B., Haase, D., Schoch, C., Ludwig,
W., Löfﬂer, H., Büchner, T., Wörmann, B., Hiddemann, W., Bohlander, S.K., 1998. MLL
and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia
with translocation t(10;11): both rearrangements are associatedwith a poor progno-
sis. Blood 91, 4662–4667.
Flandrin, G., 2002. Classiﬁcation of acute myeloid leukemias. Atlas Genet. Cytogenet.
Oncol. Haematol. 6, 212–216.
ISCN, 2009. In: Mitelman, F. (Ed.), An International System for Human Cytogenetic No-
menclature. S. Karger, Basel.
Kobayashi, H., Espinosa III, R., Thirman, M.J., Gill, H.J., Fernald, A.A., Diaz, M.O., Le Beau,
M.M., Rowley, J.D., 1993. Heterogeneity of breakpoints of 11q23 rearrangements in
hematologic malignancies identiﬁed with ﬂuorescence in situ hybridization. Blood
82, 547–551.
La Starza, R., Crescenzi, B., Krause, A., Pierini, V., Specchia, G., Bardi, A., Nieddu, R., Ariola,
C., Nanni, M., Diverio, D., Aventin, A., Sborgia, M., Martelli, M.F., Bohlander, S.K.,
Mecucci, C., 2006. Dual-color split signal ﬂuorescence in situ hybridization assays
for the detection of CALM/AF10 in t(10;11)(p13;q14–q21)-positive acute leukemia.
Haematologica 91, 1248–1251.
Liehr, T., 2014. Small supernumerary marker chromosomes. http://ssmc-tl.com/sSMC.
html (accessed 07/10/2014).
Lillington, D.M., Young, B.D., Berger, R., Martineau, M., Moorman, A.V., Secker-Walker,
L.M., 1998. The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic
and clinical study of 20 patients. European 11q23 workshop participants. Leukemia
12, 801–804.
Manabe, M., Takeda, O., Okita, J., Takakuwa, T., Harada, N., Nakano, H., Okamoto, S.,
Aoyama, Y., Kumura, T., Ohta, T., Furukawa, Y., Mugitani, A., 2013. A rare der(Y)t(Y;
1)(q12;q12) in a patient with post-polycythemic myeloﬁbrosis: a case report. Am.
J. Blood Res. 3, 186–190.
Matsuda, K., Hidaka, E., Ishida, F., Yamauchi, K., Makishima, H., Ito, T., Suzuki, T., Imagawa,
E., Sano, K., Katsuyama, T., Ota, H., 2006. A case of acute myelogenous leukemia with
MLL–AF10 fusion caused by insertion of 5′ MLL into 10p12, with concurrent 3′ MLL
deletion. Cancer Genet. Cytogenet. 171, 24–30.
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T.S., Emerenciano, M.,
Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E.,
Cavé, H., Clappier, E., Mass-Malo, K., Zuna, J., Trka, J., De Braekeleer, E., De
Braekeleer, M., Oh, S.H., Tsaur, G., Fechina, L., van der Velden, V.H., van Dongen, J.J.,
Delabesse, E., Binato, R., Silva, M.L., Kustanovich, A., Aleinikova, O., Harris, M.H.,
Lund-Aho, T., Juvonen, V., Heidenreich, O., Vormoor, J., Choi, W.W., Jarosova, M.,
Kolenova, A., Bueno, C., Menendez, P., Wehner, S., Eckert, C., Talmant, P., Tondeur,
S., Lippert, E., Launay, E., Henry, C., Ballerini, P., Lapillone, H., Callanan, M.B.,
Cayuela, J.M., Herbaux, C., Cazzaniga, G., Kakadiya, P.M., Bohlander, S., Ahlmann, M.,
Choi, J.R., Gameiro, P., Lee, D.S., Krauter, J., Cornillet-Lefebvre, P., Te Kronnie, G.,
Schäfer, B.W., Kubetzko, S., Alonso, C.N., zur Stadt, U., Sutton, R., Venn, N.C., Izraeli,
S., Trakhtenbrot, L., Madsen, H.O., Archer, P., Hancock, J., Cerveira, N., Teixeira, M.R.,
Lo Nigro, L., Möricke, A., Stanulla, M., Schrappe, M., Sedék, L., Szczepański, T.,
Zwaan, C.M., Coenen, E.A., van den Heuvel-Eibrink, M.M., Strehl, S., Dworzak, M.,
Panzer-Grümayer, R., Dingermann, T., Klingebiel, T., Marschalek, R., 2013. The MLL
recombinome of acute leukemias in 2013. Leukemia 27, 2165–2176.
Mitelman, F., Johansson, B., Mertens, F.E., 2014. Mitelman Database of Chromosome Aber-
rations in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman (accessed 07/10/
2014).
Mulaw, M.A., Krause, A., Deshpande, A.J., Krause, L.F., Rouhi, A., La Starza, R., Borkhardt, A.,
Buske, C., Mecucci, C., Ludwig, W.D., Lottaz, C., Bohlander, S.K., 2012. CALM/AF10-
positive leukemias show upregulation of genes involved in chromatin assembly
and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leuke-
mia 26, 1012–1019.
Petković, I., Konja, J., Nakić, M., 1992. Cytogenetic analysis in children with acute
nonlymphocytic leukemia. Cancer Genet. Cytogenet. 58, 155–159.
Pui, C.H., Behm, F.G., Downing, J.R., Hancock, M.L., Shurtleff, S.A., Ribeiro, R.C., Head, D.R.,
Mahmoud, H.H., Sandlund, J.T., Furman, W.L., Mark Roberts, W., Crist, W.M.,
Raimondi, S.C., 1994. 11q23/MLL rearrangement confers a poor prognosis in infants
with acute lymphoblastic leukemia. J. Clin. Oncol. 12, 909–915.
Rubnitz, J.E., Gibson, B., Smith, F.O., 2010. Acute myeloid leukemia. Hematol. Oncol. Clin.
North Am. 24, 35–63.
Stasevich, I., Utskevich, R., Kustanovich, A., Litvinko, N., Savitskaya, T., Chernyavskaya, S.,
Saharova, O., Aleinikova, O., 2006. Translocation (10;11)(p12;q23) in childhood
acute myeloid leukemia: incidence and complex mechanism. Cancer Genet.
Cytogenet. 169, 114–120.
Weise, A., Heller, A., Starke, H., Mrasek, K., Kuechler, A., Pool-Zobel, B.L., Claussen, U., Liehr,
T., 2003. Multitude multicolor chromosome banding (mMCB) — a comprehensive
one-step multicolor FISH banding method. Cytogenet. Genome Res. 103, 34–39.
Weise, A., Mrasek, K., Fickelscher, I., Claussen, U., Cheung, S.W., Cai, W.W., Liehr, T.,
Kosyakova, N., 2008. Molecular deﬁnition of high-resolution multicolor banding
probes: ﬁrst within the human DNA sequence anchored FISH banding probe set.
J. Histochem. Cytochem. 56, 487–493.
M.A.K. Othman et al. / Gene 563 (2015) 115–119
2.Results 83
2. Results  
 
 
 
 
 
 
 
 
2.10. Article .9 
 
 
Jancuskova T, Plachy R, Zemankova L, Hardekopf DW, Stika J, Zejskova L, Praulich I, 
Kreuzer KA, Rothe A, Othman MA, Kosyakova N, Pekova S. Molecular characterization 
of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient. Mol 
Cytogenet, 2014;7:47.  
 
 
 
 
 
 
 
 
 
 
 
 
CASE REPORT Open Access
Molecular characterization of the rare translocation
t(3;10)(q26;q21) in an acute myeloid leukemia
patient
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Abstract
Background: In acute myeloid leukemia (AML), the MDS1 and EVI1 complex locus - MECOM, also known as the
ecotropic virus integration site 1 - EVI1, located in band 3q26, can be rearranged with a variety of partner chromosomes
and partner genes. Here we report on a 57-year-old female with AML who presented with the rare translocation t(3;10)
(q26;q21) involving the MECOM gene. Our aim was to identify the fusion partner on chromosome 10q21 and to
characterize the precise nucleotide sequence of the chromosomal breakpoint.
Methods: Cytogenetic and molecular-cytogenetic techniques, chromosome microdissection, next generation
sequencing, long-range PCR and direct Sanger sequencing were used to map the chromosomal translocation.
Results: Using a combination of cytogenetic and molecular approaches, we mapped the t(3;10)(q26;q21) to the single
nucleotide level, revealing a fusion of the MECOM gene (3q26.2) and C10orf107 (10q21.2).
Conclusions: The approach described here opens up new possibilities in characterizing acquired as well as congenital
chromosomal aberrations. In addition, DNA sequences of chromosomal breakpoints may be a useful tool for unique
molecular minimal residual disease target identification in acute leukemia patients.
Keywords: AML, MECOM, Chromosomal microdissection, Next-generation sequencing, Molecular marker
Background
EVI1 is one of several protein isoforms encoded by the
MECOM locus at human chromosome 3q26 that also
yields the MDS1 and MDS1-EVI1 protein isoform [1].
The role of MDS1 and MDS1-EVI1 in malignancy is still
unclear, though the EVI1 transcription factor plays an
essential role in the proliferation and maintenance of
hematopoietic stem cells [2]. Aberrant EVI1 expression
occurs in approximately 8% of patients with de novo
acute myeloid leukemia (AML) [3]. The overexpression of
EVI1 can be achieved not only through rearrangements of
band 3q26 but also without the presence of 3q26 abnor-
malities, therefore indicating that other mechanisms can
lead to EVI1 activation [4-6]. Moreover, a substantial
number of patients with 3q26 rearrangements do not
express EVI1 [7]. In approximately 2% of AML cases,
inv(3)(q21q26)/t(3;3)(q21;q26) is observed, where it has
been suggested that the promoter of the house-keeping
RPN1 gene could be responsible for the activation of EVI1
[8]. Other EVI1 rearrangements include, e.g. 7q21
(CDK6), 7q34 (TCRB), 12p13 (ETV6) and 21q22 (RUNX1)
[6,9]. Even though partner chromosomes and molecular
consequences differ between various types of EVI1 rear-
rangements, elevated expression predicts poor prognosis
for the affected patients [4,10,11].
Here we report the rare case of chromosomal trans-
location t(3;10)(q26;q21) involving MECOM. Using
modern cytogenetic and molecular biological techniques
we were able to characterize the nucleotide sequence of
this breakpoint and thus identify the fusion partner on
chromosome 10.
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Case presentation
A 57-year old female was diagnosed with AML (FAB M2)
after a blood cell count and bone marrow examination
was initiated in June 2013. Hematologic parameters were
as follows: hemoglobin 6,2 g/dl, platelets 44 × 109/l,
and white blood cells (WBC) 3,34 × 109/l with 7,8%
neutrophils, 62,9% lymphocytes and 28,7% monocytes,
0% eosinophils and 0,3% basophils. A bone marrow
aspirate revealed slightly hypercellular marrow with normo-
cellular particles. Megakaryocytes were found in reduced
density. There was significant hiatus leucaemicus with
evidence of medium-sized blasts with poor basophilic
cytoplasm and distinct granulation. Flow cytometry
performed on the bone marrow revealed 31% myeloid-
appearing blasts with expression of CD34 and CD117,
and confirmed the diagnosis of AML.
Conventional cytogenetic analysis of a 24-h culture,
performed on bone marrow cells by standard techniques
and evaluated by G-banding, revealed a balanced t(3;10)
(q26;q21) in 20/22 metaphases. Involvement of the
MECOM gene was confirmed by FISH with the use of
a commercially available probe set.
Results
Cytogenetic and molecular-cytogenetic analyses of bone
marrow cultures revealed an aberrant karyotype 46,XX,t
(3;10)(q26;q21)  Figure 1. A commercial EVI1 break-apart
probe yielded a split signal in all dividing and 80% of the
interphase bone marrow cells, demonstrating the re-
arrangement of the 3q26 chromosomal region (Figure 2).
Ten derivative chromosome 10 breakpoint regions
were dissected, amplified and sequenced. In total, 81 753
reads were obtained and aligned to reference sequences of
chromosomes 3 and 10 (NCBI build 37.3). Long-range
PCR primer design resulted in a product that was then
subjected to Sanger sequencing. The nucleotide sequence
of the der(10) breakpoint (Figure 3) revealed a fusion of
theMECOM gene on 3q26 to C10orf107 on 10q21.
Additionally, the bone marrow sample was subjected
to reverse transcription real-time PCR analysis to deter-
mine the expression levels of cEVI1 (i.e., the sum of all
EVI1 mRNA variants) relative to those of the internal
reference gene ABL. We found that EVI1 expression was
26-fold higher when compared with healthy control (data
not shown).
Discussion
In the present report we describe a rare case of acute
myeloid leukemia with a t(3;10)(q26;q21) translocation
involving MECOM. To our knowledge [12], only one case
with this translocation has been reported [9], but the fu-
sion partner on chromosome 10 was not characterized.
Using a novel technical approach we were able to identify
the fusion partner and precise nucleotide sequence of the
breakpoint, which may serve as a patient-specific molecu-
lar target for subsequent real-time PCR-based minimal
Figure 1 Karyotype analyses. G-banding (left part) and multicolor FISH (mFISH) (right part) analyses showed aberrant karyotype 46,XX,t(3;10)
(q26;q21). The arrows indicate the derivative chromosomes.
Figure 2 FISH analysis. Metaphase-FISH analysis using EVI1 break-apart
probe shows normal fusion signal on chromosome 3 (green, purple,
blue) and split-signal on der(3) (green, blue) and der(10) (green, purple)
indicating rearrangements of 3q26 region.
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residual disease (MRD) monitoring. We further demon-
strated by real-time quantitative reverse transcription PCR
that the t(3;10)(q26;q21) results in EVI1 over-expression.
Deregulated expression of EVI1 and other genes (e.g.
BAALC, WT1) involved in cell proliferation, survival and
differentiation have been used as alternative MRD targets
[13-16]. However, the sensitivity of expression assays is
dependent on the level of initial expression; therefore,
these assays are suitable only in AML cases with a high
initial expression level of a specific target normalized to
an endogenous control gene at diagnosis. Even in those
cases, the sensitivity is usually not sufficient for subse-
quent MRD monitoring. Therefore, in patients presenting
with a fusion transcript and/or gene mutation, a specific
PCR assay is preferred. These PCR-based methods are
currently the most sensitive techniques for MRD follow-
up, reaching sensitivities of 10−4  10−5 [17,18].
Real-time PCR-based MRD assays allow the highly
accurate quantification of residual leukemic cells and
evaluations of treatment outcome in AML patients. The
merit of MRD monitoring during patients treatment and
prognostic relevance has been confirmed by various studies
[17,19,20]. Common targets for MRD detection include
fusion transcripts (e.g. RUNX1-RUNX1T1, PML-RARα,
DEK-NUP214, CBFβ-MYH11) [21] and mutations of clin-
ically relevant genes (e.g. NPM1, CEBPα, FLT3, c-KIT)
[17-22]. Unfortunately, approximately half of AML pa-
tients lack a molecular target suitable for MRD moni-
toring [23]. Therefore, introducing novel approaches
for the identification of unique clone-specific markers
is highly desirable. The procedure described here is
based on characterizing nucleotide sequences of unique
chromosomal breakpoints, allowing the design of a spe-
cific real-time PCR assay for MRD assessment. In this
way, AML patients could benefit from accurate and sensi-
tive MRD monitoring, even in the absence of other well-
introduced molecular marker [24].
Mapping chromosome breakpoints is a conventional
method for identifying specific genes in leukemic patients,
as well as patients with solid tumors and individuals with
balanced translocations [25-27]. A fundamental require-
ment is the ability to karyotype and precisely identify
derivative chromosomes using classic karyotyping or mo-
lecular cytogenetic tools such as mFISH and mBAND
analyses. Hybridization with even higher resolution, such
as BAC-FISH (Bacterial Artificial Chromosome FISH)
can help to narrow-down the chromosomal breakpoints
further, though it is still not subtle enough to allow sub-
sequent molecular methods to be used and to identify
nucleotide sequence. There have been a number of
methods proposed to address this issue, with varying
strengths and weaknesses. Array-CGH has improved in
resolution, allowing deletions, amplifications, and non-
balanced translocations to be more precisely character-
ized, but array-CGH in principle cannot detect targets
arising from balanced chromosomal translocations [28].
Conclusion
The combination of cytogenetic and molecular methods
described here enabled us to proceed from the chromo-
somal level (cytogenetically identified abnormality) to the
molecular level (unique DNA sequence) in a case of the
novel t(3;10)(q26;q21) translocation. Using this procedure,
acquired as well as congenital chromosomal aberrations
can be characterized. In contrast to other mapping
methods (e.g. BAC-FISH, array CGH) our technique
allows the rapid mapping of chromosomal breakpoints
down to the DNA sequence level and immediate elucida-
tion of possible genes involved. This can be invaluable for
studying such aberrations in a wide variety of fields,
including the evolution of diseases or the genetic basis of
inherited syndromes.
Methods
Cytogenetic and molecular cytogenetic analyses
The heparinized bone marrow sample was cultivated for
24 h in RPMI 1640 media supplemented with 10% fetal
calf serum, penicillin/streptomycin and L-glutamine (PAA
Laboratories, Austria) at 37°C/5% CO2. Karyotype was
investigated by G-banding and multiplex fluorescence in
situ hybridization (mFISH) with the 24XCyte probe kit
(MetaSystems, Germany). ISCN 2013 nomenclature
was used to describe chromosome abnormalities [29].
Interphase fluorescence in situ hybridization (FISH)
analysis was performed using a commercially available
EVI1 break-apart probe (MetaSystems, Germany).
DNA/RNA isolation, reverse transcription
DNA and RNA were isolated from the mononuclear frac-
tion of bone marrow samples at diagnosis. DNA was iso-
lated using the MagNA Pure automatic isolator (Roche,
Germany) according to the manufacturers instructions.
RNA was extracted by TRI Reagent (Molecular Research
Center, USA) according to the manufacturers recommen-
dations. Reverse transcription was performed using the
Figure 3 Derivative chromosome 10 breakpoint sequence. The
electropherogram shows the result of direct sequencing of
long-range PCR product which revealed fusion of MECOM gene
on chromosome 3q26.2 and C10orf107 on chromosome 10q21.2.
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Verso cDNA Synthesis Kit (Thermo Scientific, USA)
according to the manufacturers instructions.
Real-time quantitative reverse transcriptase PCR
Primers and probes to amplify and quantify EVI1-
expression were forward: 5 ACCCACTCCTTTCTTTA
TGGACC 3, reverse: 5 TGATCAGGCAGTTGGAATT
GTG 3, probe: FAM - 5 TGAGGCCTTCTCCAGGAT
TCTTGTTTCAC 3 - BHQ1. Expression was normalized
against the expression of the control gene ABL. Primers
and probe to quantify ABL gene were as follows: forward:
5 TCCTCCAGCTGTTATCTGGAAGA 3, reverse: 5 T
GGGTCCAGCGAGAAGGTT 3, probe: FAM-5 CCAG
TAGCATCTGACTTTGAGCCTCAGGG 3 - BHQ1.
PCR conditions started with a denaturation at 95°C for
8 minutes, followed by 45 cycles of denaturation at 95°C
for 20 s, annealing at 57°C for 30 s and elongation at 72°C
for 30 s.
Chromosomal breakpoint identification
The cell suspension and DNA sample were treated and
analyzed as previously described [24]. Briefly, regions
around the breakpoints of derivative chromosomes
were dissected by glass microneedles manipulated by
micromanipulator using an inverted microscope (Axiovert
10, Zeiss, Germany). The microdissected fragments were
directly subjected to amplification by degenerate oligo-
nucleotide-primed (DOP) PCR and then sequenced on
the GS Junior platform (Roche, Germany) for next gener-
ation sequencing. Obtained reads were aligned to refer-
ence sequences of chromosomes 3 and 10, using in-house
developed software. The last mapped reads from both
chromosomes were used as docking sites for primers for
long-range PCR to amplify the putative breakpoint.
Primers for long-range PCR were designed in Vector
NTI Advance (v. 11.5, Invitrogen, USA). PCR amplifica-
tion was done using the Expand Long Range dNTPack
kit (Roche, Germany). The long-range PCR product was
directly sequenced using Sanger sequencing to reveal
the precise nucleotide sequence of the breakpoint.
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A de novo acute myeloid leukemia (AML-M4)
case with a complex karyotype and yet
unreported breakpoints
Walid Al-achkar1*, Abdulmunim Aljapawe2, Moneeb Abdullah Kassem Othman3 and Abdulsamad Wafa1
Abstract
Background: Acute myelogeneous leukemia (AML) is a malignancy of the hematopoietic stem cells, for which
cytogenetic analysis is still one of the most important diagnostic and prognostic tools. Still, we are far away from
having seen and described all possible genetic changes associated with this kind of acquired disease.
Results: Bone marrow cells of a female patient with clinical diagnoses of AML and immunophenotypically
confirmed AML-M4 were studied by GTG-banding. The later was not able to resolve all karyotypic changes and the
complex karyotype was characterized in more detail by fluorescence in situ hybridization (FISH) and array-proven
multicolor banding (aMCB). To the best of our knowledge, the present case is the only one ever seen with a del(5)
(q14q34), a der(17)t(4;17)(p13;p13), a del(2)(p23), a der(4)t(4;7)(p13;q11.23), a der(22)t(11;22)(q23;q11.2) and two
complex rearranged chromosomes 11 involving chromosomes 7 and 22 as well as 2.
Conclusions: The yet unreported breakpoints observed in this case seem to be correlated with an adverse
prognosis. Overall, molecular cytogenetic studies are suited best for identification and characterization of
chromosomal rearrangements in acute leukemia and single case reports as well as large scale studies are necessary
to provide further insides in karyotypic changes taking place in human malignancies.
Keywords: Acute myeloid leukemia (AML), Chromosomal abnormalities, Fluorescence in situ hybridization (FISH),
Array-proven multicolor banding (aMCB)
Background
Acute myelogeneous leukemia (AML) is a disease of the
myeloid compartment of the hematopoietic system and
is characterized by the accumulation of undifferentiated
blast cells in the peripheral blood and bone marrow [1].
Cytogenetics is considered the most important inde-
pendent prognostic parameter in AML [2,3]. Chromo-
somal abnormalities also provide useful information for
monitoring residual disease [4]. Most of chromosomal
abnormalities are detectable by banding cytogenetic ana-
lysis, and they occur in 55% of de novo AML in adults
[5,6]. Some chromosomal aberrations in AML are recur-
rent and closely associated with specific cytomorpho-
logical subtypes according to French-American-British
(FAB) criteria [7-10]. However, 5-10% of AML patients
present with multiple chromosomal rearrangements in-
volving three or more chromosomes. These patients
usually have a poor prognosis, and it is likely that some
of these rearrangements contribute to their disease pro-
gression [2].
We present a primary AML-M4 case with yet unre-
ported translocation events including seven different
chromosomes.
Results
Prior to chemotherapy treatment banding cytogenetics
revealed a karyotype 46,XX,del(5q)[8]/46,XX,del(5q),der
(17)t(4;17)[5]/45,XX,der(2)t(2;11),der(4)t(4;7),del(5q),-7,
der(11)t(11;7;22),der(17)t(4;17),der(22)t(11;22)[9]/46,XX
[1] (Figure 1) which was further specified by molecular
cytogenetic studies (Figures 2 and 3). Dual-color FISH
using a probe specific for BCR and ABL revealed two sig-
nals of ABL on both normal chromosome 9, one BCR sig-
nal was located on chromosome 22 and the other BCR
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gene was observed on a der(11) (Figure 2A). Three-color
FISH using BCR and ABL mixed with MLL probes re-
vealed the MLL gene signal was located on the short arm
of der(11), the other MLL gene signal was observed on
der(22), BCR gene signal was located on der(22) and
the two ABL gene signals were on the both normal
chromosome 9 (Figure 2B). Dual-color FISH using WCP
and CEP-specific probes were performed to confirm the
rearrangement (data not shown). The locus-specific probe
17p13 (p53) confirmed the presence of TP53 on the nor-
mal position in short arm of chromosome 17 (data not
shown). Finally, aMCB using probes for the corresponding
chromosomes was performed as previously reported
[11] (Figure 3). Thus, the following final karyotype
was determined:
46,XX,del(5)(q14q34)[8]/46,XX,del(5)(q14q34),der(17)t
(4;17)(p13;p13)[5]/45,XX,del(2)(p23),der(4)t(4;7)(p13;
Figure 1 GTG-banding revealed a complex karyotype involving six chromosomes and monosomy 7. All derivative or clonally missing
chromosomes are highlighted by arrowheads.
Figure 2 FISH-results using locus-specific probes. (A) Metaphase FISH using probes for BCR (green) and ABL (orange) showed two orange
signals on the two chromosomes 9, one green on the chromosome 22 and the other green signal was observed on der(11). (B) Metaphase FISH
using probes for BCR (yellow) and ABL (red) mixed with MLL break-apart probe showed one fusion signal was located on the short arm of der
(11), the second fusion signal was observed on der(22), two orange signals on the two chromosomes 9, one green on the chromosome 22 and
the other green signal was observed on der(11). Abbreviations: # = chromosome; der = derivative chromosome.
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q11.23),del(5)(q14q34),-7,der(11)(11qter->11p11.2::11
p11.2->11q23::2p23->2pter),der(11)(11pter->11q13::22q
11.2->22q13.3::11q13->11q21::7p12->7pter),der(17)t
(4;17)(p13;p13),der(22)t(11;22)(q23;q11.2)[9]/46,XX[1].
The abnormal cell population (57%) showed the follow-
ing immunophenotype: CD45+dim(90.4%), HLADr+(86%),
CD117+(57%), CD34+(57%), CD18+(60%), CD38+(83%)
and expressed CD2 (50%), CD7(24.2%), CD13 (39%),
CD33 (20%), CD123 (65%), CD15 (44%) and CD11c (52%)
heterogeneously. The abnormal cells negatively reacted
with antibodies to CD10, CD64, CD14, CD16, CD5 and
CD19. This immunophenotype was consistent with AML-
M4 according to FAB classifications.
Conclusions
We described a primary AML-M4 case with cytogenetic
rearrangements involving seven different chromosomes.
According to the literature, not a single case of AML
showed a der(4)t(4;7)(p13;q11.23), a der(11)(11qter->11p
11.2::11p11.2->11q23::2p23->2pter), a der(17)t(4;17)(p13;
p13), or a der(11)(11pter->11q13::22q11.2->22q13.3::11q
13->11q21::7p12->7pter) [12]. However, a t(2;11)(p23;
q23) was observed in one case of refractory anemia with
excess blasts-1 [12]. To the best of our knowledge, the
present case is the only one ever seen case of AML with
these cytogenetic aberrations [12].
The common chromosomal abnormalities in the AML-
M4 include monosomy 5 or del(5q), monosomy 7 or del
(7q), trisomy 8, t(6;9) (p23;q34), and rearrangements in-
volving the MLL gene mapped at 11q23 [del(11)(q23);
t(9;11)(p22;q23), t(11;19)(q23;p13)], and Core Binding
Factor B (CBFβ) mapped at 16q22 [del(16)(q22), inv(16)
(p13q22), t(16;16)(p13;q22)] [13]. However, in the present
case both MLL genes were intact.
In general, a complex karyotype in MDS or AML is
associated with a median survival of less than 1 year
[11,14]. Furthermore, the adverse prognostic effect of
monosomal karyotype was evident both in the pres-
ence and absence of monosomy 5 and/or 7, which
Figure 3 Array-proven multicolor banding (aMCB) was applied to determine the involved in this complex rearrangement. In each lane
the results of aMCB analysis using probe-sets for chromosomes 2, 4, 5, 7, 11, 17 and 22 are shown. The normal chromosomes are shown in the
first column, the derivative of all five chromosomes in the following ones. In the light gray by aMCB-probes unstained regions on the derivative
chromosomes are depicted. Abbreviations: # = chromosome; der = derivative chromosome.
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suggests that tumor suppressor or other critical genes
are not necessarily clustered in specific chromosomes
but are instead distributed across several chromo-
somes [15].
Monosomy 7 is a valuable prognostic marker in AML,
and chromosome 7 defects are prominent cytogenetic le-
sions in primary myelofibrosis, associated with unfavor-
able prognosis; they present with high incidences after
leukemic transformation [16]. Similarly, deletions on
7p12 of IKZF1 gene (which encodes the transcription
factor Ikaros) are associated with a very poor outcome
and high relapse rate in B-cell acute lymphocytic leu-
kemia [17]. Monosomy 7 is known as a recurrent cyto-
genetic aberration in approximately 10% of adult and 5%
of childhood AML cases [18]. Jäger et al. [19] found two
of seven myeloproliferative neoplasms patients with loss
of IKZF1 had monosomy 7. This result suggests that
IKZF1 may represent an important tumor-suppressor
gene affected by monosomy 7 [19].
The International Prognostic Scoring System (IPSS)
classifies cytogenetic and molecular genetic data in AML
with clinical data into four risk groups: favorable, inter-
mediate-I, intermediate-II and adverse [20]. The adverse
prognostic groups included inv(3)(q21q26.2) or t(3;3)
(q21;q26.2); RPN1-EVI1; t(6;9)(p23;q34); DEK-NUP214;
t(v;11)(v;q23); MLL rearranged; -5 or del(5q); -7; abnl
(17p); complex karyotype [20].
Complex karyotypes, which occur in 10-12% of AML
patients, have consistently been associated with a very
poor outcome [21]. A complex karyotype has been de-
fined as the presence of 3 or more (in some studies ≥ 5)
chromosome abnormalities. For AML it turned out that
the presence of t(8;21), inv(16) or t(16;16), and t(15;17)
ameliorates the adverse effect of increase karyotypic
complexity [20]. As indicated in the new WHO classifi-
cation, cases with other recurring genetic abnormalities,
such as t(9;11) or t(v;11), inv(3) or t(3;3), and t(6;9)
should also be excluded from complex rearranged karyo-
type patient group [22], because these groups constitute
separate entities. One striking observation is the increas-
ing incidence of adverse versus favorable cytogenetic ab-
normalities with increasing age. This, at least in part,
contributes to the poorer outcome of AML in older
adults [23].
In conclusion, we reported a de novo case of AML-
M4 with yet unreported translocation events involving
seven different chromosomes. Taken together all fin-
dings an adverse prognosis for this specific AML-case
must be considered.
Materials and methods
Case report
A 65-year-old woman was diagnosed as suffering from
AML in September 2011. Anemia, thrombocytopenia,
fever, fatigue and weight loss were the indicative symp-
toms. Her hematologic parameters were: white blood
cells (WBC) of 34.2×109/l with 25.5% neutrophils, 36.2%
lymphocytes, and 38.3% immature cells, red blood cell
(RBC) count was 1.86×106/mm3, hemoglobin level was
6.7 g/dl and the platelet count was 19×109/l. No treatment
had been administered prior to the tests mentioned below.
All human studies have been approved by the ethics com-
mittee of the Atomic Energy Commission, Damascus,
Syria and have therefore been performed in accordance
with the ethical standards laid down in the 1964 Declar-
ation of Helsinki and its later amendments. The patient
gave his informed consent prior to its inclusion in this
study. Later the patient was lost during follow-up.
Chromosome analysis
Chromosome analysis using GTG-banding was performed
according to standard procedures [24]. A minimum of 20
metaphase cells derived from unstimulated bone marrow
culture were analyzed. Karyotypes were described accor-
ding to the International System for Human Cytogenetic
Nomenclature [25].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using LSI
BCR/ABL dual color dual fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA), MLL
break-apart probe (Q-Biogene, USA) mixed with LSI
BCR/ABL dual color dual fusion translocation probe chro-
mosome enumeration probe (CEP) for chromosomes 9
and 11 (Abbott Molecular /Vysis) and 17p13 (p53), dual
color probe (Q-Biogene, USA) were applied according to
manufacturers instructions. Whole chromosome painting
(WCP) probes for chromosomes 2, 4, 5, 7, 11, 17 and 22
were also applied (MetaSystems, Altlussheim, Germany)
[24]. FISH using the corresponding chromosome specific
array-proven multicolor banding (aMCB) probe sets based
on microdissection derived region-specific libraries was
performed as previously reported [26]. A minimum of
20 metaphase spreads were analyzed, using a fluo-
rescence microscope (AxioImager.Z1 mot, Carl Zeiss
Ltd., Hertfordshir, UK) equipped with appropriate filter
sets to discriminate between a maximum of five fluoro-
chromes plus the counterstain DAPI (4,6- diamino-
2-phenylindole). Image capture and processing were
performed using an ISIS imaging system (MetaSystems).
Flow cytometric immunophenotype
Flow cytometric analysis was performed using a general
panel of fluorescent antibodies against the following an-
tigens typical for different cell lineages and cell types:
CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
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CD57, CD64, CD103, CD117, CD123, CD138, CD209,
CD235a and CD243; In addition to antibodies to Kappa
and Lambda light Chains, IgD, sIgM, and HLADr. All
antibodies purchased from BD Biosciences. Samples ana-
lyzed on a BD FACSCalibur™ flow cytometer. Autofluo-
rescence, viability, and isotype controls were included.
Flow cytometric data acquisition and analysis were con-
ducted by BD Cellquest™ Pro software.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WA-A, AA and AW provided the case and/or did primary cytogenetic and
main part of the FISH-tests; MAKO did detailed FISH studies. WA drafted the
paper and all authors read and approved the final manuscript.
Acknowledgements
We thank Prof. I. Othman, the Director General of Atomic Energy
Commission of SYRIA (AECS) and Dr. N. Mirali, Head of Molecular Biology
and Biotechnology Department for their support. This work was supported
by the AECS, in parts by the DAAD, Stefan-Morsch-Stiftung and the
Monika-Kutzner-Stiftung.
Author details
1Department of Molecular Biology and Biotechnology, Human Genetics
Division, Atomic Energy Commission, P.O. Box 6091, Damascus, Syria.
2Department of Molecular Biology and Biotechnology, Mammalians Biology
Division, Atomic Energy Commission, Damascus, Syria. 3Institute of Human
Genetics, Jena University Hospital, Jena, Germany.
Received: 5 March 2013 Accepted: 18 March 2013
Published: 5 May 2013
References
1. Rubnitz JE: Childhood acute myeloid leukemia. Curr Treat Options Oncol
2008, 9:95–105.
2. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati
MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ,
Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and
Leukemia Group B (CALGB8461): Pretreatment cytogenetic abnormalities
are predictive of induction success, cumulative incidence of relapse, and
overall survival in adult patients with de novo acute myeloid leukemia:
results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002,
100:4325–4336.
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J,
Hann I, Stevens R, Burnett A, Goldstone A: The importance of diagnostic
cytogenetics on outcome in AML: analysis of 1,612 patients entered into
the MRC AML 10 trial. The medical research council adult and children’s
leukaemia working parties. Blood 1998, 92:2322–2333.
4. Grimwade D, Lo Coco F: Acute promyelocytic leukemia: a model for
the role of molecular diagnosis and residual disease monitoring in
directing treatment approach in acute myeloid leukemia. Leukemia 2002,
16:1959–1973.
5. Mrozek K, Heinonen K, Bloomfield CD: Prognostic value of cytogenetic
findings in adults with acute myeloid leukemia. Int J Hematol 2000,
72:261–271.
6. Mrozek K, Heinonen K, Bloomfield CD: Clinical importance of cytogenetics
in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:19–47.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C: Proposals for the classification of the acute leukaemias.
French-American-British (FAB) co-operative group. Br J Haematol 1976,
33:451–458.
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C: Proposed revised criteria for the classification of acute myeloid
leukemia. A report of the French-American-British Cooperative Group.
Ann Intern Med 1985, 103:620–625.
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C: Criteria for the diagnosis of acute leukemia of megakaryocyte
lineage (M7). A report of the French-American-British Cooperative
Group. Ann Intern Med 1985, 103:460–462.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C: Proposal for the recognition of minimally differentiated acute
myeloid leukemia (AML-M0). Br J Haematol 1991, 78:325–329.
11. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B,
Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L,
Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C:
New insights into the prognostic impact of the karyotype in MDS and
correlation with subtypes: evidence from a core dataset of 2124
patients. Blood 2007, 110:4385–4395.
12. Mitelman F, Johansson B, Mertens F (Eds): Mitelman database of
chromosome aberrations and gene fusions in cancer. 2012. Available at:
http://cgap.nci.nih.gov/Chromosomes/Mitelman [accessed 26.11.2012].
13. Chen Z, Sandberg AA: Molecular cytogenetic aspects of hematological
malignacies: clinical implications. Am J Med Genet 2002, 115:130–141.
14. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA:
Cytogenetic abnormalities in a series of 1,029 patients with primary
myelodysplastic syndromes: a report from the US with a focus on some
undefined single chromosomal abnormalities. Cancer 2008, 113:3331–3340.
15. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A:
Monosomal karyotype in myelodysplastic syndromes, with or without
monosomy 7 or 5, is prognostically worse than an otherwise complex
karyotype. Leukemia 2011, 25:266–270.
16. Mesa R, Li C, Ketterling R, Schroeder G, Knudson R, Tefferi A: Leukemic
transformation in myelofibrosis with myeloid metaplasia: a
single-institution experience with 91 cases. Blood 2005, 105:973–977.
17. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D,
Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR:
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of
Ikaros. Nature 2008, 453:110–114.
18. Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7:
epidemiology, biology, and mechanistic implications. Blood 1995,
85:1985–1999.
19. Jäger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, Pietra D,
Harutyunyan A, Klampfl T, Olcaydu D, Cazzola M, Kralovics R: Deletions of
the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia
2010, 24:1290–1298.
20. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK,
Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T,
Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS,
Löwenberg B, Bloomfield CD, European LeukemiaNet: Diagnosis and
management of acute myeloid leukemia in adults: recommendations
from an international expert panel, on behalf of the European
LeukemiaNet. Blood 2010, 115:453–474.
21. Mrozek K: Cytogenetic, molecular genetic, and clinical characteristics of
acute myeloid leukemia with a complex karyotype. Semin Oncol 2008,
358:365–377.
22. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris
NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD: The 2008
revision of the WHO classification of myeloid neoplasms and acute
leukemia: rationale and important changes. Blood 2009, 114:937–951.
23. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE,
Anderson JE, Petersdorf SH: Age and acute myeloid leukemia. Blood 2006,
107:3481–3485.
24. Al-Achkar W, Wafa A, Nweder MS: A complex translocation t(5;9;22) in
Philadelphia cells involving the short arm of chromosome 5 in a case of
chronic myelogenous leukemia. J Exp Clin Cancer Res 2007, 26:411–415.
25. Shaffer LG, Slovak ML, Cambell LJ: ISCN. International system for human
cytogenetic nomenclature. S Karger AG: Basel; 2009.
26. Weise A, Mrasek K, Fickelscher I, Claussen U, Cheung SW, Cai WW, Liehr T,
Kosyakova N: Molecular definition of high-resolution multicolor banding
probes: first within the human DNA sequence anchored FISH banding
probe set. J Histochem Cytochem 2008, 56:487–493.
doi:10.1186/1755-8166-6-18
Cite this article as: Al-achkar et al.: A de novo acute myeloid leukemia
(AML-M4) case with a complex karyotype and yet unreported
breakpoints. Molecular Cytogenetics 2013 6:18.
Al-achkar et al. Molecular Cytogenetics 2013, 6:18
http://www.molecularcytogenetics.org/content/6/1/18
2.Results 93
 3.Discussion                                                                                                                                                           94 
 
3. Discussion 
As mentioned in the introduction: normal karyotypes are found in 40-50% of all AL cases 
exclusively studied by routine GTG-banding analysis (Mrózek et al. 2009, Walker and 
Marcucci 2012, Ilyas et al. 2015). However, analyses using high resolution molecular 
(cyto)genetic techniques lead to detection of cryptic chromosomal abnormalities (Karst et al. 
2006, Tyybäkinoja et al. 2007, Gross et al. 2009, Haferlach et al. 2014). Thus, the first phase 
of the present work was dedicated to identify cryptic chromosomal aberrations in 103 CN-AL 
cases using FISH-banding technique. In the second phase a detailed characterization of newly 
identified tumor-associated breakpoints was done. The third part of this thesis was to study 
submicroscopic CNAs in AL. The fourth and final step evaluated the newly identified tumor-
associated rearrangements with regard to their potential clinical relevance. 
 
3.1.   Cytogenetic analysis in the diagnosis of AL 
Cytogenetic banding analysis has still been the standard method for detection of 
diagnostically relevant recurrent chromosomal aberrations in AL and the karyotype alone or 
together with other parameters is used to stratify patients into three prognostic groups: 
favorable, intermediate and unfavorable. For instance, APL-patients with a favorable 
prognosis due to presence of a translocation t(15;17) with the well-known PML-RARA 
rearrangement are treated by ATRA- and anthracycline- or ATRA and arsenic trioxide-based 
protocols. Other AL-patients may have an unfavorable prognosis in connection with a Ph-
translocation t(9;22), 11q23 alterations, monosomic and/or complex karyotypes; such patients 
need intensive protocols and/or allogeneic bone marrow transplantation during their first 
remission (Grimwade et al. 2010, Kayser et al. 2012, Ferrara and Schiffer 2013). As it is well 
known that, when using banding karyotyping, about 40-50% of AL patients show a 
cytogenetically normal karyotype, such patients are categorized as having an intermediate 
prognosis (Mrózek et al. 2009, Walker and Marcucci 2012, Ilyas et al. 2015). This takes into 
consideration that cryptic chromosomal aberrations may be missed due to: (i) limited 
sensitivity of chromosomal banding techniques, even in case of good chromosomal 
morphology,  the aberrations have at least 10Mb in size to be visible, (ii) cryptic or masked 
aberrations, i.e. they are not resolvable due to a similar or identical GTG-banding pattern 
and/or poor chromosome morphology, and (iii) ‘bad metaphases’ , which may be difficult to 
obtain and to be evaluated, as chromosomes may not be well-spread, clumsy or appearing as 
fuzzy with indistinct margins; thus even numerical aberrations may be missed (articles 2, 3, 
5, 6, Karst et al. 2006, Mrózek et al. 2009). In cases according to banding cytogenetics normal 
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karyotype, repeated chromosomal analysis is obviously not suited for disease monitoring 
(Murphy and Bustin 2009, Polampalli et al. 2011). 
 
3.2. Molecular cytogenetics studies of CN-AL cases  
Molecular cytogenetic approaches have shown their ability to uncover and detect cryptic 
chromosomal aberrations since more than 2 decades and also in this work (articles 2, 3, 5, 6, 
7, 8, Karst et al. 2006, Mrózek et al. 2009). Besides metaphases also interphase nuclei can be 
useful for diagnostics. In case of low mitotic index, alterations can also be detected and/or 
monitored in non-dividing cells and low mosaics level can be easily detected by that approach 
(Inaba et al. 2013, Woo et al. 2014). Such studies were also used successfully for 
determination of mosaic levels in the present work (article 7).   
Nowadays, FISH using locus-specific and chromosome enumeration probes is a routine 
technique for classification, risk stratification and predication of therapy. In (article 1) we 
reviewed the effectiveness of FISH technique in cancer diagnosis and particularly in 
leukemia. FISH approaches are especially suited to characterize chromosomal breakpoints, 
submicroscopic copy number changes and fusion genes due to translocations or other 
rearrangements. All these features are characteristically found as acquired aberrations in AL.   
 
3.2.1.  Detection of new chromosomal aberrations 
To identify yet unreported acquired chromosomal aberrations in 61 CN-ALL and 42 CN-
AML cases were studied by the whole genome oriented FISH-banding based probe set 
mMCB (Weise et al. 2003); results are summarized in articles 2, 3, 5, 6, 7, 8 plus yet 
unpublished data. Overall, balanced and unbalanced translocations, derivative 
chromosomes, isochromosomes, insertions, interstitial deletions, inverted duplications and/or 
numerical aberrations were identified in CN-ALL and CN-AML cases. It could be confirmed 
that mMCB probe set provides an optimal possibility to detect and characterize 
simultaneously all subregions in each human chromosome and for the analyses of inter-and 
intra-chromosomal rearrangements of the whole human karyotype in one single experiment 
with a resolution between 3-10 Mb. Still the sensitivity of mMCB is dependent on sizes of 
rearranged fragments and labeling of the underlying partial chromosome painting probes.  
Based on the aforementioned range of resolution it is logical to state that mMCB is not suited 
to detect submicroscopic aberrations smaller than 3 Mb. Thus, iFISH probes, LSPs, MLPA 
and array-CGH were applied additionally in the studied AL-cases. A major restriction of this 
kind of comprehensive analyses is the large amount of routine material needed. Nonetheless, 
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this kind of problem is well-known in tumor cytogenetic studies (Weise et al. 2003, Liehr 
2009, Heller et al. 2004).  
In the retrospectively studied of 61 CN-ALL cases, chromosomal abnormalities were 
identified in 34% (21/61) and new clonal cryptic rearrangements were found in 9/21 (43%) 
cases. Interestingly most of those originally considered as patients with a CN-AL had in 
reality complex karyotypes. Chromosomes 2, 3, 4, 5, 6, 7, 9, 10, 11 and 14 were most 
frequently involved in structural abnormalities. Data published in article 2 revealed a single 
cryptic and complex rearrangement for chromosome 11 involving a reciprocal translocation 
and an inversion, in article 3 a complex four-way translocation involving the chromosomes 3, 
5 and 10, in article 5 a balance three-way translocation including chromosomes 2, 9 and 18 
and in article 6 an inverted duplication on a chromosome 14 leading to an IGH@ locus 
splitting and rearrangement were reported. To the best of our knowledge these rearrangements 
have not been seen in ALL before (Cancer Genome Anatomy Project (CGAP); Atlas of 
Genetics and Cytogenetics in Oncology and Hematology; article 7, Table 1). Still, the 
majority of CN-ALL cases (66%) presented with a normal karyotype after mMCB-analysis 
(article 7). To data, only few comparable studies are available using FISH-banding 
techniques to screen for cryptic chromosomal aberrations and to define the novel 
chromosomal rearrangements. A study conducted by Karst et al. (2006) used mMCB probe 
and detected acquired cryptic chromosomal aberrations after G-banding analysis in 57% of 
ALL cases. Recently, a few similar studies have focused exclusively on the analysis of cases 
presenting with complex karyotypes (Al-Achkar et al. 2010, Ney Garcia et al. 2015).  
Several groups have applied mFISH such as SKY/M-FISH to clarify the karyotypes and 
characterize the composition of marker chromosomes or incomplete identified karyotypes 
(Rowley et al. 1999, Mathew et al. 2001, Elghezal et al. 2001, Lu et al. 2002, Nordgren et al. 
2002, Poppe et al. 2005, Mkrtchyan et al. 2006).  Rowley et al. (1999) did not find any cryptic 
abnormalities in 5 T-ALL cases with normal karyotype and clarified already known 
chromosomal rearrangements in 3 cases. Additionally, Nordgren et al. (2002) demonstrated 
that, SKY and LSPs could identify chromosomal aberrations in up to ~80% of ALL cases. 
Altogether, SKY/ M-FISH failed to detect any cryptic chromosomal abnormalities of CN-
ALL cases but, of course, could refine the result of most known chromosomal 
rearrangements. Still, mFISH technique has limitations because they enable to detect most of 
intra-chromosomal abnormalities such as interstitial deletions and inversions and inter-
chromosomal anomalies  >5 Mb (Rowley et al. 1999, Mathew et al. 2001, Elghezal et al. 
2001, Lu et al. 2002, Nordgren et al. 2002, Karst et al. 2006).  
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More specifically analyzing the data obtained here for CN-AML cases, chromosomes 9 and 
11 were found most frequently involved in structural abnormalities, and chromosome 7 in 
numerical abnormality (article 8 and yet unpublished data). This kind of chromosomal 
aberrations was recognized in 12/42 (28%) and rare clonal rearrangements were observed in 
2/42 (5%). This is in agreement with the study done by Gross et al (2009) who applied FISH-
banding technique and identified cryptic chromosomal abnormalities in 2/26 CN-AML cases. 
As well, Zhang et al. (2000) used SKY and found clonal abnormalities in 2/28 of CN-AML 
cases. In article 8 a rare cryptic three way translocation between chromosomes 10, 19 and 11 
and deletion of the 3’  MLL gene was reported by us.  
However, in the present work, there is one additional limitation of mMCB technique to be 
discussed here. Due to florescence interference of labeled subregions in each chromosome 
with same/ similar colors ambiguously identification of submicroscopic translocations, cryptic 
deletion, small amplification and cryptic insertion may happen (articles 2, 3, 5, 6, 7, 8 plus 
yet unpublished data, Karst et al. 2006, Gross et al, 2009). To overcome this problem, the 
overwhelming majority of aberrations detected here were confirmed using MCB and/or LSP 
analysis e.g. to clearly distinguish unbalanced translocations from balanced ones. 
Additionally, aCGH and MLPA, which use genomic DNA, are powerful tools in the analysis 
of unbalanced chromosomal rearrangements such as CNA gains and losses particularly in 
leukemia. Overall, iFISH, MLPA and aCGH could be the methods of choice when the mitotic 
index is low and the quality of metaphases is suboptimal (Usvasalo et al. 2009, Yasar et al. 
2010). 
Summary: The present work detected new clonal abnormalities using high resolution FISH-
banding technique in 103 AL cases reported previously to have a normal karyotype according 
to G-banding. 
 
 
3.2.2.  Further characterization of newly identified breakpoints 
Delineation of mMCB results and definition of the breakpoints, either balanced or imbalanced 
ones (losses or gains), was done using either MCB and/or (to do in more detail) large numbers 
of LSPs (BACs and commercially available probes) for the target sequences; for more details 
see articles 1-10. As the whole human genome has been sequenced and human sequences are 
harbored in BAC clones they can easily be used as FISH probes. Thus, breakpoints could be 
narrowed down and candidate genes could be determined on the molecular level using 
genome browsers. In this work, besides the CN-AL cases, seven AML and one ALL with 
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complex karyotypes were also studied in detail to characterize their breakpoints (articles 4, 
9, 10 and yet unpolished data). Interestingly, in the case published in article 9 a rare 
translocation t(3;10)(q26;q21) was detected. Other technical approaches including NGS, long-
range PCR and direct Sanger sequencing were used to map this chromosomal translocation in 
detail through co-work with a partner laboratory in Prague (Czech Republic). Thus, 
nucleotide sequence of the breakpoint revealed a fusion of the MECOM gene on 3q26 to 
C10orf107 on 10q21. Aberrant expression of MECOM gene results in disturbance of the 
normal proliferation and differentiation of HSC and finally leads to maturation arrest 
(Balgobind et al. 2010). In yet unpublished data MECOM gene rearrangements were also 
identified in two further AML cases. One case had an unbalanced translocation 
der(3)t(3;7)(q26.2q21.2). LSPs and aCGH revealed MECOM-CDK6 fusion gene. The cyclin 
dependent kinase 6 (CDK6) is disrupted or overexpressed by translocation in hematological 
malignancies, particularly in T-ALL and T cell lymphoblastic lymphoma, whereas the variant 
translocation t(3;7)(q26;q21) is less frequently reported in myeloid leukemia (Lien et al. 2000, 
Raffini et al. 2002, Storlazzi et al. 2004). The second case had a balanced translocation 
t(3;8)(q26.2;q24.2). Few such cases have been reported in the literature with PVT1-MECOM 
fusion gene and associated with loss of chromosome #7 as also observed in our CN-AML 
case (Mitelman et al. 2015). PVT1 is an oncogene and contains a long non-coding RNA. The 
role of PVT1 in leukemogenesis still is unclear, thus, aberrations in EVI1 may leads to 
deregulated expression, similar to other balanced or unbalanced chromosomal translocations 
involving chromosome 3q26 (Tseng et al. 2014, Lennon et al. 2007). However, 
overexpression of MECOM indicates for unfavorable prognosis in AML (Haferlach et al. 
2012). 
MLL gene (11q23) was identified most frequently rearrangements in the present work; in 
AML, the MLL partner genes were MLLT3 (9p21.3), MLLT4 (6q27) and MLLT10 (10p12.3) 
while in ALL the partner genes were MLLT2 (4q21) and MLLT10. In article 8 (Table 1) 
chromosomal breakpoints were narrowed down for a rare three-way translocation as 
10p12.31, 11q23.3 and 19q13.31, and the breakpoints of the altered Y-chromosome as 
Yp11.2 and Yq11.23. Additionally, 3’ MLL was deleted and aCGH confirmed the deletion 
between 118,394,728-118,952,688 according to GRCH37/hg19. Commonly, the cryptic 
insertion of MLL gene within partner genes cannot be detected by G-banding and rarely 
identified by mMCB. In article 2 (Table 1) the corresponding breakpoints were narrowed 
down and defined to be 11p15.4 and 11q24.2 on both homologous chromosomes 11. Besides, 
cryptic insertion of 5’ MLL gene into the AFF1 gene in chromosome 4q21 was detected only 
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by a dual-color break apart probe. In yet unpublished data two further cases were identified 
with cryptic MLL-gene insertions; an infant with B-ALL had an ins(10;11)(p12.3;q23.3) and 
in this case 3’MLLT10 was inserted into MLL gene. This variant translocation 
t(10;11)(p12;q23) has been frequently observed in young children with AML and very rarely 
with ALL (Lillington et al.1998, Coenen et al. 2011). The second case was an adult AML 
subtype M5 and identified insertion ins(6;11)(q27;q23). The translocation t(6;11)(q27;q23) is 
frequently seem in AML and could be detected by G-banding. To best our knowledge, yet 
only one case has been reported with an insertion of chromosome 11q13q23 into chromosome 
6 in an adult AML subtype M4 (Mitelman et al. 2015, Martineau et al. 1998). Overall, MLL 
gene plays an essential role in normal hematopoietic growth and differentiation. 
Abnormalities in this region can occur very early in HSC development (Ansari and Mandal 
2010, Ferrando et al. 2003) and MLL is important as molecular marker to be investigated in 
the early diagnosis of AL. 
In the present work, MCB and LSPs were proven to be highly useful for refining of 
conventional banding karyotypes and elucidating composition of marker chromosomes or 
incompletely identified rearrangements. All normal and complex karyotypes fall into two 
main groups: such with common and such with unique breakpoints. Thus, the potential 
pathogenic impact of the identified breakpoints is suspected to be due to non-random 
chromosomal translocations, insertions, and low or high gene dosages. The consequences of 
these abnormalities lead to identify the gene(s) which are important for leukemia 
transformation in the past (Aplan 2006) and also in the present work.  
 
Summary: Characterization of chromosomal breakpoints is required in the diagnosis of acute 
leukemia, to help in classification, risk stratification and prediction of therapy of the disease.  
 
3.3. Identifications of acquired CNAs in AL 
The better understanding of leukemogenesis and providing entries to therapy development, 
different molecular techniques for diagnostic purposes could be applied. Besides FISH, 
MLPA and aCGH are useful, i.e. approaches which have much higher resolution than FISH, 
but can only detect unbalanced aberrations and no low level mosaics. Few studies have 
applied MLPA and aCGH to identify CNAs in AL (Haferlach et al. 2014, Schwab et al. 2013, 
Strefford et al. 2007, Tyybäkinoja et al. 2007). In the present work, DNA was isolated from 
the cytogenetically worked up cell suspensions of 34/61 CN-ALL and 27/47 AML (42 normal 
and 5 complex karyotypes) cases.  Cryptic CNAs were detected in ~80% and in ~63% of 
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those CN-ALL and AML cases respectively. This is in agreement with the study conducted 
by Haferlach et al. (2014) who used aCGH and, detected CNAs in 80.3% of CN-ALL cases. 
As well, Strefford et al. (2007) also used aCGH and demonstrated that, 83% of ALL cases 
had CNAs. A study performed by Tyybäkinoja et al. (2007) also applied aCGH for 26 CN-
AML cases and found cryptic CNAs only in 4/26 (15%) of CN-AML. Additionally, a large 
study performed by Schwab et al. (2013) who used MLPA to screen for the most frequently 
deleted genes in high risk BCP-ALL found deletion of IKZF1, PAX5, CDKN2A/B and RB1 
as also reported here in article 7. 
All here reported CNAs have been checked by UCSC genome browser to exclude benign 
copy number variations (CNVs): http://genome-euro.ucsc.edu/cgi-
bin/hgGateway?redirect=auto&source=genome.ucsc.edu. Thus, all of them most likely are 
leukemia-related genetic changes, which were recognized in 27/34 of CN-ALL and in 17/27 
of AML cases. According to the result of article 7 and yet unpublished data, the CNAs in 
CN-ALL cases were identified most frequently in chromosomes  #7, #9, #10, #11, #13, #15, 
#17, #18, #20 and #21, i.e.  8-15 CNAs per chromosomes, while in AML often in 
chromosomes #7, #11, and #15, i.e. 2-3 CNAs per chromosomes (Table 6.1). One of the 
known shortcuts of aCGH is the inability to detect reliably acquired CNAs less than ~20 Kb 
in size particularly in AML. A suggestion to overcome this problem is to used high-resolution 
SNP-array-CGH analysis (article 7 plus yet unpublished data, Le Scouarnec and Gribble 
2012, Bullinger and Fröhling 2012). 
 
3.3.1. CNAs expressed as losses 
According to results shown in article 7, significant losses of CNs in CN-ALL were observed 
more frequently for chromosomes #7, #9, #10, #11, #13, #15, #17, #20 and #21. Furthermore, 
CNAs have been identified here, encompassing single or few genes, only. Chromosome 7 
involved deletion of IKZF1 at 7p12.2 in 5 of 34 (14%) studied CN-ALL cases. IKZF1 
encodes IKAROS protein that required for the development of all lymphoid lineages. 
Deletions and/or sequence mutations of IKZF1 were present in 15% of pediatric B-ALL 
(Mullighan et al. 2009b). Besides, deletion of 7q21.2 region was observed in the present work 
in 4 of 34 (12%) of CN-ALL cases and mapped for CDK6 gene. The majority of chromosome 
9 abnormalities was expressed as deletions of cell cycle regulatory genes at 9p21.3 in 8/34 
(24%) of the studied CN-ALL cases. CDKN2A/B genes deletion can be detected at initial 
diagnosis or acquired at relapse, suggesting that CDKN2A/B gene deletion is a secondary 
genetic event (Schwab et al. 2013, Kim et al. 2011, Sulong et al. 2009). 
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Table 6.1. Summary of the most common recurrent CNAs in AL detected by aCGH and 
MLPA in the present work 
CN-AL type of CNA chromosome band gene 
no. of 
cases 
CN-ALL 
Loss 
 
7 p12.2 q21.2 
IKZF1 
CDK6 
5 
4 
9 p21.3 p13.2 
CDKN2A/B 
PAX5 
8 
3 
10 q23.31 PTEN 6 
11 q14.2 PICALM 3 
13 q14.2 RB1 3 
15 q26.1 CHD2 7 
17 p13.1 TP53 4 
20 q13.2 ZNF217 4 
21 q22.2 ERG 2 
Gain 18 q21.2 DCC 3 
AML 
Loss 
 
7 -7/del(7q) ----- 4 
11 q23.3 MLL 2 
15 q26.1 CHD2 2 
Gain 8 q24.2 MYC 1 
 
Additionally, deletion of PAX5 gene located in 9p13.2 was found in 3/34 (9%). Deletion of 
PAX5 was reported in 31.7% of B-ALL and also it has been involved in several chromosomal 
translocations. In future, PAX5 could be used as one of the molecular markers in diagnosis 
and monitoring of the disease, especially in B-ALL (Schwab et al. 2013, Nebral et al. 2009, 
Mullighan et al. 2007). Deletion of PTEN gene at 10q23.31 was detected in 6/34 (17%) of the 
studied CN-ALL cases. Deletion of the tumor suppressor gene PTEN leads to activation of the 
PI3K/AKT pathway and in subsequent increase in protein synthesis, cell cycle progression, 
migration, and survival. Consequently, deletion of PTEN trends to poor outcome. Recently, 
numerous targeting drugs for the PI3K/AKT pathway for the therapy of cancer have entered 
in clinical trials (Zhao et al. 2013, Ciuffreda et al. 2014, Mendes et al. 2014). In chromosome 
13 was found deletions involving RB1 gene at 13q14.2 in 3/34 (9%) of the studied CN-ALL 
cases. Deletion of RB1 gene is highly frequent observed in B-CLL but rarely seen in ALL. 
Thus, RB1 pathway was identified as potential targets for therapy of ALL (Schwab et al. 
2013, Cavé et al. 2001).  
Interestingly, a novel recurrent submicroscopic CNA expressed as loss of 15q26.1: focal 
deletion of CHD2 gene located there was found in 7 of the 34 (20%) CN-ALL and in 2 of the 
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27 (7%) AML studied cases. In chromosome 17 deletion of TP53 gene at 17p13.1 was 
identified in 4/34 (12%) of studied CN-ALL cases. Deletions and sequence mutations of TP53 
gene associated with non-response of chemotherapy and unfavorable outcome in ALL (Hof et 
al. 2011, Stengel et al. 2014). Recurrent deletion was found also in 21q22.22 targeting 
exclusively ERG in 2/34 of studied CN-ALL cases. ERG gene is a transcription factor which 
belongs to the erythroblast transformation-specific (ETS) family. It has a key regulatory role 
in hematopoietic differentiation during early T and B cell development. Overexpression of 
ERG gene was shown in AML and T-ALL and was associated with poor prognosis. Currently, 
deletion of ERG gene is associated with a very good outcome in older children and young 
patient with BCP-ALL (Clappier et al. 2014, Marcucci et al. 2005).  
Besides, many of CNAs losses involving transcriptional regulators and co-activators genes 
like 3q26.32 (TBL1XR1; n = 1), 12p13.2 (ETV6; n = 2), and 21q22.12 (RUNX1; n= 1), or 
regulators of chromatin structure and epigenetic regulators genes like 16p13.3 (CREBBP; n = 
2) were identified - for more information refer to article 7.  
In AML losses of CNAs were observed less frequent than in CN-ALL (yet unpublished 
data). Overall, CNAs were found most often in chromosomes #7 and #11. Recurrent loss of 
the chromosome 7 and 7q was recognized in 4/27 (15%) of studied AML cases. Loss of -
7/del(7q) leads to leukemic transformation due to loss of function of such putative tumor 
suppressor gene in these regions that regulates myeloid growth and differentiation and 
associated with adverse outcome (Hosono et al. 2014, Braoudaki and Tzortzatou-
Stathopoulou 2012).  In chromosome 11 deletion of 11q23.3 including 3’  MLL gene was 
detected in 2/27 (7%) of the studied AML cases; one case had a translocation 
t(10;19;11)(p12;q13;q23) and the second had a translocation t(9;11)(p21.3;q23.3). The fact 
that both patients died in short time after HSCT might be due to presence of MLL gene 
rearrangements (article 8 and yet unpublished data).  
 
3.3.2.  Gains 
Gains of CNAs in CN-ALL and AML were found less frequent than losses. Gains of CNAs 
according to article 7 were seen in ~20% of CN-ALL studied cases. Interestingly, duplication 
of DCC gene in 18q21.2 was present in 3 of the 34 (9%). However, oncogene overexpression 
resulting from gene duplication is infrequent in ALL. Still, we found MYB and ABL1 
amplification in one case. In yet unpublished data of AML studied cases, gain of CNs was 
found in ~28% of the cases. Remarkable, amplification of MYC oncogene was detected in one 
of studied AML cases. MYC gene amplification was previously observed in approximately 
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1% of the AML and MDS cases and outcome still is unclear (Storlazzi et al. 2006, 
Tyybäkinoja et al. 2007, Mrózek 2008).  
 
3.3.3.  New candidate genes  
Besides the confirmation of involvement of yet rarely reported genes in AL also three new 
candidate genes were identified in the present study. 
CDK6 gene at 7q21.2 is the catalytic subunit of a protein kinase complex that regulates cell 
cycle G1 phase progression and G1/S transition. Deletion of CDK6 was identified in this 
study in 4 of 34 (12%) of CN-ALL cases. It has been shown recently that inhibition of CDK6 
may lead to overcome the differentiation block seen in AML with MLL translocations (Placke 
et al. 2014). Thus, further studies for this gene may also be recommended for better 
understanding of ALL biology.  
CHD2 gene was found to be heterozygously deleted in 7 of CN-ALL and 2 of AML cases. 
The CHD2 gene is a member of the chromodomain helicase DNA-binding (CHD) protein 
family, which are all characterized by a chromatin-remodeling domain (the chromodomain) 
and an SNF2-related helicase/ATPase domain (Carvill et al. 2013). Thus, in future it may be 
of interest to study CHD2 gene deletions also for presence of mutations in this gene and also 
to screen ALL patients in general for CHD2 gene mutations.  
The DCC gene is a member of the immunoglobulin superfamily of cell adhesion molecules 
and acts as a transmembrane dependence receptor for netrins, key factors in the regulation of 
axon guidance during development of the central nerve system. Amplification of DCC gene 
was previously reported only in CLL (Derks et al. 2010, Alhourani  et al. 2014), however, this 
is the first report for DCC gene amplification in ALL. To evaluate the role of the DCC gene 
and to elaborate its potential as a molecular marker in ALL still needs more studies. 
Overall, combination of molecular cyto(genetic) techniques are necessary to provide 
comprehensive details for each clinical case (Roberts and Mullighan 2015, Ilyas et al. 2015).  
 
Summary: High rates of CNAs were detected in CN-ALL, that mean all cases hold 
detectable cryptic genomic aberrations, whereas AML cases showed lower rate of CNAs and 
most likely hold more point mutations or epigenetic changes in relevant genes. Thus, besides 
here used approaches DNA sequencing and SNP-array-CGH may be necessary to be used for 
mutation detection in AL. 
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3.4.  Correlations with clinical data of patients 
Chromosomal alterations and breakpoints in CN-AL and/or in complex rearranged AL could 
be assessed in this work for 58% of the cases. As well known from literature, at diagnosis of 
AL different prognostic factors besides cytogenetics need to be investigated quickly and cost-
effectively such as age, gender, WBC count, cytomorphology of leukemic cells and 
immunophenotype (Pui et al. 2003, Burmeister et al. 2009, Döhner et al. 2010, Vardiman et 
al. 2009). Thus, the best way to evaluate the prognostic significant of each cytogenetic 
abnormality may be different. For instance, one of the well characterized recurrent 
chromosomal abnormalities in AL is the MLL (11q23) gene rearrangements which occurred in 
10% of ALL cases overall, the majority being infant B-ALL (<1 year of age). Up to 93% of 
affected infants under the age of 90 days harbor MLL rearrangements such as translocations 
t(4;11), t(11;19), or t(1;11), and most of these children cannot be rescued with the currently 
available therapies. On the other hand MLL is involved in 30%–50% of childhood and in 5% 
of adult AMLs. However, cytogenetic abnormality of MLL gene predicts a different outcome 
depending on the disease phenotype (articles 2, 8, Balgobind et al. 2011, Chowdhury and 
Brady 2008). It has been proposed that infant leukemia with and without MLL gene 
rearrangements are different diseases with different clinical characteristics and different 
responses to therapy (Tuborgh et al. 2013). The first indication on MLL-gene involvement in 
infant leukemia (<10%) is the presence of skin lesions which so called leukemia cutis. Thus, a 
skin biopsy can be the first screen for the presence of leukemic blast cells. BM aspiration 
revealed either lymphoblasts or monoblasts and the immunophenotyping of routinely 
processed BM specimens is very helpful in establishing the diagnosis of AL (Cho-Vega et al. 
2008, Vardiman et al. 2009), however, 11q23 abnormalities occur predominantly in AML 
(FAB types M5 and M4), high WBCs count and frequently associated with monoblastic cells, 
whereas in ALL highly associated with BCP-ALL, high WBC counts and CD10 negative and 
CD15 positive. All of these clinical parameters still to be considered at the diagnosis of AL 
because MLL rearrangements are easily to missed by G-banding, associated with unfavorable 
outcome in most cases and need correct therapeutic decision (article 2, 8, Pui et al. 2003, 
Burmeister  et al. 2009, Döhner et al. 2010, Vardiman et al. 2009).  
In the present work, three BCP-ALL cases with normal karyotype and four AML-M5 cases 
were studied; one normal and three complex karyotypes were identified including MLL gene 
rearrangements according to the above criteria (articles 2, 8 and yet unpublished data). 
Overall, detection or exclusion of MLL disruption or amplification is extremely necessary for 
treatment decisions, as well as for basic research enabling new insights into possible fusion 
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genes involving MLL. According to FISH the translocation partners for 11q23 are numerous 
and markedly heterogeneous. Thus, to detect the lower level of clonal abnormality, an 
additional molecular method may be needed such as RT-PCR to further evaluate the MLL 
partner fusion genes.  
Detection of specific recurrent chromosomal abnormalities such as deletion of CDKN2A/B 
can be evaluated. Deletions of CDKN2A/B (9p21.3) can be found in 30-50% of ALL as also 
were only found in the present work in 24% of studied CN-ALL cases. Deletions of 
CDKN2A/B result in inactivation of genes in this locus, mainly p16 and p15, suggesting in 
inactivation of these genes that contribute to leukemogenesis. The outcome of cases with 
CDKN2A/B deletion depends on the status of the second allele, as homozygous deletions are 
associated with poor outcome and heterozygous deletions represent markers for favorable 
outcomes (article 5, 6, 7, Schwab et al. 2013, Zhao et al. 2013, Kim et al. 2011, Sulong et al. 
2009).  
All cases were described here in this work with complex karyotypes in article 3, 4, 5, 8, 10 
and yet unpublished date, were associated with adverse prognosis and with maximal overall 
survival rate less than 2 years. This is in agreement with the study conducted by Moorman et 
al. (2007) who observed patients with complex karyotype had an unfavorable outcome and 
relapses occurring in the first 2 years after diagnosis. Actually, this subgroup does not appear 
to be associated with age, gender, or WBC count, as well with immunophenotype. Most of the 
abnormal chromosomes in complex karyotypes were identified as unbalanced and balanced 
translocations (article 3, 4, 5, 8, 10 and yet unpublished date), the unbalance translocations 
that was reported in article 3, suggesting that, activation of such oncogenes in 5q31.1 (IL3) 
and in 10p12.3 (MLLT10) are important in leukemogensis and associated with poor outcome. 
Thus, in AL cases with complex karyotypes, patients require intensive chemotherapy and 
allogeneic bone marrow transplantation during their first remission (Moorman et al. 2007, 
Mrózek 2008, Kayser et al. 2012, Ferrara and Schiffer 2013). Only, one case presented here in 
article 6 was observed with a good prognosis and with overall survival till date after first 
diagnosis for 4 years with CR and without signs for MRD.  
Summary: MLL gene rearrangements should be considered and tested by molecular 
approaches in case of a normal cytogenetic particularly, BCP-ALL with CD10-negative and 
high WBC count as well in AML with subtypes M5 and M4. 
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4. Conclusions and outlook 
The present work highlights that most if not all of CN-AL cases hold cryptic genomic 
alterations. Overall, sensitive methods to detect cryptic chromosomal / genetic aberrations in 
CN-AL are useful and necessary for genetic risk-based classification and correct 
determination of treatment protocols. 
Molecular cytogenetic approaches together with molecular methods are suited to identify 
cryptic rearrangements and potential target genes that involved in leukemogenesis and 
progression of the disease. The present work demonstrated that aCGH is a highly efficient 
tool for detection of CNAs in CN-ALL. However, while aCGH (and MLPA) provide data on 
imbalanced genomic alterations, (molecular) cytogenetics additionally detects different 
leukemic subclones within one sample, as well as balanced translocations leading to tumor-
specific fusion genes. In CN-AML, DNA sequencing and SNP-array-CGH have been used to 
detect mutations for a number of target genes that are known to key roles in myeloid 
development. It seems to be valid, there is no leukemia clone without genetic alterations; we 
just have to use the appropriate techniques to identify them. In conclusion, to obtain a 
comprehensive picture of all relevant changes in each individual acute leukemia case,  data 
from cytogenetics, FISH, MLPA, aCGH, SNP-array-CGH and DNA sequencing would need 
to be considered and included in diagnostics; however, sometimes such investigations may be 
hampered by lack of sufficient cellular material and or by financial restrictions.  
 
Overall the questions studied in this thesis could be answered as follows: 
1 How many cryptic chromosomal rearrangements were present in the 103 studied CN-
AL-patients? 
In 21/61 CN-ALL and 12/42 CN-AML cases previously overlooked cryptic 
chromosomal rearrangements could be detected; new clonal cryptic rearrangements were 
found in 9/21 (43%) of CN-ALL and in 2/42 (4%) of CN-AML cases. 
2 Can the (new) identified tumor-associated acquired chromosomal breakpoints in CN-AL 
be characterized in detail?  
83% of the overall 124 cryptic chromosomal breakpoints could be characterized in detail 
here by FISH alone; those include 11 new breakpoints in CN-ALL and 3 in CN-AML. 
3 Can the (new) identified tumor-associated acquired chromosomal breakpoints in 
complex-AL cases be characterized in detail?  
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80% of the overall 35 chromosomal breakpoints could be characterized in detail here by 
FISH alone; those included 2 breakpoints in one ALL and 11 breakpoints in seven 
corresponding AML cases. 
4 How many of the cryptic changes were submicroscopic structural CNAs detectable by 
MLPA and array-CGH?  
79% of the overall 155 cryptic chromosomal breakpoints could be characterized in detail 
here by MLPA and or aCGH; those include 3 new candidate genes for ALL and 1 for 
AML: CDK6 (7q12.2), CHD2 (15q26.2) and DCC (18q21.2). 
5 Could the new tumor-associated acquired rearrangements aligned with diagnostic, 
prognostic and therapeutic relevance?  
All here included cases were retrospectively studied, but not for all cases the clinical data 
was available. Still the new three aforementioned candidate genes CDK6, CHD2 and 
DCC were found only in patients with poor therapeutic response. 
Even though during the last years and the present study already major progress was achieved 
for ALL and AML patients, still lots of work is necessary for better understanding the biology 
of these malignant disorders. Candidate genes need to be correlated with clinical outcomes, 
and it can be expected that future studies will provide more insights into mechanisms of 
leukemiogensis, identify novel molecular markers, lead to the development of new diagnostic 
tools and to new entries of therapy development.  
5. Bibliography                                                                                                                                                   108 
 
5. Bibliography 
 
Achkar WA, Wafa A, Mkrtchyan H, Moassass F, Liehr T. 2010. A unique complex 
translocation involving six different chromosomes in a case of childhood acute lymphoblastic 
leukemia with the Philadelphia chromosome and adverse prognosis. Oncol Lett, 1:801-804. 
 
ACS. 2015. American Cancer Society. http://www.cancer.org/ [accessed 06.2015]. 
 
Alhourani E, Rincic M, Othman MA, Pohle B, Schlie C, Glaser A, Liehr T. 2014. 
Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation 
dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization 
(iFISH). Mol Cytogenet, 7:79.  
 
Ansari KI, Mandal SS. 2010. Mixed lineage leukemia: roles in gene expression, hormone 
signaling and mRNA processing. FEBS J, 277:1790-1804.  
 
Atlas of Genetics and Cytogenetics in Oncology and Hematology. 2015. 
http://atlasgeneticsoncology.org/ [accessed 06.2015]. 
 
Azofeifa J, Fauth C, Kraus J, Maierhofer C, Langer S, Bolzer A, Reichman J, Schuffenhauer 
S, Speicher MR. 2000. An optimized probe set for the detection of small interchromosomal 
aberrations by use of 24-color FISH. Am J Hum Genet, 66(5):1684-1688. 
 
Bassan R, Gatta G, Tondini C, Willemze R. 2004. Adult acute lymphoblastic leukaemia. Crit 
Rev Oncol Hematol, 50 (3):223-261. 
 
Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, 
Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo 
HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM. 2010. 
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia, Leukemia, 
24(5):942-949.  
 
Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. 2011.The heterogeneity 
of pediatric MLL-rearranged acute myeloid leukemia. Leukemia, 25(8):1239–1248. 
 
Belson M, Kingsley B, Holmes A. 2007. Risk factors for acute leukemia in children: a 
review. Environ Health Perspect, 115(1):138-145.  
 
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1981. 
The morphological classification of acute lymphoblastic leukaemia: concordance among 
observers and clinical correlations. Br J Haematol, 47(4):553-561. 
 
Benter T, Rätei R, Ludwig WD. 2001. Immunophenotyping of Acute Leukaemias. J Lab 
Med, 25 (11/12): 512-532.   
 
Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, 
Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, 
Leung W, Evans WE, Campana D, Relling MV, Pui CH. 2012. ETV6-RUNX1-positive 
childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. 
Leukemia, 26 (2):265-270. 
5. Bibliography                                                                                                                                                   109 
 
Bishop R. 2010. Applications of fluorescence in situ hybridization (FISH) in detecting 
genetic aberrations of medical significance. Bioscience Horizons, 3(1): 85-95. 
 
Braoudaki M, Tzortzatou-Stathopoulou F. 2012. Clinical cytogenetics in pediatric acute 
leukemia: an update. Clin Lymphoma Myeloma Leuk, 12(4):230-237. 
 
Bullinger L, Fröhling S. 2012. Array-based cytogenetic approaches in acute myeloid 
leukemia: clinical impact and biological insights. Semin Oncol, 39(1):37-46. 
 
Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, Cook J, Khan A, Dorschner 
MO, Weaver M, Calvert S, Malone S, Wallace G, Stanley T, Bye AM, Bleasel A, Howell KB, 
Kivity S, Mackay MT, Rodriguez-Casero V, Webster R, Korczyn A, Afawi Z, Zelnick N, 
Lerman-Sagie T, Lev D, Møller RS, Gill D, Andrade DM, Freeman JL, Sadleir LG, Shendure 
J, Berkovic SF, Scheffer IE, Mefford HC. 2013. Targeted resequencing in epileptic 
encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet, 
45(7):825-30.  
 
Caspersson T, Farber S, Foley GE, Kudynowski J, Modest EJ, Simonsson E, WaghU, Zech 
L. 1968.  Chemical differentiation along metaphase chromosomes. Exp Cell Res, 49(1):219-
222. 
 
Caspersson T, De La Chapelle A, Schröder J, Zech L. 1972. Quinacrin fluorescence of 
metaphase chromosomes. Identical pattern in diffrent tissues. Exp Cell Res, 72(1):56-59. 
 
Cavé H, Avet-Loiseau H, Devaux I, Rondeau G, Boutard P, Lebrun E, Méchinaud F, Vilmer 
E, Grandchamp B. 2001. Deletion of chromosomal region 13q14.3 in childhood acute 
lymphoblastic leukemia. Leukemia, 15(3):371-376.  
 
CGAP. 2015. Cancer Genome Anatomy Project. http://cgap.nci.nih.gov/ [accessed 06.2015]. 
 
Chilton L, Buck G, Harrison CJ, Ketterling RP, Rowe JM, Tallman MS, Goldstone AH, 
Fielding AK, Moorman AV. 2014. High hyperdiploidy among adolescents and adults with 
acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and 
outcome. Leukemia, 28(7):1511-1518. 
 
Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. 2008. Leukemia cutis. Am J Clin Pathol, 
129(1):130-42.  
 
Chowdhury T, Brady HJ. 2008. Insights from clinical studies into the role of the MLL gene 
in infant and childhood leukemia. Blood Cells Mol Dis, 40(2):192-199.  
 
Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, Vari S, 
Vaccaro V, Cognetti F, Milella M. 2014. PTEN expression and function in adult cancer stem 
cells and prospects for therapeutic targeting. Adv Biol Regul, 56:66-80.  
Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, Giroux C, Hernandez L, 
Kabongo E, Savola S, Leblanc T, Yakouben K, Plat G, Costa V, Ferster A, Girard S, 
Fenneteau O, Cayuela JM, Sigaux F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Soulier J, 
Cavé H. 2014. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell 
precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 
deletions. Leukemia, 28(1):70-77. 
5. Bibliography                                                                                                                                                   110 
 
Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, Kamps 
WA. 2006. Leukaemia incidence and survival in children and adolescents in Europe during 
1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J  
Cancer, 42(13): 2019 –2036. 
 
Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo 
HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, 
Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Reinhardt 
D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, 
Zemanova Z, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. 2011. Prognostic 
significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-
rearranged AML patients: results of an international study. Blood, 117(26):7102–7111. 
 
Craig FE, Foon KA. 2008. Flow cytometric immunophenotyping for hematologic 
neoplasms. Blood, 111(8):3941-3967. 
 
Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L. 1988. Detection of chromosome 
aberrations in metaphase and interphase tumor cells by in situ hybridization 
using chromosome-specific library probes. Hum Genet, 80(3):235-246. 
 
Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk 
RF. 2008. Significance of age in acute myeloid leukemia patients younger than 30 years: a 
common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 
and AMLSG HD93/98A. Cancer, 112(3):562-571 
 
de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. 
2004. Significant difference in outcome for adolescents with acute lymphoblastic leukemia 
treated on pediatric vs adult protocols in the Netherlands. Leukemia, 18(12):2032-2035. 
 
Derks S, van Engeland M. 2010. DCC (deleted in colorectal carcinoma). Atlas Genet 
Cytogenet Oncol Haematol, 14:945-949. 
 
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. 2012. Acute leukemia incidence 
and patient survival among children and adults in the United States, 2001-2007. Blood, 
119(1):34-43. 
 
Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, Ley TJ, Evans WE. 2012. 
The Pediatric Cancer Genome Project. Nat Genet, 44(6):619-622.  
 
Elghezal H, Le Guyader G, Radford-Weiss I, Perot C, Van Den Akker J, Eydoux P, 
Vekemans M, Romana SP. 2001. Reassessment of childhood B-lineage lymphoblastic 
leukemia karyotypes using spectral analysis. Genes Chromosomes Cancer, 30(4):383-392. 
 
Estey EH. 2013. Acute myeloid leukemia: 2013 update on risk-stratification and 
management. Am J Hematol, 88(4):318-327.  
 
Estey E, Döhner H. 2006. Acute myeloid leukaemia. Lancet, 368(9550):1894-1907. 
 
Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. 2010. 
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer, 116(5):1165-1176.  
 
5. Bibliography                                                                                                                                                   111 
 
Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look 
AT. 2003. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute 
leukemias: dominance of HOX dysregulation. Blood, 102(1):262-268. 
 
Ferrara F, Schiffer CA. 2013. Acute myeloid leukaemia in adults. Lancet, 381(9865):484-
495. 
  
Gallo Llorente L, Luther H, Schneppenheim R, Zimmermann M, Felice M, Horstmann MA. 
2014. Identification of novel NOTCH1 mutations: increasing our knowledge of 
the NOTCH signaling pathway. Pediatr Blood Cancer, 61(5):788-796.  
 
Glassman AB, Hayes KJ. 2005. The value of fluorescence in situ hybridization in the 
diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet, 
158(1):88-91. 
 
Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, 
Sallan SE, Asselin BL.2003. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber 
Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol, 21(19): 
3616-3622. 
 
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, 
Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working 
Group. 2010. Refinement of cytogenetic classification in acute myeloid leukemia:  
determination of prognostic significance of rare recurring chromosomal abnormalities among 
5876 younger adult patients treated in the United Kingdom Medical Research Council trials. 
Blood, 116(3):354-365.  
 
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. 1984. 
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on 
chromosome 22. Cell, 36(1):93-99. 
 
Gross M, Mkrtchyan H, Glaser M, Fricke HJ, Höffken K, Heller A, Weise A, Liehr T. 2009. 
Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid 
leukemia with normal GTG-banding karyotype. Int J Oncol, 34(2):417-423. 
 
Guan XY, Meltzer PS, Trent JM. 1994. Rapid generation of whole chromosome painting 
probes (WCPs) by chromosome microdissection. Genomics, 22(1):101-107. 
 
Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, 
Haferlach T, Schnittger S. 2012. Three novel cytogenetically cryptic EVI1 rearrangements 
associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid 
leukemia cases. Genes Chromosomes Cancer, 51(12):1079-1085. 
 
Haferlach C, Zenger M, Haferlach T, Wolfgang Kern W, and Schnittger S. 2014. Array 
Based Comparative Genomic Hybridization Detects Copy Number Alterations in 80.3% of 
Adult Acute Lymphoblastic Leukemia (ALL) with Normal Karyotype or Failed Chromosome 
Banding Analysis and Identifies a Subset with Only Submicroscopic Alterations Associated 
with Favorable Outcome. San Francisco: 56th ASH Annual Meeting & Exposition,  
 
Hardy RR, Hayakawa K. 2001. B cell development pathways. Annu Rev Immunol, 19:595-
621. 
5. Bibliography                                                                                                                                                   112 
 
Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. 
1983. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic 
myelocytic leukaemia. Nature, 306(5940):239-242. 
 
Heller A, Loncarevic IF, Glaser M, Gebhart E, Trautmann U, Claussen U, Liehr T. 2004. 
Breakpoint differentiation in chromosomal aberrations of hematological malignancies: 
Identification of 33 previously unrecorded breakpoints. Int J Oncol, 24(1):127-136. 
 
Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen 
R, Smith FO, Woods WG, Salzer WL, Johnstone HS, Dreyer Z, Reaman 
GH; Children's OncologyGroup. 2006. Analysis of prognostic factors of acute lymphoblastic 
leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood, 108 
(2):441-451. 
 
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, 
Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S. 2009. 
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloidleuke
mia (AML): a report from the Children's Oncology Group. Blood, 113(26):6558-6566.  
 
Hof  J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, Karawajew L, Ludwig 
WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R. 
2011. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor 
outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol, 
29(23):3185-93.  
 
Holmfeldt L, Wei L, Diaz-Flores E,  Walsh M, Zhang J, Ding L, Payne-Turner D, 
Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, 
Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria 
B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, 
Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca 
G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro 
RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, 
Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG. 
2013. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet, 45 
(3):242-252. 
 
Hömig-Hölzel C, Savola S. 2012 Multiplex ligation-dependent probe amplification (MLPA) 
in tumor diagnostics andprognostics. Diagn Mol Pathol, 21(4):189-206. 
 
Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, 
Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, 
Sekeres MA, Ogawa S, Maciejewski JP. 2014. Recurrent genetic defects on chromosome 7q 
in myeloid neoplasms. Leukemia, 28(6):1348-1351. 
 
Howard SC, Metzger ML, Wilimas JA,  Quintana Y, Pui C-H, Robison LL,  Ribeiro RC. 
2008. Childhood cancer epidemiology in low-income countries. Cancer, 112(3):461-472.  
 
Hrusak O, Trka J, Zuna J, Polouckova A,  Kalina T, Stary J. 2002. Acute lymphoblastic 
leukemia incidence during socioeconomic transition: selective increase in children from 1 to 4 
years. Leukemia, 16(4):720–725. 
 
5. Bibliography                                                                                                                                                   113 
 
Ilyas AM, Ahmad S, Faheem M, Naseer MI, Kumosani TA, Al-Qahtani MH, Gari M, Ahmed 
F. 2015. Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis. 
BMC Genomics, 16(Suppl 1):S5. 
 
Inaba H, Greaves M, Mullighan CG. 2013. Acute lymphoblastic leukaemia. Lancet, 
381(9881):1943-1955.  
 
Karst C, Gross M, Haase D, Wedding U, Höffken K, Liehr T, Mkrtchyan H. 2006. 
Novel cryptic chromosomal rearrangements detected in acute lymphoblastic leukemia 
detected  by application of new multicolor fluorescent in situ hybridization approaches. Int J 
Oncol, 28(4):891-897. 
 
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. 
Comparative genomic hybridization for molecular cytogenetic analysis of solid 
tumors.Science, 258(5083):818-821. 
 
Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-
Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, 
Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF; German-
Austrian AML Study Group. 2012. Monosomal karyotype in adult acute myeloid leukemia:  
prognostic impact and outcome after different treatment strategies. Blood, 119(2):551-558. 
 
Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, Yoon SS, Kim BK, Park MH, Lee 
DS. 2011. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-
lineage acute lymphoblastic leukemia. Blood Cells Mol Dis, 47(1):62-6. 
 
Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. 2013. The next-generation 
sequencing revolution and its impact on genomics. Cell, 155(1):27-38.  
 
Kohlmann A, Grossmann V, Nadarajah N, Haferlach T. 2013. Next-generation sequencing - 
feasibility and practicality in haematology. Br J Haematol, 160(6):736-753 
 
Lawler SD. 1977. Chromosomes in haematology. Br J Haematol, 36(4):455-460. 
 
Le Scouarnec S, Gribble SM. 2012. Characterising chromosome rearrangements: recent 
technical advances in molecular cytogenetics. Heredity,108(1):75-85. 
 
Lejeune J, Gautier M, Turpin R. 1959. Étude des chromosomes somatiques de neuf enfants 
mongoliens. C R Acad Sci Paris, 248(11):1721-1722. 
 
Lennon PA, Abruzzo LV, Medeiros LJ, Cromwell C, Zhang X, Yin CC, Kornblau SM, 
Konopieva M, Lin P. 2007. Aberrant EVI1 expression in acute myeloid leukemias associated 
with the t(3;8)(q26;q24). Cancer Genet Cytogenet, 177(1):37-42.  
 
Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, 
Claussen U.  2002a. Microdissection based high resolution multicolor banding for all 24 
human chromosomes. Int J Mol Med, 9(4):335-339. 
 
Liehr T, Heller A, Starke H, Claussen U. 2002b. FISH banding methods: applications in 
research and diagnostics. Expert Rev Mol Diagn, 2(3):217-225. 
 
5. Bibliography                                                                                                                                                   114 
 
Liehr T, Starke H, Weise A, Lehrer H, Claussen U. 2004. Multicolor FISH probe sets and 
their applications. Histol Histopathol, 19(1):229-237. 
 
Liehr T, Starke H, Heller A, Kosyakova N, Mrasek K, Gross M, Karst C, Steinhaeuser U, 
Hunstig F, Fickelscher I, Kuechler A, Trifonov V, Romanenko SA, Weise A. 2006. 
Multicolor fluorescence in situ hybridization (FISH) applied to FISH-banding. Cytogenet 
Genome Res, 114(3-4):240-244. 
 
Liehr T, Ed. 2009. Fluorescence in situ Hybridization (FISH) – Application Guide. Berlin: 
Springer Verlag. 
 
Liehr T. 2015. Multicolor FISH homepage.  http://ssmc-tl.com/mfish.html [accessed 
06.2015]. 
 
Liehr T, Othman MA, Rittscher K, Alhourani E. 2015. The current state of molecular 
cytogenetics in cancer diagnosis. Expert Rev Mol Diagn,15(4):517-526. 
 
Lien HC, Lin CW, Huang PH, Chang ML, Hsu SM.  2000. Expression of cyclin-dependent 
kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: 
comparison with CD56-negative peripheral T-cell lymphomas. Lab Invest, 80(6):893-900 
 
Lillington DM, Young BD, Berger R, Martineau M, Moorman AV, Secker-Walker LM. 
1998. The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic and clinical study 
of 20 patients. European 11q23 workshop participants. Leukemia, 12(5): 801–804. 
 
Linabery AM, Ross JA. 2008. Trends in childhood cancer incidence in the U.S. (1992 2004). 
Cancer, 112(2):416 432.  
 
Longo D, Ed. 2013. HARRISON’ S Hematology and Oncology. The McGraw-Hill 
Companies, Inc.2nd edition. 
 
Löwenberg B, Downing JR, Burnett A. 1999. Acute myeloid leukemia. N Engl J Med, 
341(14):1051-1062.  
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, 
Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, 
Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. 2005. Overexpression of the ETS-
related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal 
karyotype: a Cancer and Leukemia Group B study. J Clin Oncol, 23(36):9234-9242. 
Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, 
Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler 
M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. 2012. Age-
related prognostic impact of different types of DNMT3A mutations in adults with 
primary cytogenetically normal acute myeloid leukemia. J Clin Oncol, 30(7):742-750.  
 
Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. 1998. The 
t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. 
EU Concerted Action 11q23 Workshop participants. Leukemia, 12(5):788-791.  
5. Bibliography                                                                                                                                                   115 
 
Mathew S, Rao PH, Dalton J, Downing JR, Raimondi SC. 2001. Multicolor spectral 
karyotyping identifies novel translocations in childhood acute lymphoblastic leukemia. 
Leukemia, 15(3):468-472. 
Mendes RD, Sarmento LM, Canté-Barrett K, Zuurbier L, Buijs-Gladdines JG, Póvoa V, 
Smits WK, Abecasis M, Yunes JA, Sonneveld E, Horstmann MA, Pieters R, Barata JT, 
Meijerink JP. 2014. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused 
by illegitimate RAG-mediated recombination events. Blood, 124(4):567-578.  
 
Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J,Baurmann 
H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter 
RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J. 2014. Outcome of patients with 
abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.  
Blood, 123(19):2960-2967. 
 
Mitelman F, Johansson B, Mertens FE, editors (2015). Mitelman Database of Chromosome 
Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman. 
 
Mkrtchyan H, Glaser M, Gross M, Wedding U, Hoffken K, Liehr T, Karst C, Aroutiounian 
R. 2006. Multicolor-FISH applied to resolve complex chromosomal changes in a case of T-
ALL (FAB L2). Cytogenet Genome Res, 114(3-4):270-273. 
 
Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, 
Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow 
MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working 
Party, Medical ResearchCouncil/National Cancer Research Institute. 2007. Karyotype is 
an independent prognostic factor in adult acute lymphoblastic leukemia (ALL):  analysis 
of cytogenetic data from patients treated on the Medical Research Council  (MRC)  
UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 109(8):3189-
3197. 
 
Mrózek K.  2008. Cytogenetic, molecular genetic, and clinical characteristics of acute 
myeloid leukemia with a complex karyotype. Semin Oncol, 35(4):365-377. 
 
Mrózek K, Harper DP, Aplan PD. 2009. Cytogenetics and molecular genetics of acute 
lymphoblastic leukemia. Hematol Oncol Clin North Am, 23(5):991-1010 
 
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman 
K,Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff 
SA, Downing JR. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic 
leukaemia. Nature, 446(7137):758-764. 
 
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips 
LA,Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard 
DS,Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL. 2009a.  
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S 
A, 106(23):9414-9418.  
 
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, 
Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, 
Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui 
5. Bibliography                                                                                                                                                   116 
 
CH, Smith M, Hunger SP, Willman CL, Downing JR; Children's Oncology Group. 2009b. 
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med, 
360(5):470-480.  
 
Mullighan CG. 2012. Molecular genetics of B-precursor acute lymphoblastic leukemia. J 
Clin Invest, 122(10):3407-3415. 
 
Mullighan CG. 2013. Genomic characterization of childhood acute lymphoblastic leukemia. 
Semin Hematol, 50(4):314-324. 
 
Murphy J, Bustin SA. 2009. Reliability of real-time reverse-transcription PCR in clinical 
diagnostics: gold standard or substandard? Expert Rev Mol Diagn, 9(2):187-197. 
 
Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, Dastugue N, 
Schrappe M, Pui CH, Basso G, Silverman LB, Janka-Schaub GE. 2007. Outcome of treatment 
in children with hypodiploid acute lymphoblastic leukemia. Blood, 110 (4):1112-1115. 
 
Nebral K, Denk D, Attarbaschi A, König M, Mann G, Haas OA, Strehl S. 2009. Incidence 
and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia, 
23:134-143.  
 
Nowak-Göttl U, Kenet G, Mitchell LG.. 2009. Thrombosis in childhood acute lymphoblastic 
leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin 
Haematol, 22(1):103–114. 
 
Nordgren A, Heyman M, Sahlén S, Schoumans J, Söderhäll S, Nordenskjöld M, Blennow E. 
2002. Spectral karyotyping and interphase FISH reveal abnormalities not detected by 
conventional G-banding. Implications for treatment stratification of childhood acute 
lymphoblastic leukaemia: detailed analysis of 70 cases. Eur J Haematol, 68(1):31-41. 
 
Nowell PC, Hungerford DA. 1960. A minute chromosome in human granulocytic leukemia. 
Science, 132:1497. 
 
O'Brien P, Morin P Jr, Ouellette RJ, Robichaud GA. 2011. The Pax-5 gene: a pluripotent 
regulator of B-cell differentiation and cancer disease. Cancer Res, 71(24):7345-7350.  
 
Othman MA, Rincic M, Melo JB, Carreira IM, Alhourani E, Hunstig F, Glaser A, Liehr T. 
2014. A Novel Cryptic Three-Way Translocation t(2;9;18)(p23.2;p21.3;q21.33) with Deletion 
of Tumor Suppressor Genes in 9p21.3 and 13q14 in a T-Cell Acute Lymphoblastic Leukemia. 
Leuk Res Treatment, 2014:357123.  
 
Othman MA, Melo JB, Carreira IM, Rincic M, Glaser A, Grygalewicz B, Gruhn B, Wilhelm 
K, Rittscher K, Meyer B, Silva ML, Marques-Salles Tde J, Liehr T. 2015. High rates of 
submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia. Mol 
Cytogenet, 8:65.  
 
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, 
Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, 
Scholl C, Fröhling S. 2014. Requirement for CDK6 in MLL-rearranged acute myeloid 
leukemia, 124(1):13-23. 
 
5. Bibliography                                                                                                                                                   117 
 
Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner 
D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster 
JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, 
Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, 
Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh 
ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ. 2015. A genome wide association  
study of susceptibility to  acute lymphoblastic leukemia  in adolescents  and  young adults. 
Blood. 125(4):680-686. 
 
Pinkel D, Straume T, Gray JW. 1986. Cytogenetic analysis using quantitative, high-
sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A, 83(9):2934-2938. 
 
Pinkel D, Landegent J, Collins C, Fuscoe J, Segraves R, Lucas J, Gray J. 1988. Fluorescence 
in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and 
translocations of chromosome 4. Proc Natl Acad Sci U S A,  85(23):9138-9142. 
 
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, 
Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. 
High resolution analysis of DNA copy number variation using comparative genomic 
hybridization to microarrays. Nat Genet, 20(2):207-211. 
 
Polampalli S, Choughule A, Prabhash K, Amare P, Baisane C, Kabre S, Mahadik S, Shinde 
S, Nair R, Banavali S. 2011. Role of RT-PCR and FISH in diagnosis and monitoring of acute 
promyelocytic leukemia. Indian J Cancer, 48(1):60-67. 
Poppe B, Cauwelier B, Van Limbergen H, Yigit N, Philippé J, Verhasselt B, De Paepe A, 
Benoit Y, Speleman F. 2005. Novel cryptic chromosomal rearrangements in childhood acute 
lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization. 
Haematologica, 90(9):1179-1185. 
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. 
2014. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and 
CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and 
younger than 60 years: a systematic review and meta-analysis. Ann Hematol, 93(8):1279-
1286. 
 
Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, 
Evans WE, Gadner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-
Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, 
Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe 
M. 2003. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 
rearrangements. Leukemia, 17(4):700-706. 
 
Pui CH, Mullighan CG, Evans WE, Relling MV. 2012. Pediatric acute lymphoblastic 
leukemia: where are we going and how do we get there?  Blood, 120(6):1165-1174. 
 
Raffini LJ, Slater DJ, Rappaport EF, Lo Nigro L, Cheung NK, Biegel JA, Nowell PC, Lange 
BJ, Felix CA.  2002. Panhandle and reverse-panhandle PCR enable cloning of der(11) and 
der(other) genomic breakpoint junctions of MLL translocations and identify complex 
translocation of MLL, AF-4, and CDK6.  Proc Natl Acad Sci U S A, 99(7):4568-4573. 
 
5. Bibliography                                                                                                                                                   118 
 
Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas 
A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière 
D, Dombret H,Thomas X; GET-LALA group. 2008. Central nervous system involvement in 
adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-
LALA group. Leukemia Res, 32(11):1741–1750.  
 
Riegel M. 2014. Human molecular cytogenetics: From cells to nucleotides. Genet Mol Biol, 
37(1 Suppl):194-209.  
Roberts KG, Mullighan CG. 2015. Genomics in acute lymphoblastic leukaemia: insights 
and treatment implications. Nat Rev Clin Oncol, 12(6):344-357. 
Rothenberg EV, Moore JE, Yui MA. 2008. Launching the T-cell lineage  developmental  
programme. Nat Rev Immunol, 8(1):9-21.  
 
Rowley JD. 1973a.  Identificaton of a translocation with quinacrine fluorescence in a patient 
with acute leukemia. Ann Genet, 16(2):109-112. 
 
Rowley JD. 1973b. Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 
243(5405):290-293. 
 
Rowley JD. 1999. The role of chromosome translocations in leukemogenesis. Semin 
Hematol, 36(4 Suppl 7):59–72. 
Rowley JD, Reshmi S, Carlson K, Roulston D. 1999. Spectral karyotype analysis of T-cell 
acute leukemia. Blood, 93(6):2038-2042. 
Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler 
CM,Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, 
Fröhling S,Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. 
2012. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with 
specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 
119(9):2114-2121. 
 
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, 
Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, 
Sauerland MC, Berdel WE, Büchner T, Wörmann BJ, Hiddemann W, Spiekermann K. 2012. 
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 
unmutated, AML with a normal karyotype. Blood, 119(19):4383-4386. 
 
Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T. 2006. Impact of 
trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. 
Genes Chromosomes Cancer, 45(12):1164-1168. 
 
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative 
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe 
amplification. Nucleic Acids Res, 30(12):e57. 
 
5. Bibliography                                                                                                                                                   119 
 
Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, 
Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. 1996. Multicolor spectral 
karyotyping of human chromosomes. Science, 273(5274):494-497. 
 
Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, Russell LJ, Moorman 
AV, Harrison CJ. 2013. Genes commonly deleted in childhood B-cell precursor acute 
lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica, 
98(7):1081-8.  
 
Senger G, Chudoba I, Plesch A. 1998. Multicolor-FISH – the identification of chromosome 
aberrations by 24 colors. BIOforum, 9:499-503. 
 
Shaffer LG, McGowan-Jordan J, Schmid M, Ed. ISCN An International System for Human 
Cytogenetic Nomenclature 2013. Basel: S Karger. 
 
Shah A, Andersson TM, Rachet B, Björkholm M, Lambert PC. 2013. 
Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based 
 study. Br J Haematol, 162(4):509-516. 
 
Speicher MR, Gwyn Ballard S, Ward DC. 1996. Karyotyping human chromosomes by 
combinatorial multi-fluor FISH. Nat Genet, 12(4):368-375. 
 
Speicher MR, Carter NP. 2005. The new cytogenetics: blurring the boundaries with 
molecular biology. Nat Rev Genet, 6(10):782-792.  
 
Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, 
Haferlach C. 2014. TP53 mutations occur in 15.7% of ALL and are associated with MYC-
rearrangement, low hypodiploidy, and a poor prognosis. Blood, 124:251-258. 
 
Stiller CA. 2004. Epidemiology and genetics of childhood cancer. Oncogene, 23(38):6429–
6444.  
 
Storlazzi CT, Anelli L, Albano F, Zagaria A, Ventura M, Rocchi M, Panagopoulos I, 
Pannunzio A, Ottaviani E, Liso V, Specchia G. 2004. A novel chromosomal translocation 
t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Ann Hematol, 
83(2):78-83.  
Storlazzi CT, Fioretos T, Surace C, Lonoce A, Mastrorilli A, Strömbeck B, D'Addabbo P, 
Iacovelli F, Minervini C, Aventin A, Dastugue N, Fonatsch C, Hagemeijer A, Jotterand M, 
Mühlematter D, Lafage-Pochitaloff M, Nguyen-Khac F, Schoch C, Slovak ML, Smith A, Solè 
F, Van Roy N, Johansson B, Rocchi M. 2006. MYC-containing double minutes in 
hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as 
the target gene. Hum Mol Genet, 15(6):933-942.  
Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van 
Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, 
Moorman AV, Harrison CJ. 2007.  Genome complexity in acute lymphoblastic leukemia is 
revealed by array-based comparative genomic hybridization. Oncogene, 26(29):4306-4318. 
Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, 
Parker H, Wright SL, Stewart AR, Bailey S, Bown NP, Hall AG, Harrison CJ. 2009. A 
5. Bibliography                                                                                                                                                   120 
 
comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia 
reveals genomic deletion, copy number neutral loss of heterozygosity, and association with 
specific cytogenetic subgroups. Blood, 113(4):100-107.  
 
Tanke HJ, Wiegant J, van Gijlswijk RP, Bezrookove V, Pattenier H, Heetebrij RJ, Talman 
EG, Raap AK, Vrolijk J. 1999. New strategy for multi-colour fluorescence in situ 
hybridisation: COBRA: COmbined Binary RAtio labelling. Eur J Hum Genet, 7(1):2-11. 
 
Teitell MA, Pandolfi PP. 2009. Molecular genetics of acute lymphoblastic leukemia.Annu 
Rev Pathol, 4:175-198. 
 
Tjio HJ,  Levan A. 1956. The chromosome numbers of man. Hereditas, 42(1-2):1–6. 
 
Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland 
B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, 
Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A. 2014. PVT1 dependence in cancer 
with MYC copy-number increase. Nature, 512(7512):82-86. 
 
Tuborgh A, Meyer C, Marschalek R, Preiss B, Hasle H, Kjeldsen E. 2013. Complex three-
way translocation involving MLL, ELL, RREB1, and CMAHP genes in an infant with acute 
myeloid leukemia and t(6;19;11)(p22.2;p13.1;q23.3). Cytogenet Genome Res, 141(1):7-15. 
Tyybäkinoja A, Elonen E, Piippo K, Porkka K, Knuutila S. 2007. Oligonucleotide array-
CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid 
leukemia. Leukemia, 21(3):571-574. 
Usvasalo A, Räty R, Harila-Saari A, Koistinen P, Savolainen ER, Vettenranta K, Knuutila S, 
Elonen E, Saarinen-Pihkala UM. 2009. Acute lymphoblastic leukemias with normal 
karyotypes are not without genomic aberrations. Cancer Genet Cytogenet, 192(1):10-17. 
 
Vaitkevičienė G, Forestier E, Hellebostad M, Heyman M, Jonsson OG, Lähteenmäki PM, 
Rosthoej S, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology and 
Oncology (NOPHO). 2011. High white blood cell count at diagnosis of childhood acute 
lymphoblastic leukaemia: biological background and prognostic impact. Results from the 
NOPHO ALL-92 and ALL-2000 studies. Eur J Haematol, 86(1):38-46. 
 
Van Vlierberghe P, Ferrando A. 2012. The molecular basis of T cell acute lymphoblastic 
leukemia. J Clin Invest, 122(10):3398-3406.  
 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le 
Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. 2009. The 2008 revision of 
the World Health Organization (WHO) classification  of myeloid neoplasms and  
acute leukemia: rationale  and important changes. Blood, 114(5):937-951.  
 
Vardiman JW. 2010. The World Health Organization (WHO) classification of tumors of the 
hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. 
Chem Biol Interact, 184(1-2):16-20.  
 
Walker A, Marcucci G. 2012. Molecular prognostic factors in cytogenetically normal acute 
myeloid leukemia. Expert Rev Hematol, 5(5):547-558. 
 
5. Bibliography                                                                                                                                                   121 
 
Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, 
Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrózek 
K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, 
McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ. 2009. 
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad 
Sci U S A, 106(31):12950-12955.  
 
Wang HC, Fedoroff S. 1972. Banding in human chromosomes treated with trypsin. Nat New 
Biol, 235(54):52–54. 
 
Weise A, Heller A, Starke H, Mrasek K, Kuechler A, Pool-Zobel BL, Claussen U, Liehr T. 
2003. Multitude multicolor chromosome banding (mMCB) - a comprehensive one-step 
multicolor FISH banding method. Cytogenet Genome Res, 103(1-2):34-39. 
 
Woo JS, Alberti MO, Tirado CA. 2014. Childhood B-acute lymphoblastic leukemia: 
a genetic update. Exp Hematol Oncol, 3:16. 
 
Yamamoto JF, Goodman MT. 2008. Patterns of leukemia incidence in the United States by 
subtype and demographic characteristics, 1997-2002. Cancer Causes Control, 19(4):379-390. 
 
Yasar D, Karadogan I, Alanoglu G, Akkaya B, Luleci G, Salim O, Timuragaoglu A, Toruner 
GA, Berker-Karauzum S. 2010. Array comparative genomic hybridization analysis of adult 
acute leukemia patients. Cancer Genet Cytogenet, 197(2):122-129. 
 
Yunis JJ. 1976. High resolution of human chromosomes. Science, 191(4233):1268–1270. 
 
Zhang FF, Murata-Collins JL, Gaytan P, Forman SJ, Kopecky KJ, Willman CL, Appelbaum 
FR, Slovak ML.  2000. Twenty-four-color spectral karyotyping reveals chromosome 
aberrations in cytogenetically normal acute myeloid leukemia. Genes Chromosomes Cancer, 
28(3):318-328.  
 
Zhao Y, Huang H, Wei G. 2013. Novel agents and biomarkers for acute lymphoid leukemia. 
J Hematol Oncol, 6:40.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Appendix                                                                                                                                                           122 
 
6. Appendix 
 
6.1. Tables 
 
Table 1.1 Immunological classifications of ALL 
 
 
 
Table 1.2 Cytogenetic prognostic markers in ALL subtypes. 
 
 
lymphoid-lineage in ALL  Expression (CD) 
pro-B-ALL CD19, CD22, CD72, CD74, CD79a, HLA-DR, TdT 
common ALL CD10, CD19, CD20,  CD22, CD72, CD74, CD79a, HLA-DR 
pre-B-ALL CD10, CD19, CD20, CD22, CD72, CD74, CD79a, HLA-DR, 
IgM, Pax5  
mature-B-ALL CD5, CD19, CD20, CD21, CD22, CD24,CD72, CD79a, 
HLA-DR, IgD, IgG, IgM, TdT 
pro-T-ALL cyCD3, CD7, CD10, CD34, TdT 
pre-T-ALL CD2, cyCD3, CD5, CD7, CD10, CD34, TdT  
cortical-T-ALL CD1a, CD2, cyCD3, CD4, CD5, CD7, CD8, CD10, TdT  
mature -T-ALL CD2, cyCD3, mCD3, CD4, CD5, CD7, CD8, CD10, TCRβ 
ALL subtypes cytogenetic abnormality outcome 
pre-B-cell ALL  
 
t(12;21) 
hyperdiploid (>50 chromosomes) 
ERG deletion 
favorable  
t(1;19) intermediate 
t(9;22) 
 t(17;19) 
t(v;11)(v;q23); MLL rearranged 
complex karyotype 
hypodiploidy (<44 chromosomes) 
CRLF2 rearrangements 
iAMP21  
poor 
PAX5 rearrangements   
ABL1 rearrangements   
PDGFRB rearrangements   
JAK2 rearrangements   
unkown 
B-cell ALL t(8;14) 
t(8;22) 
t(2;8) 
intermediate 
T-cell ALL 7q34 or 14q11 rearrangements intermediate 
all normal karyotype intermediate 
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Table 1.3 Recurrent structural chromosomal aberrations in ALL 
 
 
 
 
 
ALL Subtypes   Aberrations Fusion genes 
Pre-B-cell ALL  
 
t(1;19)(q23;p13)  
t(4;11)(q21;q23) 
t(5;14)(q31;q32) 
t(6;11) (q27;q23) 
t(6;14)(q32;p22).   
t(9;11)(p22q23)  
dic(9;12)(p13;p13) 
t(9;22)(q34;q11) 
t(10;11)(p13-14;q14-21)  
t(12;21)(p13;q22) 
t(11;19)(q23;13.3)  
t(14;19)(q32;q13) 
t(17;19)(q22;p13) 
t(X;14)(p22;q32)/t(Y;14)(p11.2;q32) 
PBX1/E2A 
MLL/AF4  
IL3/IGH 
MLL/AF6 
ID4/IGH 
MLL/MLLT3(AF9) 
PAX5/ETV6 
BCR/ABL  
MLL/MLLT10(AF10) 
TEL/AML1 
MLL/ENL  
IGH/ CEBPA  
HLF/E2A 
CRLF2/IGH 
ins(4;11)(q21;q23 
ins(5;11)(q31;q13q23)  
MLL /AFF1 
MLL /AFF4 
inv(11)(q13q23) 
inv(14)(q11q32) 
inv(19)(p13q13) 
MLL/ BTBD18 
CEBPE/IGH 
TCF3/TFPT 
T-cell ALL  
 
t(1;7)(p34;q34)  
t(1;7)(p32;q34)  
t(1;14)(p32;q11)  
t(5;14)(q35;q32) 
t(6;7)(q23;q34) 
t(7;9)(q34;q32) 
t(7;9)(q34;q34) 
t(7;10)(q24;q24) 
t(7;11)(q34;p13) 
t(7;12)(q34;p12) 
t(7;19)(q34;p13) 
t(8;14)(q24;q11) 
t(10;11)(p13;q14) 
t(10;14)(q24;q11) 
t(11;14)(p15;q11)  
t(11;14)(p13;q11) 
t(11;19)(q23;p13) 
t(12;14)(p13;q11) 
LCK/TCRβ  
TAL1/TCRβ  
TAL1/TCRδ 
TLX3/ BCL11B 
MYB/ TCRβ 
TAL2/TCRβ 
TAN1/TCRβ 
HOX11/TCRβ   
RHOM2/TCRδ   
TCRβ/ LMO3 
TCRβ/LYL1  
MYC/TCRα/δ  
MLLT10(AF10)/HOXA 
HOX11/TCRδ   
LMO1/TCRδ    
LMO2/TCRδ  
MLL/ENL  
CCND2/ TCRδ  
inv(7)(p15q34) 
inv(14)(q13q32.33)  
HOXA/TCRβ 
NKX2.1 
Mmature B-cell 
ALL  
 
t(8;14)(q24;q32)  
t(8;22)(q24;q11)  
t(2;8)(p12;q24)  
MYC/IGH 
MYC/IgL 
MYC/Igk 
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Table 1.4 Common DNA CNAs detected in ALL  
gene/CNA detected  Location / Frequency ALL subtype  
del  TAL1  1p32/20%–30% T-ALL 
del  EBF1 5q33.3 / 2% B-ALL 
amp  MYB 6q23.3/ 8% T-ALL 
del  6q (TSG) 6q16 / 20-30% B-ALL / T-ALL 
del  IKZF1 7p12.2 / 15% B-ALL 
amp  NUP214–ABL1 9q34.12-9q34.13 /4% T-ALL 
del CDKN2A/B & MTAP 9p21.3 /30% B-ALL / T-ALL 
del PAX5  9p13.3 /30% B-ALL 
del  PTEN  10q23.3 /10% T-ALL 
del ATM 11q22.3 / 15% B-ALL / T-ALL 
del  ETV6  12p13.2 / 13% B-ALL / T-ALL 
del  RB1  13q14.2 / 4% B-ALL / T-ALL 
del  CREBBP 16p13.3 / 19% Relapsed B-ALL 
del  TP53  17p13.1 3% B-ALL / T-ALL 
amp iAMP21 (RUNX1)  21q22.12 / 2% B-ALL  
del ERG  21q22.2 / 4% B-ALL 
del CRLF2  Xp22.2 / 5% B-ALL 
 
 
 
 
Table 1.5 Immunological classifications of AML 
 
 
 
 
 
myeloid-lineage in AML  Expression (CD) 
M0 CD7, CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR  
M1 CD7, CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR, 
MPO 
M2 CD7, CD11b, CD13, CD14, CD15, CD19, CD33, CD34, 
CD38, CD45, CD56, CD64, CD65, CD117, HLA-DR, MPO 
M3 CD9, CD13, CD33, CD45, CD65, CD68, CD117, HLA-DR, 
MPO 
M4 CD2, CD4, CD7, CD11c, CD13, CD14, CD15, CD33, CD34, 
CD45,  CD56, CD64, CD65, CD117, HLA-DR, lyzozome, 
MPO 
M5 CD2, CD4, CD7, CD11b, CD11c, CD13, CD14, CD15, CD33, 
CD36, CD45, CD64, CD65, CD68, CD117, HLA-DR, 
Llyzozome, MPO 
M6 CD34, CD36, CD45, CD117, CD235a, GPHA, HLA-DR,   
M7 CD4, CD33, CD34, CD36, CD41, CD42a, CD45, CD61, 
CD117, HLA-DR, VWF 
acute basophilic leukemia CD11b, CD13, CD33, CD45, CD123, CD203c, HLA-DR, 
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Table 1.6 WHO classification of AML 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AML with recurrent genetic abnormalities  
AML with t(8;21)(q22;q22), RUNX1-RUNX1T1 
AML with inv(16)(p13q22) or t(16;16)(p13;q22), CEFB-MYH11 
acute promyelocytic leukemia with t(15;17)(q22;q12), PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
AML with mutated NPM1 (provisional entity) 
AML with mutated CEBPA (provisional entity) 
AML with myelodysplasia-related features  
Secondary, therapy related AML and MDS  
AML, not otherwise specified  
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/acute monocytic leukemia 
Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia variants) 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
myeloid sarcoma 
myeloid proliferations related to Down syndrome  
transient abnormal myelopoiesis 
myeloid leukemia associated with Down syndrome 
blastic plasmacytoid dendritic cell neoplasm  
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Table 1.7 Common chromosomal abnormalities in AML subtypes 
AML 
subtypes  
cytogenetic abnormality affected genes 
M0 complex Karyotype, +4, +11, +13, +21 ? 
M1 t(9;22)(q34;q11) 
-3, -5, del(5q),-7, del(7q), +11, +13, +21 
BCR/ABL 
M2 t(8;21)(q22;q22) 
t(2;4)(p23;q35) 
t(7;11)(p15;p15) 
t(6;9)(p23;q34) 
t(11;19)(q23,p13)  
t(11;20)(p15;q11) 
del(2p), +4, -5, del(5q), -7, del(7q), +8, del(9q),+11, 
+21, -Y 
RUNX1T1/RUNX1 
? 
HOX9/ NUP98 
DEK/NUP214 
MLL/ELL 
NUP98/TOP1 
M3 t(15;17)(q22;q12-21)   
t(11;17)(q23;q12) 
del(7q), i(17q), +21 
PML/RARA 
PLZF/RARA 
M4 inv(16)(p13q22),t(16;16)(p13;q22) 
t(1;7)(q10;p10) 
t(6;9)(p23;q34) 
t(8;16)(p11;p13) 
t(10;11)(p13;q23) 
t(11;17)(q23.q25) 
t(11;19)(q23,p13)  
t(12;22)(p13;q21) 
t(16;21)(p11.2;q22) 
del(16)(q22), +4, -5, del(5q), -7, del(7q), +8, del(9q), 
del(11)(q23q24), +22 
CBFA/MYH11 
? 
DEK/NUP214 
KAT6A/CREBBP 
MLL-MLLT10 
MLL/SEPT9 
MLL/ELL 
ETV6/RUNX1 
FUS/ERG 
M5 t(6;11)(q27;q23),   
t(9;11)(p21;q23),  
t(10;11)(p13;q23), ins(10;11)(p11;q23q24),  
t(11;17)(q23;q25)  
t(11;19)(q23;p13) 
t(8;16)(p11;p13) 
abn11q23  
+8  
MLL/MLLT4 
MLL/MLLT3 
MLL/MLLT10 
MLL/SEPT9 
MLL/ELL 
KAT6A/CREBBP 
MLL 
M6 inv(3)(q21;q26), ins(3;3)(q26;q21q26), 
t(3;3)(q21;q26) 
t(3;5)(q25.1;q35) 
dup(1q), -5,-7, del(7p), del(9q), del(20)(q11), i(21q) 
RPN1/MECOM 
NPM/MLF1 
 
M7 t(1;22)(p13;q13) 
del(20q11), +21 
RBM15/MKL1 
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Table 1.8 Cytogenetic prognostic markers in AML 
outcome  cytogenetic abnormality 
favorable t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
t(15;17)(q24.1;q21.1)/PML-RARA 
Mutated NPM1 without FLT3-ITD (normal karyotype)  
Mutated CEBPA (normal karyotype) 
intermediate t(9;11)(p22;q23); MLLT3-MLL 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
del(7q), del(9q), del(11q), abn(12p). del(20q)  
-Y, +8, +11, +13, +21, 
normal karyotype 
adverse  t(v;11)(v;q23); MLL rearranged 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(1;22)(p13;q13)/RBM15-MKL1 
complex karyotype ≥3 abnormalities 
–5 or del(5q); –7; abnl(17p),  
mutations in IDH1 and/ 
or IDH2,  BAALC overexpression 
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Supplementary Table 1 (Article 7) 
case 
number age [y] gender banding cytogenetic result FISH probes 
molecular 
approaches 
B-ALLs 
P1 1 F 46,XX[7] mMCB MLPA  
aCGH 
P8 30 M 46,XY[8] mMCB 
LSPs #21 
MLPA 
P13 34 M 46,XY[8] mMCB 
LSPs #10, #17 
MLPA  
aCGH 
P14 18 M 46,XY[20] mMCB n.d. 
P17 27  46,XX[7] mMCB aCGH 
P22 42 F 46,XX[20] mMCB n.d. 
P23 59 F 46,XX[14]/47,XX,+14[6] mMCB 
MCB#14  
LSPs #14 
MLPA  
aCGH 
P25 71 F 46,XX[5] mMCB n.d. 
P28 84 M 46,XY[5] mMCB 
MCB#11 
LSPs #9, #11 
MLPA  
aCGH 
P29 59 M 46,XY[5] mMCB n.d. 
P37 52 M 46,XY[5] mMCB n.d. 
P40 57 F 46,XX[6] mMCB 
MCB #11 
n.d. 
P41 31 M 46,XY[4] mMCB 
MCB #15 
WCP #8 
n.d. 
P43 69 F 46,XX[20] mMCB 
MCB #11 
CEP #4 
LSPs #11 
MLPA  
aCGH 
P44 24 M 46,XY[3] mMCB 
WCP #4, #10 
n.d. 
P48 39 M 46,XY[20] mMCB 
M-FISH 
MCB #6, #11 
WCP #6, #11 
subCTM11 
LSPs #6, #11 
aCGH 
P49 39 F 46,XX[10] mMCB aCGH 
P50 21 F 46,XX[2] mMCB n.d. 
P51 59 F 46,XX[6] mMCB MLPA  
aCGH 
P52 21 M 46,XY[4] mMCB  MLPA  
aCGH 
P53 34 M 46,XY[5] mMCB  MLPA  
aCGH 
P55 19 M 46,XY[6] mMCB  MLPA  
aCGH 
P56 47 M 46,XY[20] mMCB  MLPA  
aCGH 
P57 56 M 46,XY[3] mMCB  MLPA  
aCGH 
P58 20 F 46,XX[20] mMCB 
MCB #14 
WCP #8, #14 
LSPs #9, #14 
MLPA  
aCGH 
P59 25 M 46,XY[2] mMCB  n.d. 
P62 34 F 46,XX[3] mMCB n.d. 
P64 4 F 46,XX,?der(19)[20] 
 
 
mMCB 
MCB #5, #9, #16, #19 
WCP#5, #9, #16, 
#19, X 
LSPs #5, #9, #16, 
#19    
aCGH 
P65 18 M 46,XY[10] mMCB 
MCB #8, #14,  
LSPs #8, #14 
n.d. 
P66 0.5 F n.d. M-FISH 
MCB #10, #11; #14; 
WCP #10, #11, #14, 
LSPs #10, #11, #14  
aCGH 
P67 12 M 46,XY[15] M-FISH n.d. 
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MCB #1, #7  
LSPs #1, #7, #11 
T-ALLs  
P3 19 M 46,XY[8] mMCB n.d. 
P5 22 F 46,XX[12] mMCB MLPA  
aCGH 
P6 16 M 46,XY[9] mMCB 
M-FISH 
MCB #3, #5, #10 
WCP #4  
MLPA  
aCGH 
P7 26 M 46,XY[7] mMCB  
M-FISH 
MCB #2, #9, #11, #18  
WCP #10, #14 
subCTM #11 
LSPs #2, #9, #18 
MLPA  
aCGH 
P15 44 F 46,XX[5] mMCB n.d. 
P18 36 M 46,XY[5] mMCB 
MCB5 
LSPs #18 
MLPA 
P26 28 F 46,XX[5] mMCB n.d. 
P32 27 M 46,XX[17] mMCB 
MCB #6, #10, #14 
subCTM #6 
LSPs #9, #12, #13 
MLPA 
P35 40 M 46,XY[10] mMCB 
LSPs #9 
MLPA  
aCGH 
P36 58 M 46,XY[20] mMCB n.d. 
P38 22 M 46,XY[3] mMCB MLPA  
aCGH 
P61 18 F 46,XX[20] mMCB 
M-FISH 
MCB #2, #4;#7, #10 
WCP #2, #7, #10 
LSPs #2;#7, #10   
MLPA  
aCGH 
B- or T ALLs (not clinically well defined)  
P2 23 F 46,XX[11] mMCB n.d. 
P4 18 F 46,XX[2] mMCB n.d. 
P9 4 F 46,XX[2] mMCB n.d. 
P10 15 F 46,XX[5] mMCB n.d. 
P11 26 M 46,XY[8] mMCB  
WCP #11, #22 
aCGH 
P12 24 F 46,XX [5] mMCB n.d. 
P16 17 F 46,XX[7] mMCB 
LSPs #9; #12 
MLPA  
aCGH 
P19 9 M 46,XY[5] mMCB n.d. 
P21  62 M 46,XY[11] mMCB aCGH 
P24 23 M 46,XY[12] mMCB 
LSPs #18 
MLPA 
P27 71 F 46,XX[5] mMCB n.d. 
P30 46 M 46,XY[6] mMCB 
MCB #9 
MLPA 
P31 58 M 46,XY[5] mMCB n.d. 
P33 76 F 46,XX[4]/45,X,-X[14] mMCB 
LSPs #9, #12, #18 
MLPA  
aCGH 
P34 61 M 46,XY[7] mMCB 
MCB5  
LSPs #5 
n.d. 
P39 52 F 46,XX[5] mMCB n.d 
P46 63 M 46,XY[8] mMCB 
CEP #7 
WCP#5, #10 
MLPA  
aCGH 
P47 59 M 46,XX[6] mMCB MLPA  
aCGH 
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Supplementary Table 2 (Article 7) 
probe locus 
CEB108/T7 (Abbott/Vysis) 1p36.3 
ZytoLight®SPEC ALK (ZytoVision) 2p23.2~23.1 
D2S447 (Abbott/Vysis)  2q37.3 
ZytoLight®SPEC TFG (ZytoVision) 3q12.2 
RP11-114M1 and RP11-91K9 (TBL1XR1) 3q26.32 
D3S4559 (Abbott/Vysis) 3p26.3 
CEP4 = D4Z1 (Abbott/Vysis) 4p11-q11 
C84c11/T3 (Abbott/Vysis) 5p15.33 
LSI D5S721 (Abbott/Vysis) 5p15.2 
LSI EGR1/D5S23 (Abbott/Vysis) 5q31 
POSEIDON PDGFRB (Kreatech) 5q33  
D5S2907 (Abbott/Vysis) 5q35.3 
ZytoLight®SPEC MYB (ZytoVision) 6q23.2~q23.3 
ZytoLight®SPEC CEN6 = D6Z1 (ZytoVision) 6p11.1-q11.1 
ZytoLight®SPEC ESR1 (ZytoVision) 6q25.1 
RP11-112P10 (RELN) 7q22.1 
VIJyRM2000 (Abbott/Vysis) 7q36.3 
ZytoLight®SPEC CDKN2A (ZytoVision) 9p21.3 
ZytoLight®SPEC CEN9 = D9Z3 (ZytoVision) 9q12 
LSI ABL (Abbott/Vysis) 9q34 
Z96139 (Abbott/Vysis) 10p15.3 
ZytoLight®SPEC WT1  (ZytoVision) 10p13 
ZytoLight®SPEC CEN 10 = D10Z1 (ZytoVision) 10p11.1-q11.1 
ZytoLight®SPEC PTEN (ZytoVision) 10q23.3 
ZytoLight®SPEC FGFR2 (ZytoVision) 10q26.13 
D10S2290 (Abbott/Vysis) 10q26.3 
D11S2071 (Abbott/Vysis) 11p15.5 
POSEIDON NUP98 (Kreatech) 11p15.4 
ZytoLight®SPEC BIRC3 (ZytoVision) 11q22.2 
ZytoLight®SPEC ATM (ZytoVision) 11q22.3 
LSI MLL (Abbott/Vysis) or POSEIDON MLL (Kreatech) 11q23.3 
D11S1037 (Abbott/Vysis) 11q25 
8M16/SP6 (Abbott/Vysis) 12p13.3 
ZytoLight®SPEC ETV6 (ZytoVision) 12p13.2 
LSI 13 (RB1) (Abbott/Vysis) 13q14.2 
LSI D13S25 (Abbott/Vysis) 13q14.3 
LSI IGH (Abbott/Vysis) 14q32.33 
D14S1420 (Abbott/Vysis) 14q32.33 
ZytoLight®SPEC FUS (ZytoVision) 16p11.2 
ZytoLight®SPEC TP53 (ZytoVision) or LSI p53 (Abbott/Vysis) 17p13.1 
CEP 18 = D18Z1 (Abbott/Vysis) 18p11.1-q11.1 
LSI BCL2 (Abbott/Vysis) 18q21 
RP11-346H17 (DCC) 18q21.2 
ZytoLight®SPEC MALT1 (ZytoVision) 18q21.32 
ZytoLight®SPEC 19q13 (ZytoVision) 19q13.3 
POSEIDON MLLT1 (Kreatech) 19p13.3 
ZytoLight®SPEC 19p13 (ZytoVision) 19q13.43 
ZytoLight®SPEC RUNX1 (ZytoVision) 21q22.12 
ZytoLight®SPEC ERG (ZytoVision) 21q12.13 
LSI BCR (Abbott/Vysis) 22q11.2 
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